Per Svenningsson

Om mig
Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Om mig

Per Svenningsson är professor i neurologi och forskargruppsledare vid institutionen för klinisk neurovetenskap, Karolinska Institutet. Han är också verksam som överläkare vid Karolinska Universitetssjukhuset.

Artiklar

Journal article: CELL DEATH & DISEASE. 2025;16(1):693
The CHCHD2-CHCHD10 protein complex is modulated by mitochondrial dysfunction and alters lipid homeostasis in the mouse brain
Gerlach J; Pireddu P; Zhang X; Wetzel S; Mennuni M; Milenkovic D; Nolte H; da Silva Rodrigues F; Branzell N; Kaya I; Villegas RG; Rubalcava-Gracia D; Alsina D; Feederle R; Andren PE; Langer T; Svenningsson P; Filograna R
Journal article: MOVEMENT DISORDERS CLINICAL PRACTICE. 2025
High Cerebrospinal DOPA Decarboxylase Level Predicts Cognitive Decline in Parkinson's Disease
Sturchio A; Paslawski W; Khosousi S; Markaki I; Nalls MA; Singleton AB; Iwaki H; Svenningsson P
Journal article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025;26(18):9213
Repeat Variants, Biomarkers, and Molecular Signatures in Parkinson's Disease: ATXN2, ATXN3, CACNA1A, PRNP, TBP, C9ORF72, TOMM40, APOE, and POLG-A Swedish Perspective
Laffita-Mesa JM; Paucar M; Svenningsson P
Article: BRITISH JOURNAL OF PHARMACOLOGY. 2025
Cholesterol modulates trafficking of galanin receptor subtype 1 but not subtype 2: Insights from live-cell imaging
Li T; Vukojevic V; Oasa S; Bai Y; Yang Y; Li H; Tang Y; Terenius L; Hokfelt T; Svenningsson P; Xu Z-QD
Journal article: CHEMISTRY-METHODS. 2025
Derivatization of Small Molecules using Deuterated Analog of Reactive Matrix to Facilitate Identification in Mass Spectrometry Imaging
Vallianatou T; Balestri LJI; Nilsson A; Zhang X; Svenningsson P; Odell LR; Andren PE; Shariatgorji R
Journal article: SLEEP MEDICINE CLINICS. 2025;20(3):259-268
Clinical and Biofluid Biomarkers of Sleep Dysfunction in Parkinson's Disease
Gomez-Ocadiz R; Svenningsson P
Journal article: NEUROTHERAPEUTICS. 2025;22(5):e00690
Montelukast alleviates neuroinflammation and improves motor functions in the line 61 model of Parkinson's disease: An exploratory study
Strempfl K; Zattoni M; Mrowetz H; Unger MS; Schoerghofer N; Altendorfer B; Neddens J; Flunkert S; Hutter-Paier B; He Y; Wallin J; Poupardin RW; Pietrantonio F; Paiement N; Zerbe H; Felder T; Svenningsson P; Aigner L
Journal article: NPJ PARKINSONS DISEASE. 2025;11(1):258
Brain-region-specific lipid dysregulation in L-DOPA-induced dyskinesia in a primate model of Parkinson's disease
Kaya I; Vallianatou T; Nilsson A; Bjarterot P; Shariatgorji R; Svenningsson P; Bezard E; Andren PE
Journal article: MOVEMENT DISORDERS CLINICAL PRACTICE. 2025
Levodopa-Carbidopa Intestinal Gel Improves Dyskinesia in Parkinson's Disease: Post Hoc Analysis from the COSMOS Study
Fasano A; Spanaki C; Gurevich T; Jech R; Svenningsson P; Szasz J; Vela-Desojo L; Simu M; Bergmann L; Saad A; Parra JC; Kovacs N
Journal article: NEUROIMAGE-CLINICAL. 2025;48:103857
Effects of Parkinson's disease on mechanical and microstructural properties of the brain
Olsson C; Skorpil M; Svenningsson P; Moreno R
Article: MOVEMENT DISORDERS. 2025;40(8):1551-1560
Cortical Effects of Dopamine Replacement Account for Clinical Response Variability in Parkinson's Disease
Wiesman AI; Vinding MC; Tsitsi P; Svenningsson P; Waldthaler J; Lundqvist D
Journal article: JOURNAL OF ALZHEIMERS DISEASE. 2025;:13872877251360404
Cerebrospinal fluid biomarkers of Alzheimer's disease in Lewy body diseases: The performance of fully automated immunoassays
Chong JR; Hye A; Boada M; Svenningsson P; Fladby T; Aarsland D
Journal article: JCI INSIGHT. 2025;10(13):e188413
Stearoyl-CoA desaturase inhibition normalizes brain lipid saturation, α-synuclein homeostasis, and motor function in mutant Gba1-Parkinson mice
Nuber S; Hsiang H; Keewan E; Moors TE; Reitz SJ; Tiwari A; Ho GPH; Su E; Hahn W; Adom M-A; Pathak R; Blizzard M; Kim S; Ko HS; Zhang X; Svenningsson P; Selkoe DJ; Fanning S
Article: NPJ PARKINSONS DISEASE. 2025;11(1):170
Cutaneous nerve fiber pathology and function in Parkinson's disease and atypical parkinsonism - a cohort study
Andreasson M; Paslawski W; Terkelsen AJ; Samuelsson K; Zetterberg H; Blennow K; Karlsson P; Svenningsson P
Article: ANNALS OF NEUROLOGY. 2025;98(4):762-763
Widespread Skin Telangiectasias in Spinocerebellar Ataxia Type 27B
Alm V; Thonberg H; Svenningsson P; Paucar M
Journal article: ANALYTICAL CHEMISTRY. 2025;97(21):10957-10961
Quantitative Mass Spectrometry Imaging Protocols for Spatially Heterogeneous Samples
Shariatgorji R; Niehues M; Nilsson A; Angerer T; Stroth N; Paslawski W; Jabre S; Svenningsson P; Andren PE
Journal article: LANCET NEUROLOGY. 2025;24(6):548-556
Gene therapy for Parkinson's disease: trials and technical advances
Winston G; Kharas N; Svenningsson P; Jha A; Kaplitt MG
Article: PCN REPORTS. 2025;4(2):e70123
[¹⁸F]FE-PE2I PET is a diagnostic tool in dementia with Lewy bodies
Sturchio A; Svensson JE; Tiger M; Moren AF; Varrone A; Svenningsson P; Okubo Y; Tateno A
Journal article: PCN REPORTS. 2025;4(2)
[18F]FE‐PE2I PET is a diagnostic tool in dementia with Lewy bodies
Sturchio A; Svensson JE; Tiger M; Morén AF; Varrone A; Svenningsson P; Okubo Y; Tateno A
Article: MOLECULAR PSYCHIATRY. 2025;30(6):2504-2516
Enduring modulation of dorsal raphe nuclei regulates (R,S)-ketamine-mediated resilient stress-coping behavior
Camargo A; Nilsson A; Shariatgorji R; Appleton E; Branzell N; Doyon D; Giovenzana M; Zhang X; Dautan D; Andren PE; Svenningsson P
Article: MOVEMENT DISORDERS. 2025;40(6):1134-1142
NLX-112 Randomized Phase 2A Trial: Safety, Tolerability, Anti-Dyskinetic, and Anti-Parkinsonian Efficacy
Svenningsson P; Odin P; Bergquist F; Wirdefeldt K; Nyholm D; Andreasson M; Markaki I; Johansson AC; Jergil M; Jankosky C; Varney MA; Herbrecht F; Johnson SA; Newman-Tancredi A
Journal article: FRONTIERS IN IMMUNOLOGY. 2025;16:1574755
Engineered sequestrins inhibit aggregation of pathogenic alpha-synuclein mutants
Hjelm LC; Paslawski W; Lendel C; Svedmark SF; Svenningsson P; Stahl S; Lindberg H; Lofblom J
Article: NEUROBIOLOGY OF DISEASE. 2025;208:106848
Leveraging animal models to understand non-motor symptoms of Parkinson's disease
Wichmann T; Nelson A; Torres ERS; Svenningsson P; Marongiu R
Article: ANALYTICAL CHEMISTRY. 2025;97(16):9033-9041
Met-ID: An Open-Source Software for Comprehensive Annotation of Multiple On-Tissue Chemical Modifications in MALDI-MSI
Bjarterot P; Nilsson A; Shariatgorji R; Vallianatou T; Kaya I; Svenningsson P; Kall L; Andren PE
Article: BRAIN. 2025;148(4):1099-1105
ATP1A3 dysfunction causes motor hyperexcitability and afterhyperpolarization loss in a dystonia model
Akkuratov EE; Sorrell F; Picton LD; Sousa VC; Paucar M; Jans D; Svensson L-B; Lindskog M; Fritz N; Liebmann T; Sillar KT; Rosewich H; Svenningsson P; Brismar H; Miles GB; Aperia A
Article: MOVEMENT DISORDERS. 2025;40(4):672-682
An X-Linked Ataxia Syndrome in a Family with Hearing Loss Associated with a Novel Variant in the BCAP31 Gene
Paucar M; Li T; Bergendal A; Savitcheva I; Pourhamidi K; Laffita-Mesa JM; Nordgren A; Engvall M; Uhlen P; Lagerstedt-Robinson K; Svenningsson P
Article: MOVEMENT DISORDERS. 2025;40(4):739-744
Effects of Montelukast on Neuroinflammation in Parkinson's Disease: An Open Label Safety and Tolerability Trial with CSF Markers and [¹¹C]PBR28 PET
Wallin J; Forsberg A; Svenningsson P
Article: NEUROPSYCHOPHARMACOLOGY. 2025;50(5):721-730
A molecular mechanism mediating clozapine-enhanced sensorimotor gating
Mantas I; Flais I; Branzell N; Ionescu TM; Kim E; Zhang X; Cash D; Hengerer B; Svenningsson P
Article: NATURE COMMUNICATIONS. 2025;16(1):2748
Computational memory capacity predicts aging and cognitive decline
Mijalkov M; Storm L; Zufiria-Gerboles B; Vereb D; Xu Z; Canal-Garcia A; Sun J; Chang Y-W; Zhao H; Gomez-Ruiz E; Passaretti M; Garcia-Ptacek S; Kivipelto M; Svenningsson P; Zetterberg H; Jacobs H; Luedge K; Brunner D; Mehlig B; Volpe G; Pereira JB
Article: EXPERIMENTAL NEUROLOGY. 2025;385:115118
Early alterations of functional connectivity, regional brain volumes and astrocyte markers in the beta-sitosterol beta-d-glucoside (BSSG) rat model of parkinsonism
Monnot C; Kalomoiri M; Macnicol E; Kim E; Mesquita M; Damberg P; Van Kampen JM; Kay DG; Turkheimer F; Robertson HA; Cash D; Svenningsson P
Article: MOVEMENT DISORDERS. 2025;40(2):363-369
The ZFHX3 GGC Repeat Expansion Underlying Spinocerebellar Ataxia Type 4 has a Common Ancestral Founder
Chen Z; Alvarez Jerez P; Anderson C; Paucar M; Lee J; Nilsson D; Macpherson H; Scardamaglia A; Montgomery K; Hardy J; Singleton AB; Tucci A; Mathews KD; Fu Y-H; Engvall M; Laffita-Mesa J; Nennesmo I; Wedell A; Ptacek LJ; Blauwendraat C; Gustavsson EK; Svenningsson P; Ryten M; Houlden H
Article: MOLECULAR BIOLOGY OF THE CELL. 2025;36(2):br4-9
Parkinson disease-associated toxic exposures selectively up-regulate vesicular glutamate transporter vGlut2 in a model of human cortical neurons
Clark KA; White AJ; Paslawski W; Alexander KD; Peng S; Young-Pearse TL; Svenningsson P; Selkoe DJ; Ho GPH
Article: ANALYTICAL CHEMISTRY. 2025;97(2):1338-1346
Comprehensive Approach for Sequential MALDI-MSI Analysis of Lipids, N-Glycans, and Peptides in Fresh-Frozen Rodent Brain Tissues
Lee Y-R; Kaya I; Wik E; Baijnath S; Loden H; Nilsson A; Zhang X; Sehlin D; Syvanen S; Svenningsson P; Andren PE
Journal article: FRONTIERS IN IMMUNOLOGY. 2025;16
Engineered sequestrins inhibit aggregation of pathogenic alpha-synuclein mutants
Hjelm LC; Paslawski W; Lendel C; Svedmark SF; Svenningsson P; Ståhl S; Lindberg H; Löfblom J
Article: EUROPEAN JOURNAL OF NEUROLOGY. 2025;32(1):e16582
Levodopa-entacapone-carbidopa intestinal gel: Data from the Swedish national registry for Parkinson's disease
Othman M; Bergquist F; Odin P; Scharfenort M; Johansson A; Markaki I; Svenningsson P; Dizdar N; Nyholm D
Article: LANCET NEUROLOGY. 2024;23(12):1225-1237
Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study
Ma Y; Farris CM; Weber S; Schade S; Nguyen H; Perez-Soriano A; Giraldo DM; Fernandez M; Soto M; Camara A; Painous C; Munoz E; Valldeoriola F; Marti MJ; Clarimon J; Kallunki P; Ma TC; Alcalay RN; Gomes BF; Blennow K; Zetterberg H; Constantinescu J; Mengel D; Kadam V; Parchi P; Brockmann K; Tropea TF; Siderowf A; Synofzik M; Kang UJ; Compta Y; Svenningsson P; Mollenhauer B; Concha-Marambio L
Article: ACS CHEMICAL NEUROSCIENCE. 2024;15(22):4095-4104
SARS-CoV-2 and HSV-1 Induce Amyloid Aggregation in Human CSF Resulting in Drastic Soluble Protein Depletion
Christ W; Kapell S; Sobkowiak MJ; Mermelekas G; Evertsson B; Sork H; Saher O; Bazaz S; Gustafsson O; Cardenas EI; Villa V; Ricciarelli R; Sandberg JK; Bergquist J; Sturchio A; Svenningsson P; Malm T; Espay AJ; Pernemalm M; Lindeen A; Klingstrom J; El Andaloussi S; Ezzat K
Article: NPJ PARKINSONS DISEASE. 2024;10(1):198
CSF d18:1 sphingolipid species in Parkinson disease and dementia with Lewy bodies with and without GBA1 variants
Lerche S; Wurster I; Valente EM; Avenali M; Samaniego D; Martinez-Vicente M; Hernandez-Vara J; Laguna A; Sturchio A; Svenningsson P; France NP; Barlow C; Sankaranarayanan S; Brockmann K
Article: FRONTIERS IN NEUROSCIENCE. 2024;18:1409366
Case report: Neuroacanthocytosis associated with novel variants in the VPS13A gene with concomitant nucleotide expansion for CANVAS and assessment with osmotic gradient ektacytometry
Paucar M; Wincent J; Rubin C; Peikert K; Kyhle J; Hertegard S; Moller R; Beshara S; Svenningsson P
Article: MOVEMENT DISORDERS. 2024;39(10):1881-1885
Increased CSF DOPA Decarboxylase Correlates with Lower DaT-SPECT Binding: Analyses in Biopark and PPMI Cohorts
Khosousi S; Sturchio A; Appleton E; Paslawski W; Ta M; Nalls M; Singleton AB; Iwaki H; Svenningsson P
Article: NATURE COMMUNICATIONS. 2024;15(1):8176
Claustrum and dorsal endopiriform cortex complex cell-identity is determined by Nurr1 and regulates hallucinogenic-like states in mice
Mantas I; Flais I; Masarapu Y; Ionescu T; Frapard S; Jung F; Le Merre P; Saarinen M; Tiklova K; Salmani BY; Gillberg L; Zhang X; Chergui K; Carlen M; Giacomello S; Hengerer B; Perlmann T; Svenningsson P
Article: NPJ PARKINSONS DISEASE. 2024;10(1):172
GPR37 processing in neurodegeneration: a potential marker for Parkinson's Disease progression rate
Argerich J; Garma LD; Lopez-Cano M; Alvarez-Montoya P; Gomez-Acero L; Fernandez-Duenas V; Munoz-Manchado AB; Aso E; Boxer A; Andres-Benito P; Svenningsson P; Ciruela F
Article: JOURNAL OF INTERNAL MEDICINE. 2024;296(3):234-248
Spinocerebellar ataxia type 4 is caused by a GGC expansion in the ZFHX3 gene and is associated with prominent dysautonomia and motor neuron signs
Paucar M; Nilsson D; Engvall M; Laffita-Mesa J; Soderhall C; Skorpil M; Halldin C; Fazio P; Lagerstedt-Robinson K; Solders G; Angeria M; Varrone A; Risling M; Jiao H; Nennesmo I; Wedell A; Svenningsson P
Article: JOURNAL OF NEUROIMAGING. 2024;34(5):603-611
Combined MR quantitative susceptibility mapping and multi-shell diffusion in Parkinson's disease
Forsman OA; Sjostrom H; Svenningsson P; Granberg T
Article: MOVEMENT DISORDERS CLINICAL PRACTICE. 2024;11(9):1095-1102
Motor Efficacy of Subcutaneous DIZ102, Intravenous DIZ101 or Intestinal Levodopa/Carbidopa Infusion
Bergquist F; Ehrnebo M; Nyholm D; Johansson A; Lundin F; Odin P; Svenningsson P; Dizdar N; Eriksson E
Article: NEUROBIOLOGY OF DISEASE. 2024;199:106593
Reducing the lipase LIPE in mutant α-synuclein mice improves Parkinson-like deficits and reveals sex differences in fatty acid metabolism
Adom MA; Hahn WN; Mccaffery TD; Moors TE; Zhang X; Svenningsson P; Selkoe DJ; Fanning S; Nuber S
Article: SCIENCE. 2024;385(6712):eado6593
Morphine-responsive neurons that regulate mechanical antinociception
Fatt MP; Zhang M-D; Kupari J; Altinkok M; Yang Y; Hu Y; Svenningsson P; Ernfors P
Article: NPJ PARKINSONS DISEASE. 2024;10(1):159
MRI subtypes in Parkinson's disease across diverse populations and clustering approaches
Inguanzo A; Mohanty R; Poulakis K; Ferreira D; Segura B; Albrecht F; Muehlboeck J-S; Granberg T; Sjostrom H; Svenningsson P; Franzen E; Junque C; Westman E
Article: SCIENCE ADVANCES. 2024;10(32):eadn1524
AlphaFold accelerated discovery of psychotropic agonists targeting the trace amine-associated receptor 1
Diaz-Holguin A; Saarinen M; Vo DD; Sturchio A; Branzell N; de Vaca IC; Hu H; Mitjavila-Domenech N; Lindqvist A; Baranczewski P; Millan MJ; Yang Y; Carlsson J; Svenningsson P
Article: ACS CHEMICAL NEUROSCIENCE. 2024;15(15):2822-2829
Applying Spatial Metabolomics To Investigate Age- and Drug-Induced Neurochemical Changes
Vallianatou T; Angerer TB; Kaya I; Nilsson A; Shariatgorji R; Svenningsson P; Andren PE
Article: SCIENCE ADVANCES. 2024;10(31):eado9959
Multiplexed mapping of the interactome of GPCRs with receptor activity-modifying proteins
Kotliar IB; Bendes A; Dahl L; Chen Y; Saarinen M; Ceraudo E; Dodig-Crnkovic T; Uhlen M; Svenningsson P; Schwenk JM; Sakmar TP
Article: NATURE BIOTECHNOLOGY. 2024;42(7):1046-1050
Spatial multimodal analysis of transcriptomes and metabolomes in tissues
Vicari M; Mirzazadeh R; Nilsson A; Shariatgorji R; Bjaerterot P; Larsson L; Lee H; Nilsson M; Foyer J; Ekvall M; Czarnewski P; Zhang X; Svenningsson P; Kaell L; Andren PE; Lundeberg J
Article: NEUROPSYCHOPHARMACOLOGY. 2024;49(7):1129-1139
Two polygenic mouse models of major depressive disorders identify TMEM161B as a potential biomarker of disease in humans
El Yacoubi M; Altersitz C; Latapie V; Rizkallah E; Arthaud S; Bougarel L; Pereira M; Wierinckx A; El-Hage W; Belzeaux R; Turecki G; Svenningsson P; Martin B; Lachuer J; Vaugeois J-M; Jamain S
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2024;27(5):pyae021
Altered Serotonin 1B Receptor Binding After Escitalopram for Depression Is Correlated With Treatment Effect
Garde M; Matheson GJ; Varnaes K; Svenningsson P; Hedman-Lagerloef E; Lundberg J; Farde L; Tiger M
Article: NPJ PARKINSONS DISEASE. 2024;10(1):93
PARKIN is not required to sustain OXPHOS function in adult mammalian tissues
Filograna R; Gerlach J; Choi H-N; Rigoni G; Barbaro M; Oscarson M; Lee S; Tiklova K; Ringner M; Koolmeister C; Wibom R; Riggare S; Nennesmo I; Perlmann T; Wredenberg A; Wedell A; Motori E; Svenningsson P; Larsson N-G
Article: JOURNAL OF THE NEUROLOGICAL SCIENCES. 2024;459:122979
Cerebrospinal fluid glial fibrillary acidic protein, in contrast to amyloid beta protein, is associated with disease symptoms in Huntington's disease
Korpela S; Sundblom J; Zetterberg H; Constantinescu R; Svenningsson P; Paucar M; Niemela V
Article: JOURNAL OF PARKINSONS DISEASE. 2024;14(3):557-563
Chronotropic Incompetence in Parkinson's Disease: A Possible Marker of Severe Disease Phenotype?
Andreasson M; Nickander J; Stahlberg M; Fedorowski A; Svenningsson P
Journal article: ELIFE. 2024;12
Transcriptomic atlas of midbrain dopamine neurons uncovers differential vulnerability in a Parkinsonism lesion model
Yaghmaeian Salmani B; Lahti L; Gillberg L; Jacobsen JK; Mantas I; Svenningsson P; Perlmann T
Article: ELIFE. 2024;12:RP89482
Transcriptomic atlas of midbrain dopamine neurons uncovers differential vulnerability in a Parkinsonism lesion model
Salmani BY; Lahti L; Gillberg L; Jacobsen JK; Mantas I; Svenningsson P; Perlmann T
Article: PARKINSONISM & RELATED DISORDERS. 2024;121:106047
Putaminal T1/T2-weighted ratio is increased in PSP compared to PD and healthy controls, a multi-cohort study
Sjostrom H; van Westen D; Hall S; Tjerkaski J; Westman E; Muehlboeck S; Hansson O; Svenningsson P; Granberg T
Journal article: NUKLEARMEDIZIN-NUCLEAR MEDICINE. 2024;63(02):117-118
Novel α-Synuclein Fibrils PET tracers in PFF Mouse Model of Parkinson’s Disease
Yousefi BH; Uzuegbunam B; Bagheri S; Li J; Paslawski W; Svenningsson P; Agren H; Arzberger T; Luster M; Weber W; Librizzi D
Article: JOURNAL OF AFFECTIVE DISORDERS. 2024;349:286-296
Maternal deprivation causes CaMKII downregulation and modulates glutamate, norepinephrine and serotonin in limbic brain areas in a rat model of single prolonged stress
Dorovic D; Lazarevic V; Delovic JA; Stevanovic V; Paslawski W; Zhang X; Velimirovic M; Petronijevic N; Puskas L; Savic MM; Svenningsson P
Article: NPJ PARKINSONS DISEASE. 2024;10(1):51
Oscillatory and non-oscillatory features of the magnetoencephalic sensorimotor rhythm in Parkinson's disease
Vinding MC; Waldthaler J; Eriksson A; Manting CL; Ferreira D; Ingvar M; Svenningsson P; Lundqvist D
Article: NPJ PARKINSONS DISEASE. 2024;10(1):47
Generation of G51D and 3D mice reveals decreased α-synuclein tetramer-monomer ratios promote Parkinson's disease phenotypes
Nuber S; Zhang X; Mccaffery TD; Moors TE; Adom M-A; Hahn WN; Martin D; Ericsson M; Tripathi A; Dettmer U; Svenningsson P; Selkoe DJ
Article: MOVEMENT DISORDERS. 2024;39(2):259-266
A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease
Cardoso F; Goetz CG; Mestre TA; Sampaio C; Adler CH; Berg D; Bloem BR; Burn DJ; Fitts MS; Gasser T; Klein C; de Tijssen MAJ; Lang AE; Lim S-Y; Litvan I; Meissner WG; Mollenhauer B; Okubadejo N; Okun MS; Postuma RB; Svenningsson P; Tan LCS; Tsunemi T; Wahlstrom-Helgren S; Gershanik OS; Fung VSC; Trenkwalder C
Article: SCIENTIFIC DATA. 2024;11(1):150
The Swedish National Facility for Magnetoencephalography Parkinson's disease dataset
Vinding MC; Eriksson A; Comarovschii I; Waldthaler J; Manting CL; Oostenveld R; Ingvar M; Svenningsson P; Lundqvist D
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2024;25(1):683
Secretome Analyses Identify FKBP4 as a GBA1-Associated Protein in CSF and iPS Cells from Parkinson's Disease Patients with GBA1 Mutations
Kojima R; Paslawski W; Lyu G; Arenas E; Zhang X; Svenningsson P
Journal article: NEUROSCIENCE APPLIED. 2024;3:105358
Increased CSF DOPA decarboxylase correlates with lower DaTSCAN binding: analyses in Biopark and PPMI cohorts
Khosousi S; Sturchio A; Appleton E; Paslawski W; Ta M; Nalls M; Singleton AB; Iwaki H; Svenningsson P
Article: BMJ OPEN. 2023;13(12):e077766
Quantifying Parkinson's disease severity using mobile wearable devices and machine learning: the ParkApp pilot study protocol
Ymeri G; Salvi D; Olsson CM; Wassenburg MV; Tsanas A; Svenningsson P
Article: ANALYTICAL CHEMISTRY. 2023;95(50):18352-18360
Rapid Metabolic Profiling of 1 μL Crude Cerebrospinal Fluid by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging Can Differentiate De Novo Parkinson's Disease
Vallianatou T; Nilsson A; Bjarterot P; Shariatgorji R; Slijkhuis N; Aerts JT; Jansson ET; Svenningsson P; Andren PE
Article: PARKINSONS DISEASE. 2023;2023:6502727-7
Sex Differences in the Allele Distribution of PGLYRP2 Variant rs892145 in Parkinson's Disease
Ran C; Wirdefeldt K; Sydow O; Svenningsson P; Diaz Heijtz R
Journal article: BIORXIV. 2023;:2023.11.22.568247
Expanding the GPCR-RAMP interactome.
Kotliar IB; Bendes A; Dahl L; Chen Y; Saarinen M; Ceraudo E; Dodig-Crnković T; Uhle'n M; Svenningsson P; Schwenk JM; Sakmar TP
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023;24(22):16445
In Silico and In Vitro Study towards the Rational Design of 4,4′-Disarylbisthiazoles as a Selective α-Synucleinopathy Biomarker
Uzuegbunam BC; Li J; Paslawski W; Weber W; Svenningsson P; Agren H; Yousefi BH
Article: PARKINSONISM & RELATED DISORDERS. 2023;116:105765
Elevated ApoE, ApoJ and lipoprotein-bound α-synuclein levels in cerebrospinal fluid from Parkinson's disease patients - Validation in the BioFIND cohort
Paslawski W; Svenningsson P
Article: NATURE COMMUNICATIONS. 2023;14(1):6750
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases
Smith R; Capotosti F; Schain M; Ohlsson T; Vokali E; Molette J; Touilloux T; Hliva V; Dimitrakopoulos IK; Puschmann A; Jogi J; Svenningsson P; Andreasson M; Sandiego C; Russell DS; Miranda-Azpiazu P; Halldin C; Stomrud E; Hall S; Bratteby K; Tampio L'Estrade E; Luthi-Carter R; Pfeifer A; Kosco-Vilbois M; Streffer J; Hansson O
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2023;26(9):599-606
In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics
Agren R; Betari N; Saarinen M; Zeberg H; Svenningsson P; Sahlholm K
Article: NATURE COMMUNICATIONS. 2023;14(1):5804
Prosaposin maintains lipid homeostasis in dopamine neurons and counteracts experimental parkinsonism in rodents
He Y; Kaya I; Shariatgorji R; Lundkvist J; Wahlberg LU; Nilsson A; Mamula D; Kehr J; Zareba-Paslawska J; Biverstal H; Chergui K; Zhang X; Andren PE; Svenningsson P
Article: TRANSLATIONAL NEURODEGENERATION. 2023;12(1):42
Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson's disease
Paslawski W; Khosousi S; Hertz E; Markaki I; Boxer A; Svenningsson P
Article: FRONTIERS IN INTEGRATIVE NEUROSCIENCE. 2023;17:1249554
Pupil light reflex dynamics in Parkinson's disease
Tsitsi P; Nilsson M; Waldthaler J; Seimyr GO; Larsson O; Svenningsson P; Markaki I
Journal article: ELIFE. 2023;12
Age-related differences in the functional topography of the locus coeruleus and their implications for cognitive and affective functions
Veréb D; Mijalkov M; Canal-Garcia A; Chang Y-W; Gomez-Ruiz E; Gerboles BZ; Kivipelto M; Svenningsson P; Zetterberg H; Volpe G; Betts M; Jacobs HI; Pereira JB
Article: ELIFE. 2023;12:RP87188
Age-related differences in the functional topography of the locus coeruleus and their implications for cognitive and affective functions
Vereb D; Mijalkov M; Canal-Garcia A; Chang Y-W; Gomez-Ruiz E; Gerboles BZ; Kivipelto M; Svenningsson P; Zetterberg H; Volpe G; Betts M; Jacobs HIL; Pereira JB
Article: JOURNAL OF THE NEUROLOGICAL SCIENCES. 2023;451:120707
Genetic screening for Huntington disease phenocopies in Sweden: A tertiary center case series focused on short tandem repeat (STR) disorders
Paucar M; Laffita-Mesa J; Niemela V; Malmgren H; Nennesmo I; Lagerstedt-Robinson K; Nordenskjold M; Svenningsson P
Article: NPJ PARKINSONS DISEASE. 2023;9(1):118
Spatial lipidomics reveals brain region-specific changes of sulfatides in an experimental MPTP Parkinson's disease primate model
Kaya I; Nilsson A; Luptakova D; He Y; Vallianatou T; Bjarterot P; Svenningsson P; Bezard E; Andren PE
Article: NPJ PARKINSONS DISEASE. 2023;9(1):109
Cortex-wide topography of 1/f-exponent in Parkinson's disease
Helson P; Lundqvist D; Svenningsson P; Vinding MCC; Kumar A
Article: MOVEMENT DISORDERS. 2023;38(7):1209-1222
Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson's Disease: A Randomized, Double-Blind, Multicenter Phase 1 Trial
Huttunen HJJ; Booms S; Sjogren M; Kerstens V; Johansson J; Holmnas R; Koskinen J; Kulesskaya N; Fazio P; Woolley M; Brady A; Williams J; Johnson D; Dailami N; Gray W; Levo R; Saarma M; Halldin C; Marjamaa J; Resendiz-Nieves J; Grubor I; Lind G; Eerola-Rautio J; Mertsalmi T; Andreasson M; Paul G; Rinne J; Kivisaari R; Bjartmarz H; Almqvist P; Varrone A; Scheperjans F; Widner H; Svenningsson P
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2023;77(4):e22269
[¹¹C]PBB3 binding in Aβ(-) or Aβ(+) corticobasal syndrome
Cselenyi Z; Wallin J; Tjerkoski J; Bloth B; Svensson S; Nennesmo I; Sunnemark D; Jelic V; Farde L; Svenningsson P
Article: ACTA NEUROLOGICA SCANDINAVICA. 2023;2023:1-10
The Impact of COVID-19 on Parkinson's Disease: A Case-Controlled Registry and Questionnaire Study on Clinical Markers and Patients' Perceptions
Weber GC; Timpka J; Bergquist F; Backstrom D; Dizdar N; Gunnarsson K; Nyholm D; Svenningsson P; Odin P
Journal article: MEDRXIV. 2023;:2023.02.25.23286442
Age-related differences in the functional topography of the locus coeruleus: implications for cognitive and affective functions.
Veréb D; Mijalkov M; Canal-Garcia A; Chang Y-W; Gomez-Ruis E; Gerboles BZ; Kivipelto M; Svenningsson P; Zetterberg H; Volpe G; Betts MJ; Jacobs H; Pereira JB
Article: JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY. 2023;34(5):836-846
On-Tissue Chemical Derivatization for Comprehensive Mapping of Brain Carboxyl and Aldehyde Metabolites by MALDI-MS Imaging
Kaya I; Schembri LS; Nilsson A; Shariatgorji R; Baijnath S; Zhang X; Bezard E; Svenningsson P; Odell LR; Andren PE
Article: ANNALS OF NEUROLOGY. 2023;93(5):1023-1028
β2-Adrenoreceptor Agonists, Montelukast, and Parkinson Disease Risk
Liu B; Svenningsson P; Ludvigsson JF; Lundholm C; Wallin J; Larsson H; Sjolander A; Williams DM; Pedersen NL; Wirdefeldt K
Article: NPJ PARKINSONS DISEASE. 2023;9(1):56
Aberrant somatic calcium channel function in cNurr1 and LRRK2-G2019S mice
Skiteva O; Yao N; Mantas I; Zhang X; Perlmann T; Svenningsson P; Chergui K
Article: EJNMMI RESEARCH. 2023;13(1):29
[¹⁸F]FE-PE2I DAT correlates with Parkinson's disease duration, stage, and rigidity/bradykinesia scores: a PET radioligand validation study
Kerstens VS; Fazio P; Sundgren M; Halldin C; Svenningsson P; Varrone A
Article: MOVEMENT DISORDERS CLINICAL PRACTICE. 2023;10(4):579-585
Reading Alterations in Parkinson's Disease Indicate Worse Cognitive Status
Tsitsi P; Nilsson M; Seimyr GO; Larsson O; Svenningsson P; Markaki I
Article: PARKINSONISM & RELATED DISORDERS. 2023;108:105313
Complement system changes in blood in Parkinson's disease and progressive Supranuclear Palsy/Corticobasal Syndrome
Khosousi S; Hye A; Velayudhan L; Bloth B; Tsitsi P; Markaki I; Svenningsson P
Article: JOURNAL OF NEUROLOGY. 2023;270(2):864-876
Comorbidities and clinical outcomes in adult- and juvenile-onset Huntington's disease: a study of linked Swedish National Registries (2002-2019)
Furby H; Moore S; Nordstroem A-L; Houghton R; Lambrelli D; Graham S; Svenningsson P; Petersen A
Article: STEM CELL REPORTS. 2023;18(1):337-353
Single-cell transcriptomics reveals correct developmental dynamics and high-quality midbrain cell types by improved hESC differentiation
Nishimura K; Yang S; Lee KW; Asgrimsdottir ES; Nikouei K; Paslawski W; Gnodde S; Lyu G; Hu L; Salto C; Svenningsson P; Hjerling-Leffler J; Linnarsson S; Arenas E
Article: NEUROIMAGE-CLINICAL. 2023;37:103347
Longitudinal DAT changes measured with [18F]FE-PE2I PET in patients with Parkinson?s disease; a validation study
Kerstens VS; Fazio P; Sundgren M; Brumberg J; Halldin C; Svenningsson P; Varrone A
Article: NPJ PARKINSONS DISEASE. 2022;8(1):171
Impaired migratory phenotype of CD4⁺ T cells in Parkinson's disease
Mamula D; Khosousi S; He Y; Lazarevic V; Svenningsson P
Article: NEUROPSYCHOPHARMACOLOGY. 2022;47(13):2319-2329
TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT_1A receptor agonist SEP-383856
Saarinen M; Mantas I; Flais I; Agren R; Sahlholm K; Millan MJ; Svenningsson P
Article: PARKINSONISM & RELATED DISORDERS. 2022;105:139-144
Motor and nonmotor symptoms in patients treated with 24-hour daily levodopa-carbidopa intestinal gel infusion: Analysis of the COmedication Study assessing Mono- and cOmbination therapy with levodopa-carbidopa inteStinal gel (COSMOS)
Kovacs N; Szasz J; Vela-Desojo L; Svenningsson P; Femia S; Parra JC; Sanchez-Solino O; Bergmann L; Gurevich T; Fasano A
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;23(22):14290
Impaired Aversive Memory Formation in GPR37L1KO Mice
Veenit V; Zhang X; Paslawski W; Mantas I; Svenningsson P
Article: JOURNAL OF MOLECULAR NEUROSCIENCE. 2022;72(11):2313-2325
Prosaposin Reduces α-Synuclein in Cells and Saposin C Dislodges it from Glucosylceramide-enriched Lipid Membranes
Kojima R; Zurbruegg M; Li T; Paslawski W; Zhang X; Svenningsson P
Article: JOURNAL OF ALZHEIMERS DISEASE. 2022;90(1):333-348
High Soluble Amyloid-β₄₂ Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer's Disease-Causing Mutations
Sturchio A; Dwivedi AK; Malm T; Wood MJA; Cilia R; Sharma JS; Hill EJ; Schneider LS; Graff-Radford NR; Mori H; Nuebling G; El Andaloussi S; Svenningsson P; Ezzat K; Espay AJ
Article: SCIENTIFIC REPORTS. 2022;12(1):17578
Mitochondrial biogenesis, telomere length and cellular senescence in Parkinson's disease and Lewy body dementia
Asghar M; Odeh A; Fattahi AJ; Henriksson AE; Miglar A; Khosousi S; Svenningsson P
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;23(19):12056
Decreased Prosaposin and Progranulin in the Cingulate Cortex Are Associated with Schizophrenia Pathophysiology
He Y; Zhang X; Flais I; Svenningsson P
Article: MOVEMENT DISORDERS. 2022;37(10):2129-2134
Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels
te Vruchte D; Sturchio A; Priestman DA; Tsitsi P; Hertz E; Andreasson M; Markaki I; Wallom K-L; Platt F; Svenningsson P
Article: MOVEMENT DISORDERS. 2022;37(10):2110-2121
Common Variants Near ZIC1 and ZIC4 in Autopsy-Confirmed Multiple System Atrophy
Hopfner F; Tietz AK; Ruf VC; Ross OA; Koga S; Dickson D; Aguzzi A; Attems J; Beach T; Beller A; Cheshire WP; van Deerlin V; Desplats P; Deuschl G; Duyckaerts C; Ellinghaus D; Evsyukov V; Flanagan ME; Franke A; Frosch MP; Gearing M; Gelpi E; van Gerpen JA; Ghetti B; Glass JD; Grinberg LT; Halliday G; Helbig I; Hollerhage M; Huitinga I; Irwin DJ; Keene DC; Kovacs GG; Lee EB; Levin J; Marti MJ; Mackenzie I; McKeith I; Mclean C; Mollenhauer B; Neumann M; Newell KL; Pantelyat A; Pendziwiat M; Peters A; Porcel LM; Rabano A; Matej R; Rajput A; Rajput A; Reimann R; Scott WK; Seeley W; Selvackadunco S; Simuni T; Stadelmann C; Svenningsson P; Thomas A; Trenkwalder C; Troakes C; Trojanowski JQ; Uitti RJ; White CL; Wszolek ZK; Xie T; Ximelis T; Yebenes J; Mueller U; Schellenberg GD; Herms J; Kuhlenbaumer G; Hoeglinger G
Article: NEUROLOGY. 2022;99(10):e965-e976
Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease
Bergquist F; Ehrnebo M; Nyholm D; Johansson A; Lundin F; Odin P; Svenningsson P; Hansson F; Bring L; Eriksson E; Dizdar N
Article: SCIENCE ADVANCES. 2022;8(34):eabo1543
PRC2-mediated repression is essential to maintain identity and function of differentiated dopaminergic and serotonergic neurons
Toskas K; Yaghmaeian-Salmani B; Skiteva O; Paslawski W; Gillberg L; Skara V; Antoniou I; Sodersten E; Svenningsson P; Chergui K; Ringner M; Perlmann T; Holmberg J
Article: NEUROSCIENCE LETTERS. 2022;784:136767
Glucocerebrosidase variant T369M is not a risk factor for Parkinsons disease in Sweden
Ran C; Brodin L; Gellhaar S; Westerlund M; Fardell C; Nissbrandt H; Soderkvist P; Sydow O; Markaki I; Hertz E; Wirdefeldt K; Svenningsson P
Article: NPJ PARKINSONS DISEASE. 2022;8(1):71
α-Synuclein induced cholesterol lowering increases tonic and reduces depolarization-evoked synaptic vesicle recycling and glutamate release
Lazarevic V; Yang Y; Paslawski W; Svenningsson P
Article: FRONTIERS IN AGING NEUROSCIENCE. 2022;14:830704
Toward Novel [¹⁸F]Fluorine-Labeled Radiotracers for the Imaging of α-Synuclein Fibrils
Uzuegbunam BC; Li J; Paslawski W; Weber W; Svenningsson P; Agren H; Yousefi BH
Article: BEHAVIOURAL BRAIN RESEARCH. 2022;422:113763
Neural correlates of impaired response inhibition in the antisaccade task in Parkinson's disease
Waldthaler J; Vinding MC; Eriksson A; Svenningsson P; Lundqvist D
Article: NEUROPSYCHOLOGY. 2022;36(3):206-215
Changes in Emotion Processing in Early Parkinson's Disease Reflect Disease Progression
Eriksson A; Tsitsi P; Vinding MC; Ingvar M; Svenningsson P; Lundqvist D
Article: SCIENTIFIC REPORTS. 2022;12(1):2763
A replication study, systematic review and meta-analysis of automated image-based diagnosis in parkinsonism
Papathoma P-E; Markaki I; Tang C; Lindstrom ML; Savitcheva I; Eidelberg D; Svenningsson P
Article: NPJ PARKINSONS DISEASE. 2022;8(1):12
Behavioural and neuroplastic effects of a double-blind randomised controlled balance exercise trial in people with Parkinson's disease
Freidle M; Johansson H; Ekman U; Lebedev AV; Schalling E; Thompson WH; Svenningsson P; Lovden M; Abney A; Albrecht F; Steurer H; Leavy B; Holmin S; Hagstromer M; Franzen E
Article: ACS CHEMICAL BIOLOGY. 2022;17(1):147-158
Region-Specific and Age-Dependent Multitarget Effects of Acetylcholinesterase Inhibitor Tacrine on Comprehensive Neurotransmitter Systems
Fridjonsdottir E; Vallianatou T; Mantas I; Shariatgorji R; Nilsson A; Schembri LS; Odell LR; Svenningsson P; Andren PE
Article: JIMD REPORTS. 2022;63(1):93-100
Neurocognitive profile of adults with the Norrbottnian type of Gaucher disease
Tsitsi P; Markaki I; Waldthaler J; Machaczka M; Svenningsson P
Article: MOVEMENT DISORDERS. 2022;37(1):119-129
Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [¹¹C]PBR28 and Machine Learning Analysis
Jucaite A; Cselenyi Z; Kreisl WC; Rabiner EA; Varrone A; Carson RE; Rinne JO; Savage A; Schou M; Johnstrom P; Svenningsson P; Rascol O; Meissner WG; Barone P; Seppi K; Kaufmann H; Wenning GK; Poewe W; Farde L
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2021;23(1):410
The Effect of Early Life Stress on Emotional Behaviors in GPR37KO Mice
Veenit V; Zhang X; Ambrosini A; Sousa V; Svenningsson P
Article: MOLECULAR PSYCHIATRY. 2021;26(12):7308-7315
Ependymal cells-CSF flow regulates stress-induced depression
Seo J-S; Mantas I; Svenningsson P; Greengard P
Article: NEUROLOGY-GENETICS. 2021;7(6):e628
Adult-Onset Ataxia With Neuropathy and White Matter Abnormalities Due to a Novel SAMD9L Variant.
Paucar M; Tesi B; Eshtad S; Eriksson C; Hashim F; Nilsson D; Pourhamidi K; Hellström-Lindberg E; Bryceson YT; Svenningsson P
Article: FASEB JOURNAL. 2021;35(12):e22055
Cytosolic GPR37, but not GPR37L1, multimerization and its reversal by Parkin: A live cell imaging study
Li T; Oasa S; Ciruela F; Terenius L; Vukojevic V; Svenningsson P
Article: MOLECULAR PSYCHIATRY. 2021;26(12):7425-7435
Ketamine decreases neuronally released glutamate via retrograde stimulation of presynaptic adenosine A1 receptors
Lazarevic V; Yang Y; Flais I; Svenningsson P
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2021;22(23):12859
GM1 Is Cytoprotective in GPR37-Expressing Cells and Downregulates Signaling
Hertz E; Saarinen M; Svenningsson P
Article: SCIENTIFIC DATA. 2021;8(1):306
Wide-field mosaics of the corneal subbasal nerve plexus in Parkinson's disease using in vivo confocal microscopy
Badian RA; Allgeier S; Scarpa F; Andreasson M; Bartschat A; Mikut R; Colonna A; Bellisario M; Utheim TP; Koehler B; Svenningsson P; Lagali N
Article: OCULAR SURFACE. 2021;22:204-212
The pattern of the inferocentral whorl region of the corneal subbasal nerve plexus is altered with age
Badian RA; Andreasson M; Svenningsson P; Utheim TP; Lagali N
Article: NPJ PARKINSONS DISEASE. 2021;7(1):75
A non-invasive olfactory bulb measure dissociates Parkinson's patients from healthy controls and discloses disease duration
Iravani B; Arshamian A; Schaefer M; Svenningsson P; Lundstrom JN
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2021;22(16):8907
Trace Amine-Associated Receptor 1 Contributes to Diverse Functional Actions of O-Phenyl-Iodotyramine in Mice but Not to the Effects of Monoamine-Based Antidepressants
Mantas I; Millan MJ; Di Cara B; Groenink L; Veiga S; Cistarelli L; Brocco M; Bertrand M; Svenningsson P; Zhang X
Journal article: ANGEWANDTE CHEMIE-INTERNATIONAL EDITION. 2021;133(33):18170-18178
Structure‐Guided Design of G‐Protein‐Coupled Receptor Polypharmacology
Kampen S; Vo DD; Zhang X; Panel N; Yang Y; Jaiteh M; Matricon P; Svenningsson P; Brea J; Loza MI; Kihlberg J; Carlsson J
Article: ANGEWANDTE CHEMIE-INTERNATIONAL EDITION. 2021;60(33):18022-18030
Structure-Guided Design of G-Protein-Coupled Receptor Polypharmacology
Kampen S; Duy Vo D; Zhang X; Panel N; Yang Y; Jaiteh M; Matricon P; Svenningsson P; Brea J; Loza MI; Kihlberg J; Carlsson J
Article: MOVEMENT DISORDERS. 2021;36(8):1853-1862
Concomitant Medication Usage with Levodopa-Carbidopa Intestinal Gel: Results from the COSMOS Study
Fasano A; Gurevich T; Jech R; Kovacs N; Svenningsson P; Szasz J; Parra JC; Bergmann L; Johnson A; Sanchez-Solino O; Tang Z; Vela-Desojo L
Article: FRONTIERS IN NEUROSCIENCE. 2021;15:698633
Plasma Levels of Brain-Derived Neurotrophic Factor and S100B in Relation to Antidepressant Response to Ketamine
Jiang H; Veldman ER; Tiger M; Ekman C-J; Lundberg J; Svenningsson P
Article: ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY. 2021;8(7):1456-1470
Multi-cohort profiling reveals elevated CSF levels of brain-enriched proteins in Alzheimer's disease
Bergstrom S; Remnestal J; Yousef J; Olofsson J; Markaki I; Carvalho S; Corvol J-C; Kultima K; Kilander L; Lowenmark M; Ingelsson M; Blennow K; Zetterberg H; Nellgard B; Brosseron F; Heneka MT; Bosch B; Sanchez-Valle R; Manberg A; Svenningsson P; Nilsson P
Article: NATURE PROTOCOLS. 2021;16(7):3298-3321
Spatial visualization of comprehensive brain neurotransmitter systems and neuroactive substances by selective in situ chemical derivatization mass spectrometry imaging
Shariatgorji R; Nilsson A; Fridjonsdottir E; Strittmatter N; Dannhorn A; Svenningsson P; Goodwin RJA; Odell LR; Andren PE
Article: JOURNAL OF AFFECTIVE DISORDERS. 2021;290:240-244
P11 (S100A10) as a potential predictor of ketamine response in patients with SSRI-resistant depression
Veldman ER; Mamula D; Jiang H; Tiger M; Ekman C-J; Lundberg J; Svenningsson P
Article: MOLECULAR PSYCHIATRY. 2021;26(7):3253-3265
P11 deficiency increases stress reactivity along with HPA axis and autonomic hyperresponsiveness
Sousa VC; Mantas I; Stroth N; Hager T; Pereira M; Jiang H; Jabre S; Paslawski W; Stiedl O; Svenningsson P
Article: BIOLOGICAL PSYCHIATRY. 2021;90(1):16-27
TAAR1-Dependent and-Independent Actions of Tyramine in Interaction With Glutamate Underlie Central Effects of Monoamine Oxidase Inhibition
Mantas I; Vallianatou T; Yang Y; Shariatgorji M; Kalomoiri M; Fridjonsdottir E; Millan MJ; Zhang X; Andren PE; Svenningsson P
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2021;118(24):e1922586118
Involvement of Scratch2 in GalR1-mediated depression-like behaviors in the rat ventral periaqueductal gray
Yang Y; Li Y; Liu B; Li C; Liu Z; Deng J; Luo H; Li X; Wu J; Li H; Wang C-Y; Zhao M; Wu H; Lallemend F; Svenningsson P; Hokfelt TGM; Xu Z-QD
Article: NATURE COMMUNICATIONS. 2021;12(1):3400
A multicentre validation study of the diagnostic value of plasma neurofilament light
Ashton NJ; Janelidze S; Al Khleifat A; Leuzy A; van der Ende EL; Karikari TK; Benedet AL; Pascoal TA; Lleo A; Parnetti L; Galimberti D; Bonanni L; Pilotto A; Padovani A; Lycke J; Novakova L; Axelsson M; Velayudhan L; Rabinovici GD; Miller B; Pariante C; Nikkheslat N; Resnick SM; Thambisetty M; Scholl M; Fernandez-Eulate G; Gil-Bea FJ; Lopez de Munain A; Al-Chalabi A; Rosa-Neto P; Strydom A; Svenningsson P; Stomrud E; Santillo A; Aarsland D; van Swieten JC; Palmqvist S; Zetterberg H; Blennow K; Hye A; Hansson O
Article: JOURNAL OF PERSONALIZED MEDICINE. 2021;11(6):519
Does Information from the Parkinson KinetiGraph™ (PKG) Influence the Neurologist's Treatment Decisions?-An Observational Study in Routine Clinical Care of People with Parkinson's Disease
Sundgren M; Andreasson M; Svenningsson P; Noori R-M; Johansson A
Article: NATURE. 2021;594(7861):117-123
MIR-NATs repress MAPT translation and aid proteostasis in neurodegeneration
Simone R; Javad F; Emmett W; Wilkins OG; Almeida FL; Barahona-Torres N; Zareba-Paslawska J; Ehteramyan M; Zuccotti P; Modelska A; Siva K; Virdi GS; Mitchell JS; Harley J; Kay VA; Hondhamuni G; Trabzuni D; Ryten M; Wray S; Preza E; Kia DA; Pittman A; Ferrari R; Manzoni C; Lees A; Hardy JA; Denti MA; Quattrone A; Patani R; Svenningsson P; Warner TT; Plagnol V; Ule J; de Silva R
Article: MOVEMENT DISORDERS. 2021;36(6):1430-1434
Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease
Markaki I; Ntetsika T; Sorjonen K; Svenningsson P
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2021;41(6):1291-1300
Simplified quantification of [¹⁸F]FE-PE2I PET in Parkinson's disease: Discriminative power, test-retest reliability and longitudinal validity during early peak and late pseudo-equilibrium
Brumberg J; Kerstens V; Cselenyi Z; Svenningsson P; Sundgren M; Fazio P; Varrone A
Article: ACS CHEMICAL NEUROSCIENCE. 2021;12(10):1811-1823
Integration of Mass Spectrometry Imaging and Machine Learning Visualizes Region-Specific Age-Induced and Drug-Target Metabolic Perturbations in the Brain
Vallianatou T; Shariatgorji R; Nilsson A; Karlgren M; Hulme H; Fridjonsdottir E; Svenningsson P; Andren PE
Article: JOURNAL OF PARKINSONS DISEASE. 2021;11(2):865-875
Fixation Duration and Pupil Size as Diagnostic Tools in Parkinson's Disease
Tsitsi P; Benfatto MN; Seimyr GO; Larsson O; Svenningsson P; Markaki I
Article: NEUROGENETICS. 2021;22(1):71-79
Increasing involvement of CAPN1 variants in spastic ataxias and phenotype-genotype correlations
Mereaux J-L; Firanescu C; Coarelli G; Kvarnung M; Rodrigues R; Pegoraro E; Tazir M; Taithe F; Valter R; Huin V; Lidstrom K; Banneau G; Morais S; Parodi L; Coutelier M; Papin M; Svenningsson P; Azulay J-P; Alonso I; Nilsson D; Brice A; Le Guern E; Press R; Vazza G; Loureiro JL; Goizet C; Durr A; Paucar M; Stevanin G
Article: TRANSLATIONAL NEURODEGENERATION. 2021;10(1):8
Ecto-GPR37: a potential biomarker for Parkinson's disease
Morato X; Garcia-Esparcia P; Argerich J; Llorens F; Zerr I; Paslawski W; Borras E; Sabido E; Petaja-Repo UE; Fernandez-Duenas V; Ferrer I; Svenningsson P; Ciruela F
Article: NEUROLOGY-GENETICS. 2021;7(1):e546
V374A KCND3 Pathogenic Variant Associated With Paroxysmal Ataxia Exacerbations
Paucar M; Agren R; Li T; Lissmats S; Bergendal A; Weinberg J; Nilsson D; Savichetva I; Sahlholm K; Nilsson J; Svenningsson P
Article: BIOLOGICAL PSYCHIATRY. 2021;89(3):227-235
Genome-wide Association Analysis of Parkinson's Disease and Schizophrenia Reveals Shared Genetic Architecture and Identifies Novel Risk Loci
Smeland OB; Shadrin A; Bahrami S; Broce I; Tesli M; Frei O; Wirgenes KV; O'Connell KS; Krull F; Bettella F; Steen NE; Sugrue L; Wang Y; Svenningsson P; Sharma M; Pihlstrom L; Toft M; O'Donovan M; Djurovic S; Desikan R; Dale AM; Andreassen OA
Article: MOVEMENT DISORDERS. 2021;36(2):481-491
Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease
Niemela V; Landtblom A-M; Nyholm D; Kneider M; Constantinescu R; Paucar M; Svenningsson P; Abujrais S; Burman J; Shevchenko G; Bergquist J; Sundblom J
Article: MOVEMENT DISORDERS. 2021;36(2):508-514
A Novel Duplication inATXN2as Modifier for Spinocerebellar Ataxia 3 (SCA3) andC9ORF72-ALS
Laffita-Mesa JM; Nennesmo I; Paucar M; Svenningsson P
Article: FRONTIERS IN NEUROLOGY. 2021;11:589471
Tau Isoform-Driven CBD Pathology Transmission in Oligodendrocytes in Humanized Tau Mice
Zareba-Paslawska J; Patra K; Kluzer L; Revesz T; Svenningsson P
Article: SCIENCE ADVANCES. 2021;7(2):eabe5948
Mass spectrometry imaging identifies abnormally elevated brain L-DOPA levels and extrastriatal monoaminergic dysregulation in L-DOPA-induced dyskinesia
Fridjonsdottir E; Shariatgorji R; Nilsson A; Vallianatou T; Odell LR; Schembri LS; Svenningsson P; Fernagut P-O; Crossman AR; Bezard E; Andren PE
Article: NPJ PARKINSONS DISEASE. 2021;7(1):4
Parkinson's disease with restless legs syndrome-an in vivo corneal confocal microscopy study
Andreasson M; Lagali N; Badian RA; Utheim TP; Scarpa F; Colonna A; Allgeier S; Bartschat A; Koehler B; Mikut R; Reichert K-M; Solders G; Samuelsson K; Zetterberg H; Blennow K; Svenningsson P
Article: MOVEMENT DISORDERS CLINICAL PRACTICE. 2021;8(1):44-50
Associations Between Fluctuations in Daytime Sleepiness and Motor and Non-Motor Symptoms in Parkinson's Disease
Hoglund A; Hagell P; Broman J-E; Palhagen S; Sorjonen K; Fredrikson S; Svenningsson P
Article: MOVEMENT DISORDERS. 2020;35(12):2270-2278
Association and Familial Coaggregation of Idiopathic Dystonia with Psychiatric Outcomes
Martino D; Brander G; Svenningsson P; Larsson H; Fernandez de la Cruz L
Article: ANALYTICAL CHEMISTRY. 2020;92(21):14676-14684
Cross-validated Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging Quantitation Protocol for a Pharmaceutical Drug and Its Drug-Target Effects in the Brain Using Time-of-Flight and Fourier Transform Ion Cyclotron Resonance Analyzers
Kallback P; Vallianatou T; Nilsson A; Shariatgorji R; Schintu N; Pereira M; Barre F; Wadensten H; Svenningsson P; Andren PE
Article: PARKINSONISM & RELATED DISORDERS. 2020;80:S3-S6
Why target brain adenosine receptors? A historical perspective
Fredholm BB; Svenningsson P
Article: MOVEMENT DISORDERS. 2020;35(11):2101-2106
Cerebrospinal Fluid Levels of Kininogen-1 Indicate Early Cognitive Impairment in Parkinson's Disease
Markaki I; Bergstrom S; Tsitsi P; Remnestal J; Manberg A; Hertz E; Paslawski W; Sorjonen K; Uhlen M; Mangone G; Carvalho S; Rascol O; Meissner WG; Magnin E; Wuellner U; Corvol J-C; Nilsson P; Svenningsson P
Article: PARKINSONISM & RELATED DISORDERS. 2020;79:135-137
Involuntary movements, vocalizations and cognitive decline
Sveinsson O; Udd B; Svenningsson P; Gassner C; Engstrom C; Laffita-Mesa J; Solders G; Hertegard S; Savitcheva I; Jung HH; Tolnay M; Frey BM; Paucar M
Article: PARKINSONISM & RELATED DISORDERS. 2020;79:18-25
Automated brainstem volumetry can aid in the diagnostics of parkinsonian disorders
Sjostrom H; Granberg T; Hashim F; Westman E; Svenningsson P
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2020;47(10):2407-2416
High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson's disease cohort
Fazio P; Ferreira D; Svenningsson P; Halldin C; Farde L; Westman E; Varrone A
Article: NEUROPHARMACOLOGY. 2020;174:108136
NMDA receptors are altered in the substantia nigra pars reticulata and their blockade ameliorates motor deficits in experimental parkinsonism
Sitzia G; Mantas I; Zhang X; Svenningsson P; Chergui K
Article: EJNMMI RESEARCH. 2020;10(1):95
Reliability of dopamine transporter PET measurements with [¹⁸F]FE-PE2I in patients with Parkinson's disease
Kerstens VS; Fazio P; Sundgren M; Matheson GJ; Franzen E; Halldin C; Cervenka S; Svenningsson P; Varrone A
Article: JOURNAL OF INTERNAL MEDICINE. 2020;288(1):103-115
Broader phenotypic traits and widespread brain hypometabolism in spinocerebellar ataxia 27
Paucar M; Lundin J; Alshammari T; Bergendal A; Lindefeldt M; Alshammari M; Solders G; Di Re J; Savitcheva I; Granberg T; Laezza F; Iwarsson E; Svenningsson P
Article: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 2020;374(1):126-133
Effects of a Novel Psychomotor Stabilizer, IRL790, on Biochemical Measures of Synaptic Markers and Neurotransmission
Becanovic K; de Donno MV; Sousa VC; Tedroff J; Svenningsson P
Article: MOVEMENT DISORDERS. 2020;35(6):1046-1054
A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia
Svenningsson P; Odin P; Dizdar N; Johansson A; Grigoriou S; Tsitsi P; Wictorin K; Bergquist F; Nyholm D; Rinne J; Hansson F; Sonesson C; Tedroff J
Article: TRANSLATIONAL PSYCHIATRY. 2020;10(1):159
A randomized placebo-controlled PET study of ketamine′s effect on serotonin_1B receptor binding in patients with SSRI-resistant depression
Tiger M; Veldman ER; Ekman C-J; Halldin C; Svenningsson P; Lundberg J
Article: LAKARTIDNINGEN. 2020;117:FX4L
[Orthostatic tremor - a disregarded diagnosis].
Af Edholm Arvidsson K; Paucar M; Svenningsson P
Journal article: NEUROLOGY. 2020;94(15_supplement)
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in the Japanese and the Rest of the World Parkinson’s Disease Population With a GBA Mutation: Results from Part 1 of the MOVES-PD Study (809)
Peterschmitt MJ; Saiki H; Hatano T; Gasser T; Isaacson S; Kulisevsky J; Simuni T; Takahashi Y; Wills A-M; Guedes LC; Svenningsson P; Takahashi R; Waters C; Katsuno M; Ji AJ; Gaemers SJM; Minini P; Nembo B; Sardi P; Saubadu S; Sharma J; Fischer T
Article: JOURNAL OF PARKINSONS DISEASE. 2020;10(2):653-664
Individually Tailored Internet -Based Cognitive -Behavioral Therapy for Daily Functioning in Patients with Parkinsons Disease: A Randomized Controlled Trial
Kraepelien M; Schibbye R; Mansson K; Sundstrom C; Riggare S; Andersson G; Lindefors N; Svenningsson P; Kaldo V
Article: MOVEMENT DISORDERS. 2020;35(4):606-615
PET molecular imaging of phosphodiesterase 10A: An early biomarker of Huntington's disease progression
Fazio P; Fitzer-Attas CJ; Mrzljak L; Bronzova J; Nag S; Warner JH; Landwehrmeyer B; Al-Tawil N; Halldin C; Forsberg A; Ware J; Dilda V; Wood A; Sampaio C; Varrone A; Svenningsson P; Paucar M; Sundblom J; Nyholm D; Widner H; Heiberg A; Frich J; Nielsen J; Hjermind L; Roos R
Article: NEUROBIOLOGY OF DISEASE. 2020;137:104738
Simultaneous mass spectrometry imaging of multiple neuropeptides in the brain and alterations induced by experimental parkinsonism and L-DOPA therapy
Hulme H; Fridjonsdottir E; Gunnarsdottir H; Vallianatou T; Zhang X; Wadensten H; Shariatgorji R; Nilsson A; Bezard E; Svenningsson P; Andren PE
Article: FRONTIERS IN AGING NEUROSCIENCE. 2020;12:84
Deficits in Motor Performance, Neurotransmitters and Synaptic Plasticity in Elderly and Experimental Parkinsonian Mice Lacking GPR37
Zhang X; Mantas I; Fridjonsdottir E; Andren PE; Chergui K; Svenningsson P
Article: PARKINSONS DISEASE. 2020;2020:2410863-12
Feasibility Aspects of Exploring Exercise-Induced Neuroplasticity in Parkinson's Disease: A Pilot Randomized Controlled Trial
Johansson H; Freidle M; Ekman U; Schalling E; Leavy B; Svenningsson P; Hagstromer M; Franzen E
Article: FRONTIERS IN PHARMACOLOGY. 2020;11:304
Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses
Schintu N; Zhang X; Stroth N; Mathe AA; Andren PE; Svenningsson P
Article: LAKARTIDNINGEN. 2020;117:FU7H
[Recent advances in Huntington's disease].
Niemelä V; Petersén Å; Loutfi G; Svenningsson P; Paucar M
Article: LAKARTIDNINGEN. 2020;117:FWED
[Parkinson's disease - heterogeneous and complex in its clinical presentation].
Bergquist F; Johansson A; Dizdar N; Widner H; Nyholm D; Odin P; Svenningsson P
Article: LAKARTIDNINGEN. 2020;117:FX4F
[Ataxia - a group of heterogeneous diseases].
Paucar M; Dahl N; Engvall M; Svenningsson P; Solders G
Article: ALZHEIMERS & DEMENTIA. 2020;16(2):292-304
Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study
Brosseron F; Kolbe C-C; Santarelli F; Carvalho S; Antonell A; Castro-Gomez S; Tacik P; Namasivayam AA; Mangone G; Schneider R; Latz E; Wuellner U; Svenningsson P; Sanchez-Valle R; Luis Molinuevo J; Corvol J-C; Heneka MT
Article: BRAIN COMMUNICATIONS. 2020;2(1):fcaa052
Reduction of spontaneous cortical beta bursts in Parkinson's disease is linked to symptom severity
Vinding MC; Tsitsi P; Waldthaler J; Oostenveld R; Ingvar M; Svenningsson P; Lundqvist D
Article: NEUROPHARMACOLOGY. 2020;162:107829
Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia
Mantas I; Yang Y; Mannoury-la-Cour C; Millan MJ; Zhang X; Svenningsson P
Article: INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH. 2019;42(4):371-376
Pain in persons with mild-moderate Parkinson's disease: a cross-sectional study of pain severity and associated factors
Joseph C; Jonsson-Lecapre J; Wicksell R; Svenningsson P; Franzen E
Article: BMC NEUROLOGY. 2019;19(1):280
The EXPANd trial: effects of exercise and exploring neuroplastic changes in people with Parkinson's disease: a study protocol for a double-blinded randomized controlled trial
Franzen E; Johansson H; Freidle M; Ekman U; Wallen MB; Schalling E; Lebedev A; Lovden M; Holmin S; Svenningsson P; Hagstromer M
Article: NEUROPSYCHOPHARMACOLOGY. 2019;44(12):2091-2098
Molecular imaging identifies age-related attenuation of acetylcholine in retrosplenial cortex in response to acetylcholinesterase inhibition
Vallianatou T; Shariatgorji M; Nilsson A; Fridjonsdottir E; Kallback P; Schintu N; Svenningsson P; Andren PE
Article: SCIENTIFIC REPORTS. 2019;9(1):15358
Polyneuropathy in Gaucher disease type 1 and 3-a descriptive case series
Andreasson M; Solders G; Bjorkvall CK; Machaczka M; Svenningsson P
Article: JOURNAL OF PARKINSONS DISEASE. 2019;9(4):705-709
Plasma IL-6 and IL-17A Correlate with Severity of Motor and Non-Motor Symptoms in Parkinson's Disease
Green HF; Khosousi S; Svenningsson P
Journal article: TREMOR AND OTHER HYPERKINETIC MOVEMENTS. 2019;9(0)
Progressive Ataxia with Elevated Alpha-Fetoprotein: Diagnostic Issues and Review of the Literature
Paucar M; Taylor AMR; Hadjivassiliou M; Fogel BL; Svenningsson P
Article: NATURE METHODS. 2019;16(10):1021-1028
Comprehensive mapping of neurotransmitter networks by MALDI-MS imaging
Shariatgorji M; Nilsson A; Fridjonsdottir E; Vallianatou T; Kallback P; Katan L; Savmarker J; Mantas I; Zhang X; Bezard E; Svenningsson P; Odell LR; Andren PE
Article: PARKINSONISM & RELATED DISORDERS. 2019;66:158-165
Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study
Puschmann A; Jimenez-Ferrer I; Lundblad-Andersson E; Martensson E; Hansson O; Odin P; Widner H; Brolin K; Mzezewa R; Kristensen J; Soller M; Rodstrom EY; Ross OA; Toft M; Breedveld GJ; Bonifati V; Brodin L; Zettergren A; Sydow O; Linder J; Wirdefeldt K; Svenningsson P; Nissbrandt H; Belin AC; Forsgren L; Swanberg M
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2019;20(17):E4247-4247
Fluoxetine Suppresses Glutamate- and GABA-Mediated Neurotransmission by Altering SNARE Complex
Lazarevic V; Mantas I; Flais I; Svenningsson P
Article: NEUROLOGY-GENETICS. 2019;5(4):e344
Altered CSF levels of monoamines in hereditary spastic paraparesis 10 A case series
Andreasson M; Lagerstedt-Robinson K; Samuelsson K; Solders G; Blennow K; Paucar M; Svenningsson P
Article: NEUROSCIENCE LETTERS. 2019;706:217-222
GBA RNAi but not catalytic inhibition of glucocerebrosidase with Conduritol-β-epoxide increases levels of total α-synuclein in SH-SY5Y cells
Zurbruegg M; Chan M-Y; Svenningsson P
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2019;116(30):15226-15235
α-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients
Paslawski W; Zareba-Paslawska J; Zhang X; Holzl K; Wadensten H; Shariatgorji M; Janelidze S; Hansson O; Forsgren L; Andren PE; Svenningsson P
Article: FRONTIERS IN NEUROSCIENCE. 2019;13:697
GRP78 Level Is Altered in the Brain, but Not in Plasma or Cerebrospinal Fluid in Parkinson's Disease Patients
Baek J-H; Mamula D; Tingstam B; Pereira M; He Y; Svenningsson P
Article: ACTA NEUROPATHOLOGICA. 2019;138(1):23-47
Binding of -synuclein oligomers to Cx32 facilitates protein uptake and transfer in neurons and oligodendrocytes
Reyes JF; Sackmann C; Hoffmann A; Svenningsson P; Winkler J; Ingelsson M; Hallbeck M
Article: NEUROPHARMACOLOGY. 2019;152:51-57
GPR37 and GPR37L1 differently interact with dopamine 2 receptors in live cells
Hertz E; Terenius L; Vukojevic V; Svenningsson P
Article: NPJ PARKINSONS DISEASE. 2019;5:11
Vertical saccades and antisaccades: complementary markers for motor and cognitive impairment in Parkinson's disease
Waldthaler J; Tsitsi P; Svenningsson P
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2019;20(11):E2631-2631
MCEE Mutations in an Adult Patient with Parkinson's Disease, Dementia, Stroke and Elevated Levels of Methylmalonic Acid
Andreasson M; Zetterstroem RH; von Doebeln U; Wedell A; Svenningsson P
Article: JOURNAL OF PARKINSONS DISEASE. 2019;9(2):361-367
Decreased Cerebrospinal Fluid Aβ₄₂ in Patients with Idiopathic Parkinson's Disease and White Matter Lesions
Markaki I; Klironomos S; Svenningsson P
Article: SCIENTIFIC REPORTS. 2019;9(1):6079
Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism
Sjostrom H; Surova Y; Nilsson M; Granberg T; Westman E; van Westen D; Svenningsson P; Hansson O
Journal article: NEUROLOGY. 2019;92(15_supplement)
Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson’s disease patients with a GBA mutation (S4.002)
Fischer T; Gasser T; Isaacson S; Kulisevsky J; Mir P; Simuni T; Wills AM; Guedes LC; Svenningsson P; Waters C; Ji A; Li J; Minini P; Nembo B; Sardi SP; Saubadu S; Sharma J; Peterschmitt MJ
Article: STEM CELL REPORTS. 2019;12(4):696-711
SQSTM1/p62-Directed Metabolic Reprogramming Is Essential for Normal Neurodifferentiation
Calvo-Garrido J; Maffezzini C; Schober FA; Clemente P; Uhlin E; Kele M; Stranneheim H; Lesko N; Bruhn H; Svenningsson P; Falk A; Wedell A; Freyer C; Wredenberg A
Article: AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS. 2019;180(3):232-245
Identification of symbol digit modality test score extremes in Huntington's disease
Braisch U; Muche R; Rothenbacher D; Landwehrmeyer GB; Long JD; Orth M; Bachoud-Levi A-C; Bentivoglio A-R; Biunno I; Bonelli RM; Burgunder J-M; Dunnett SB; Ferreira JJ; Handley OJ; Heiberg A; Illmann T; Landwehrmeyer GB; Levey J; Ramos-Arroyo M; Nielsen JE; Koivisto SP; Paivarinta M; Roos RAC; Sebastian AR; Tabrizi SJ; Vandenberghe W; Verellen-Dumoulin C; Uhrova T; Wahlstrom J; Zaremba J; Baake V; Barth K; Bos R; Come A; Guedes LC; Finisterra AM; Garde MB; Bos R; Betz S; Callaghan J; Capodarca S; Wildson SC; da Silva V; Di Renzo M; Ecker D; Finisterra M; Fullam R; Genoves C; Gilling M; Handley OJ; Hvalstedt C; Held C; Koppers K; Lamanna C; Laura M; Descals AM; Martinez-Horta S; Mestre T; Minster S; Monza D; Mutze L; Oehmen M; Padieu H; Paterski L; Peppa N; Koivisto SP; Rindal B; Roren N; Sasinkova P; Seliverstov Y; Timewell E; Townhill J; Cubillo PT; van Walsem MR; Witjes-Ane M-N; Witkowski G; Wright A; Yudina E; Zielonka D; Zielonka E; Zinzi P; Braunwarth E-M; Brugger F; Buratti L; Hametner E-M; Hepperger C; Holas C; Hotter A; Hussl A; Larcher B; Mahlknecht P; Muller C; Pinter B; Poewe W; Seppi K; Sprenger F; Wenning G; Dupuis M; Minet C; Ribai P; Van Paemel D; Verellen-Dumoulin C; Klempir J; Majerova V; Roth J; Babiloni B; Debruxelles S; Duche C; Goizet C; Jameau L; Lafoucriere D; Spampinato U; Bachoud-Levi A-C; Boisse M-F; de langavant LC; Lemoine L; Morgado G; Youssov K; Annic A; Barthelemy R; De Bruycker C; Cabaret M; Carette A-S; Carriere N; Decorte E; Defebvre L; Delliaux M; Delval A; Depelchin A; Destee A; Dewulf-Pasz N; Dondaine T; Dugauquier F; Dujardin K; Krystkowiak P; Lemaire M-H; Manouvrier S; Peter M; Plomhause L; Sablonniere B; Simonin C; Tard C; Thibault-Tanchou S; Vuillaume I; Bellonet M; Benoit A; Blin S; Courtin F; Duru C; Fasquel V; Godefroy O; Krystkowiak P; Mantaux B; Roussel M; Tir M; Schuler B; Wannepain S; Azulay J-P; Chabot C; Delfini M; Eusebio A; Fluchere F; Grosjean H; Mundler L; Nowak M; Bioux S; Bliaux E; Girard C; Guyant-Marechal L; Hannequin D; Hannier V; Jourdain S; Maltete D; Pouliquen D; Blondeau L; Calvas F; Cheriet S; Delabaere H; Demonet J-F; Pariente J; Pierre M; Beuth M; Gelderblom H; Priller J; Pruess H; Spruth E; Thiel S; Ellrichmannberlin G; Herrmann L; Hoffmann R; Kaminski B; Saft C; Bosredon C; Hunger U; Lohle M; Maass A; Ossig C; Schmidt S; Storch A; Wolz A; Wolz M; Kohl Z; Kozay C; Ullah J; Winkler J; Bergmann U; Boeringer R; Capetian P; Kammel G; Lambeck J; Meier S; Rijntjes M; Zucker B; Boelmans K; Ganos C; Goerendt I; Heinicke W; Hidding U; Lewerenz J; Munchau A; Orth M; Schmalfeld J; Stubbe L; Zittel S; Diercks G; Dressler D; Francis F; Gayde-Stephan S; Gorzolla H; Kramer B; Minschke R; Schrader C; Tacik P; Longinus B; Luesebrink A; Muhlau M; Peinemann A; Staedtler M; Weindl A; Winkelmann J; Ziegler C; Bechtel N; Beckmann H; Bohlen S; Goepfert N; Hoelzner E; Lange H; Reilmann R; Rohm S; Rumpf S; Sass C; Schepers S; Weber N; Barth K; Buck A; Connemann J; Ecker D; Geitner C; Held C; Kesse A; Landwehrmeyer B; Lezius F; Lewerenz J; Nepper S; Niess A; Orth M; Schneider A; Schwenk D; Sussmuth S; Trautmann S; Weydt P; Klebe S; Musacchio T; Leypold C; Noeth K; Cormio C; de Tommaso M; Franco G; Sciruicchio V; Serpino C; Calandra-Buonaura G; Capellari S; Cortelli P; Gallassi R; Poda R; Sambati L; Scaglione C; Maserati MS; Agosti C; Barlati S; Compostella S; Marchina E; Padovani A; Bertini E; Ghelli E; Ginestroni A; Mechi C; Paganini M; Piacentini S; Pradella S; Romoli AM; Sorbi S; Abbruzzese G; di Poggio MB; Ferrandes G; Mandich P; Marchese R; Tamburini T; Baake V; van den Bogaard SJA; Bos R; Dumas EM; t'Hart EP; Kampstra A; Roos RAC; Schoonderbeek A; Aaserud O; Bjorgo K; Borgeod N; Dramstad E; Fannemel M; Frich JC; Gorvell PF; Heiberg A; Lorentzen E; Retterstol L; Rosby O; Sikiric A; Stokke B; van Walsem M; Wehus R; Bjornevoll I; Sando SB; Haug MG; Storseth HH; Arntsen V; Dziadkiewicz A; Konkel A; Narozanska E; Nowak M; Robowski P; Sitek E; Slawek J; Soltan W; Szinwelski M; Arkuszewski M; Blaszczyk M; Boczarska-Jedynak M; Ciach-Wysocka E; Gorzkowska A; Nska-Myga BJ; Kaczmarczyk A; Klodowska-Duda G; Opala G; Rudzinska M; Stompel D; Banaszkiewicz K; Bocwinska D; Bojakowska-Jaremek K; Dec M; Grabska N; Krawczyk M; Kubowicz E; Malec-Litwinowicz M; Rudzinska M; Stenwak A; Szczudlik A; Szczygiel E; Wojcik M; Wasielewska A; Bryl JAA; Ciesielska A; Klimberg A; Marcinkowski J; Samara H; Sempolowicz J; Sniewski BW; Zielonka D; Gogol A; Janik P; Jamrozik Z; Kaminska A; Kwiecinski H; Antczak J; Jachinska K; Krysa W; Rakowicz M; Richter P; Rola R; Ryglewicz D; Sienkiewicz-Jarosz H; Stepniak I; Sulek A; Witkowski G; Zaremba J; Zdzienicka E; Ziora-Jakutowicz K; Januario C; Julio F; Guedes LC; Coelho M; Finisterra AM; Ferreira JJ; Mestre T; Mendes T; Rosa MM; Valadas A; Kopishinskaya S; Korotysh M; Duran Herrera C; Garcia Moreno P; Bas J; Busquets N; Calopa M; Jauma Classen S; Rodriguez Dedicha N; Teresa Buongiorno M; de la Cerda Santa Maria A; Munoz E; Santacruz P; Aguilar Barbera M; Rojo Sebastian A; Arribas Pardo S; Badenes Guia D; Calzado N; Casas Hernanz L; Tartari Diaz-Zorita JP; Lopez Catena J; Quilez Ferrer P; Tome Carruesco G; Floriach Robert M; Mareca Viladrich C; Roca E; Miguel Ruiz Idiago J; Villa Riballo A; Campolongo A; Fernandez de Bobadilla R; Kulisevsky Bojarsky J; Martinez-Horta S; Pagonabarraga J; Perez Perez J; Ribosa R; Villa C; Angeles Acera Gil M; Berganzo Corrales K; Carlos Gomez Esteban J; Gonzalez A; Merino BT; Cubo E; Gil Polo C; Mariscal N; Gutierrez Romero S; Matias Arbelo J; Malo de Molina R; Martin I; Manuel Perianez J; Udaeta B; Alonso-Frech F; Frades B; Avila Villanueva M; Ascension Zea Sevilla M; Alonso Frech F; del Mar Fenollar M; Garcia-Ramos Garcia R; Villanueva C; Bascunana M; Fatas Ventura M; Ribas GG; de Yebenes JG; Lopez-Sendon Moreno JL; Mananes Barral V; Trigo Cubillo P; Garcia Ruiz PJ; Garcia A; Guerrero Lopez R; Herranz Barcenas A; Martinez-Descals A; Puertas Martin V; Rodriguez Martinez N; Sainz Artiga MJ; Sanchez V; Pueyo AM; Gonzalez S; Menendez Guisasola L; Rene Ribacoba MPP; Salvador C; Sanchez Lozano P; Garcia Caldentey J; Legarda Ramirez I; Navas Arques P; Rodriguez Lopera M; Vives Pastor B; Gaston I; Garcia-Amigot F; Dolores Martinez-Jaurrieta M; Antonia Ramos-Arroyo M; Carrillo F; Caceres Redondo MT; Mir P; Vargas Gonzalez L; Garcia Moreno JM; Mendez Lucena C; Chacon Pena J; Redondo L; Sanchez Sanchez V; Melgar Fernandez C; Paredes Mata M; Romero Lemos MD; Bosca M; Andres Burguera J; Carmen Peiro Vilaplana FCB; Solis P; Jeweinat Figuerola B; Millan Palanca P; Berglund P; Constantinescu R; Fredlund G; Hosterey-Ugander U; Linnsand P; Neleborn-Lingefjard L; Wahlstrom J; Palhagen S; Svenningsson P; Paucar M; Wallden T; Ekwall C; Goller M-L; Sundblom J; Burgunder J-M; Stebler Y; Kaelin A; Romero I; Schupbach M; Zaugg SW; Jung H; Petersen J; Auer M; Harrower T; Vernon N; Akhtar S; Crooks J; Curtis A; de Souza J; Piedad J; Rickards H; Wright J; Coleman C; Craven J; Haig-Brown D; Pallett A; Simpson S; Weekes R; Coulthard E; Gethin L; Hayward B; Sieradzan K; Wright A; Busse M; Butcher C; Dunnett S; Clenaghan C; Fullam R; Hunt S; Jones L; Jones U; Khalil H; Minster S; Owen M; Price K; Townhill J; Rosser A; Edwards M; Ho C; McGill M; Porteous M; Pearson P; Harrower T; Irvine S; Brockie P; Foster J; Johns N; McKenzie S; Rothery J; Thomas G; Yates S; Deith C; Ireland J; Ritchie S; Andrew A; Frost J; Noad R; Cosgrove J; Gallantree D; Hamer S; Hobson E; Jamieson S; Kraus A; Longthorpe M; Markova I; Musgrave H; Peacy C; Raman A; Rowett L; Toscano J; Wild S; Yardumian P; Clayton C; Dipple H; Freire-Patino D; Hallam C; Middleton J; Alusi S; Davies R; Foy K; Gerrans E; Leggett H; Pate L; Anjum U; Coebergh J; Eddy C; Lahiri N; McEntagart M; Patton M; Peterson M; Rose S; Andrews T; Brown S; Bruno S; Chu E; Doherty K; Golding C; Haider S; Hensman D; Lahiri N; Lewis M; Novak M; Patel A; Robertson N; Rosser E; Tabrizi S; Taylor R; Warner T; Wild E; Arran N; Bek J; Callaghan J; Craufurd D; Fullam R; Hare M; Howard L; Huson S; Johnson L; Jones M; Krishnamoorthy A; Murphy H; Oughton E; Partington-Jones L; Rogers D; Sollom A; Snowden J; Stopford C; Thompson J; Tinkler P; Trender-Gerhard I; Verstraelen N; Westmoreland L; Cass G; Davidson L; Davison J; Fullerton N; Holmes K; Komati S; McDonnell S; Mohammed Z; Morgan K; Savage L; Singh B; Wood J; Chu E; Knight C; O'Neill M; Das Purkayastha D; Nemeth AH; Siuda G; Valentine R; Dixon K; Armstrong R; Harrison D; Hughes M; Large S; Donovan JO; Palmer A; Parkinson A; Soltysiak B; Timings L; Williams J; Burn J; Weekes R; Craven J; Bailey W; Coleman C; Haig-Brown D; Simpson S; Hare M; Majeed T; Verstraelen N; Bandmann O; Bradbury A; Fairtlough H; Fillingham K; Foustanos I; Gill P; Kazoka M; O'Donovan K; Nevitt L; Peppa N; Quarrell O; Taylor C; Tidswell K; O'Donovan K; Agarwal V; Anderson M; Gunner K; Harris K; Hayward E; Heywood M; Keys L; Kipps C; MacKinnon L; Smalley S; Gowers L; Powell K; Bethwaite P; Edwards R; Fuller K; Phillips M; Tan L; Burgunder J-M; Lau PN; Pica E; Shoulson I; Gusella JG; Foroud T; Antonijevic I; vankammen D; Foroud T; Dorsey R; Warner J; Giuliano J; Vetter L; Suchowersky O; Beck C; Oakes D; Marshall F; Marder K; Frucht S; Moskowitz C; Clouse R; Wasserman P; Shannon K; Jaglin J; Jankovic J; Palao A; Harrison M; Singer C; Quesada M; Hersch S; Rosas D; Tanev K; Malarick K; Colcher A; Sanchez-Ramos J; Kostyk S; Paulsen J; Perlmutter J; Tabbal S; Ross C; Dorsey R; Nucifora F; Dubinsky R; Dubinsky H; Suchowersky O; Klimek ML; Jones R; Testa C; Morgan J; Mohlo E; Kang U; Agarwal P; Factor S; Jennings D; Higgins D; Adams J; Frank S; Saint-Hilaire M; Diggin M; Furtado S; Walker F; O'Neill C; Hunt V; Quaid K; LeDoux M; Raymond L; Leavitt B; Decolongon J; Perlman S; Peavy G; Goldstein J; Kumar R; McCusker E; Griffith J; Loy C; Wheelock V; Tempkin T; Martin A; Nance M; Mallonee W; Suter G; Revilla F; Gartner M; Drazinic C; Fitzpatrick MJ; Panisset M; Duff K; Scott B; Weiner W; Robottom B; Chiu E; Yastrubetskaya O; Churchyard A; Greenamyre TJ; Oakes D; Beck C; Robertson S; Eaton K; Lindsay P; Deuel L; MacDonald M; Hickey C; Muratori L; Louis E; Leserman A; Doucette N; Uc E; Rodnitzky R; Vik S; Davis R; Dietrich S; Segro V; Erickson D; Hunt V; Lucarelli N; Broyles J; Delarosa J; Louis E; Panegyres P; Schmidt A; Barton S; Sperin E; Testa C; Thiede F; Zauber SE; Wesson M; McInnis R; Welsh C; Wesson M; Coleman A
Article: MOVEMENT DISORDERS CLINICAL PRACTICE. 2019;6(3):254-258
First Clinicogenetic Description of Parkinson's Disease Related to GBA Mutation S107L
Hertz E; Thornqvist M; Holmberg B; Machaczka M; Sidransky E; Svenningsson P
Article: HEALTH INFORMATICS JOURNAL. 2019;25(1):91-105
Patients are doing it for themselves: A survey on disease-specific knowledge acquisition among people with Parkinson's disease in Sweden
Riggare S; Hoglund PJ; Forsberg HH; Eftimovska E; Svenningsson P; Hagglund M
Article: SCIENTIFIC REPORTS. 2019;9(1):2604
Attenuated beta rebound to proprioceptive afferent feedback in Parkinson's disease
Vinding MC; Tsitsi P; Piitulainen H; Waldthaler J; Jousmaki V; Ingvar M; Svenningsson P; Lundqvist D
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2019;46(2):367-375
PET imaging of [¹¹C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding
Varnas K; Cselenyi Z; Jucaite A; Halldin C; Svenningsson P; Farde L; Varrone A
Article: CEREBELLUM AND ATAXIAS. 2019;6:9
The cerebellar phenotype of Charcot-Marie-Tooth neuropathy type 4C.
Skott H; Muntean-Firanescu C; Samuelsson K; Verrecchia L; Svenningsson P; Malmgren H; Cananau C; Espay AJ; Press R; Solders G; Paucar M
Article: NPJ PARKINSONS DISEASE. 2018;4:35
Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia-a phase 1b trial
Svenningsson P; Johansson A; Nyholm D; Tsitsi P; Hansson F; Sonesson C; Tedroff J
Article: NEUROPHARMACOLOGY. 2018;143:38-48
Riluzole attenuates the efficacy of glutamatergic transmission by interfering with the size of the readily releasable neurotransmitter pool
Lazarevic V; Yang Y; Ivanova D; Fejtova A; Svenningsson P
Article: PARKINSONISM & RELATED DISORDERS. 2018;:S1353-8020(18)30399-7
WITHDRAWN: Novel Xp21.1 deletion associated with unusual features in a large McLeod syndrome kindred.
Sveinsson O; Udd B; Svenningsson P; Gassner C; Engström C; Laffita-Mesa JM; Solders G; Hertegård S; Savitcheva I; Jung HH; Tolnay M; Frey BM; Paucar M
Article: MOLECULAR PSYCHIATRY. 2018;23(10):2066-2077
Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit
Yao N; Skiteva O; Zhang X; Svenningsson P; Chergui K
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2018;115(37):E8765-E8774
Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition
Siebzehnrubl FA; Reber KA; Urbach YK; Schulze-Krebs A; Canneva F; Moceri S; Habermeyer J; Achoui D; Gupta B; Steindler DA; Stephan M; Huu PN; Bonin M; Riess O; Bauer A; Aigner L; Couillard-Despres S; Paucar MA; Svenningsson P; Osmand A; Andreew A; Zabel C; Weiss A; Kuhn R; Moussaoui S; Blockx I; Van der Linden A; Cheong RY; Roybon L; Petersen A; von Hoersten S
Article: FRONTIERS IN NEUROLOGY. 2018;9:756
24S-Hydroxycholesterol Correlates With Tau and Is Increased in Cerebrospinal Fluid in Parkinson's Disease and Corticobasal Syndrome
Bjorkhem I; Patra K; Boxer AL; Svenningsson P
Article: FRONTIERS IN GENETICS. 2018;9:317
Pathological Study of a FMR1 Premutation Carrier With Progressive Supranuclear Palsy
Paucar M; Nennesmo I; Svenningsson P
Article: NEUROLOGY-GENETICS. 2018;4(4):e259
GLRA1 mutation and long-term follow-up of the first hyperekplexia family
Paucar M; Waldthaler J; Svenningsson P
Article: CEREBELLUM. 2018;17(4):465-476
Novel Features and Abnormal Pattern of Cerebral Glucose Metabolism in Spinocerebellar Ataxia 19
Paucar M; Bergendal A; Gustavsson P; Nordenskjold M; Laffita-Mesa J; Savitcheva I; Svenningsson P
Journal article: JOURNAL OF HUNTINGTON'S DISEASE. 2018;7(3):209-222
Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study
McNulty P; Pilcher R; Ramesh R; Necuiniate R; Hughes A; Farewell D; Holmans P; Jones L
Journal article: ALZHEIMERS & DEMENTIA. 2018;14(7S_Part_29):p1547-p1548
P4‐264: A GENE THERAPY APPROACH FOR REDUCTION OF TAU BY TAU LONG NON‐CODING RNA GENE (MAPT‐AS1) NATURAL ANTISENSE TRANSCRIPT
de Silva R; Zareba-Paslawska J; Almeida F; Svenningsson P; Warner T; Simone R
Article: JOURNAL OF MEDICINAL CHEMISTRY. 2018;61(12):5269-5278
Docking Screens for Dual Inhibitors of Disparate Drug Targets for Parkinson's Disease
Jaiteh M; Zeifman A; Saarinen M; Svenningsson P; Brea J; Loza MI; Carlsson J
Article: TRAFFIC. 2018;19(9):690-709
Dynamic lateral organization of opioid receptors (kappa, mu_wt and mu_N40D) in the plasma membrane at the nanoscale level
Rogacki MK; Golfetto O; Tobin SJ; Li T; Biswas S; Jorand R; Zhang H; Radoi V; Ming Y; Svenningsson P; Ganjali D; Wakefield DL; Sideris A; Small AR; Terenius L; Jovanovic-Talisman T; Vukojevic V
Article: NEUROIMAGE. 2018;172:808-816
A mass spectrometry imaging approach for investigating how drug-drug interactions influence drug blood-brain barrier permeability
Vallianatou T; Strittmatter N; Nilsson A; Shariatgorji M; Hamm G; Pereira M; Kallback P; Svenningsson P; Karlgren M; Goodwin RJA; Andren PE
Article: MOVEMENT DISORDERS. 2018;33(4):592-599
Nigrostriatal dopamine transporter availability in early Parkinson's disease
Fazio P; Svenningsson P; Cselenyi Z; Halldin C; Farde L; Varrone A
Article: FRONTIERS IN PHARMACOLOGY. 2018;9:166
Striatal Tyrosine Hydroxylase Is Stimulated via TAAR1 by 3-Iodothyronamine, But Not by Tyramine or β-Phenylethylamine
Zhang X; Mantas I; Alvarsson A; Yoshitake T; Shariatgorji M; Pereira M; Nilsson A; Kehr J; Andren PE; Millan MJ; Chergui K; Svenningsson P
Article: BLOOD CELLS MOLECULES AND DISEASES. 2018;68:86-92
Novel hyperkinetic dystonia-like manifestation and neurological disease course of Swedish Gaucher patients
Machaczka M; Paucar M; Bjorkvall CK; Smith NJC; Cox TM; Forsgren L; Svenningsson P
Journal article: TREMOR AND OTHER HYPERKINETIC MOVEMENTS. 2017;7(0):529
Paroxysmal Kinesigenic Dyskinesia
Paucar M; Malmgren H; Svenningsson P
Article: PARKINSONISM & RELATED DISORDERS. 2017;44:51-57
Quantitative susceptibility mapping differentiates between parkinsonian disorders
Sjostrom H; Granberg T; Westman E; Svenningsson P
Article: METHODS OF INFORMATION IN MEDICINE. 2017;56(99):e123-e128
Patient-driven N-of-1 in Parkinson's Disease Lessons Learned from a Placebo-controlled Study of the Effect of Nicotine on Dyskinesia
Riggare S; Unruh KT; Sturr J; Domingos J; Stamford JA; Svenningsson P; Hagglund M
Article: JOURNAL OF PARKINSONS DISEASE. 2017;7(4):619-628
Correlations Between Methionine Cycle Metabolism, COMT Genotype, and Polyneuropathy in L-Dopa Treated Parkinson's Disease: A Preliminary Cross-Sectional Study
Andreasson M; Brodin L; Laffita-Mesa JM; Svenningsson P
Article: NEUROPSYCHOLOGY. 2017;31(6):605-612
Patients With Parkinson's Disease Display a Dopamine Therapy Related Negative Bias and an Enlarged Range in Emotional Responses to Facial Emotional Stimuli
Lundqvist D; Svard J; Palmquist AM; Fischer H; Svenningsson P
Article: NEUROLOGY. 2017;89(8):845-853
In vivo retention of ¹⁸F-AV-1451 in corticobasal syndrome
Smith R; Scholl M; Widner H; van Westen D; Svenningsson P; Hagerstrom D; Ohlsson T; Jogi J; Nilsson C; Hansson O
Journal article: ALZHEIMERS & DEMENTIA. 2017;13(7S_Part_3):p146-p147
[IC‐P‐199]: [18]F‐AV‐1451 PET IN CLINICALLY DIAGNOSED CORTICOBASAL DEGENERATION
Smith R; Schöll M; Widner H; van Westen D; Svenningsson P; Hagerstrom D; Ohlsson T; Jögi J; Nilsson C; Hansson O
Article: FRONTIERS IN NEUROLOGY. 2017;8:295
Saccadic Impairments in Patients with the Norrbottnian From of Gaucher's Disease Type 3
Blume J; Beniaminov S; Bjorkvall CK; Machaczka M; Svenningsson P
Article: FRONTIERS IN PSYCHIATRY. 2017;8:102
Neuropeptide Y and Calcitonin Gene-Related Peptide in Cerebrospinal Fluid in Parkinson's Disease with Comorbid Depression versus Patients with Major Depressive Disorder
Svenningsson P; Palhagen S; Mathe AA
Article: MOLECULAR PSYCHIATRY. 2017;22(6):792-801
Genetic evidence for role of integration of fast and slow neurotransmission in schizophrenia
Devor A; Andreassen OA; Wang Y; Maki-Marttunen T; Smeland OB; Fan C-C; Schork AJ; Holland D; Thompson WK; Witoelar A; Chen C-H; Desikan RS; McEvoy LK; Djurovic S; Greengard P; Svenningsson P; Einevoll GT; Dale AM
Article: EXPERIMENTAL NEUROLOGY. 2017;292:11-20
Asymmetric dopaminergic degeneration and levodopa alter functional corticostriatal connectivity bilaterally in experimental parkinsonism
Monnot C; Zhang X; Nikkhou-Aski S; Damberg P; Svenningsson P
Article: NEUROLOGY. 2017;88(21):1996-2002
Vagotomy and Parkinson disease A Swedish register-based matched-cohort study
Liu B; Fang F; Pedersen NL; Tillander A; Ludvigsson JF; Ekbom A; Svenningsson P; Chen H; Wirdefeldt K
Article: PLOS ONE. 2017;12(5):e0177036
Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation
Rame M; Caudal D; Schenker E; Svenningsson P; Spedding M; Jay TM; Godsil BP
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2017;27(5):504-514
Distribution and levels of 5-HT_1B receptors in anterior cingulate cortex of patients with bipolar disorder, major depressive disorder and schizophrenia - An autoradiography study
Veldman ER; Svedberg MM; Svenningsson P; Lundberg J
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2017;114(10):2735-2740
Alterations of p11 in brain tissue and peripheral blood leukocytes in Parkinson's disease
Green H; Zhang X; Tiklova K; Volakakis N; Brodin L; Berg L; Greengard P; Perlmann T; Svenningsson P
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2017;27:s52-s53
P.3.004 Loss of dopamine mediated by 6-hydroxydopamine alters structural and functional connectivity in a model of parkinsonism
Monnot C; Zhang X; Aski SN; Damberg P; Svenningsson P
Article: JOURNAL OF COMPARATIVE NEUROLOGY. 2017;525(4):955-975
Cell- and region-specific expression of depression-related protein p11 (S100a10) in the brain
Milosevic A; Liebmann T; Knudsen M; Schintu N; Svenningsson P; Greengard P
Article: NPJ PARKINSONS DISEASE. 2017;3:7
Synaptic proteins in CSF relate to Parkinson's disease stage markers
Bereczki E; Bogstedt A; Hoglund K; Tsitsi P; Brodin L; Ballard C; Svenningsson P; Aarsland D
Article: PARKINSONS DISEASE. 2017;2017:4020198-7
Genetic Variations and mRNA Expression of NRF2 in Parkinson's Disease
Ran C; Wirdefeldt K; Brodin L; Ramezani M; Westerlund M; Xiang F; Anvret A; Willows T; Sydow O; Johansson A; Galter D; Svenningsson P; Belin AC
Article: TREMOR AND OTHER HYPERKINETIC MOVEMENTS. 2017;7:529
Paroxysmal Kinesigenic Dyskinesia
Paucar M; Malmgren H; Svenningsson P
Article: PROTEOMICS CLINICAL APPLICATIONS. 2016;10(12):1242-1253
CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease
Remnestal J; Just D; Mitsios N; Fredolini C; Mulder J; Schwenk JM; Uhlen M; Kultima K; Ingelsson M; Kilander L; Lannfelt L; Svenningsson P; Nellgard B; Zetterberg H; Blennow K; Nilsson P; Haggmark-Manberg A
Article: JOURNAL OF NUCLEAR MEDICINE. 2016;57(10):1529-1534
Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using ¹⁸F-FE-PE2I in Healthy Controls and Parkinson Disease Patients
Sonni I; Fazio P; Sehain M; Halldin C; Svenningsson P; Farde L; Varrone A
Article: CEREBELLUM. 2016;15(5):636-640
PSP-CBS with Dopamine Deficiency in a Female with a FMR1 Premutation
Paucar M; Beniaminov S; Paslawski W; Svenningsson P
Article: CEREBELLUM. 2016;15(5):632-635
POLG-Associated Ataxia Presenting as a Fragile X Tremor/Ataxia Phenocopy Syndrome
Paucar M; Engvall M; Gordon L; Tham E; Synofzik M; Svenningsson P
Article: AMERICAN JOURNAL OF HUMAN GENETICS. 2016;99(3):735-743
Absence of the Autophagy Adaptor SQSTM1/p62 Causes Childhood-Onset Neurodegeneration with Ataxia, Dystonia, and Gaze Palsy
Haack TB; Ignatius E; Calvo-Garrido J; Iuso A; Isohanni P; Maffezzini C; Lonnqvist T; Suomalainen A; Gorza M; Kremer LS; Graf E; Hartig M; Berutti R; Paucar M; Svenningsson P; Stranneheim H; Brandberg G; Wedell A; Kurian MA; Hayflick SA; Venco P; Tiranti V; Strom TM; Dichgans M; Horvath R; Holinski-Feder E; Freyer C; Meitinger T; Prokisch H; Senderek J; Wredenberg A; Carroll CJ; Klopstock T
Article: NEUROBIOLOGY OF AGING. 2016;45:212.e5-212.e11
Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden
Ran C; Brodin L; Forsgren L; Westerlund M; Ramezani M; Gellhaar S; Xiang F; Fardell C; Nissbrandt H; Soderkvist P; Puschmann A; Ygland E; Olson L; Willows T; Johansson A; Sydow O; Wirdefeldt K; Galter D; Svenningsson P; Belin AC
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2016;113(32):E4726-E4735
Depression-like behavior in rat: Involvement of galanin receptor subtype 1 in the ventral periaqueductal gray
Wang P; Li H; Barde S; Zhang M-D; Sun J; Wang T; Zhang P; Luo H; Wang Y; Yang Y; Wang C; Svenningsson P; Theodorsson E; Hokfelt TGM; Xu Z-QD
Article: NEUROLOGY-GENETICS. 2016;2(4):e84
PROGRESSIVE BRAIN CALCIFICATIONS AND SIGNS IN A FAMILY WITH THE L9R MUTATION IN THE PDGFB GENE
Paucar M; Almqvist H; Saeed A; Bergendal G; Ygge J; Holmin S; Bjorkhem I; Svenningsson P
Article: NEUROIMAGE. 2016;136:129-138
Simultaneous imaging of multiple neurotransmitters and neuroactive substances in the brain by desorption electrospray ionization mass spectrometry
Shariatgorji M; Strittmatter N; Nilsson A; Kallback P; Alvarsson A; Zhang X; Vallianatou T; Svenningsson P; Goodwin RJA; Andren PE
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2016;113(28):7906-7911
Epigenetics and energetics in ventral hippocampus mediate rapid antidepressant action: Implications for treatment resistance
Bigio B; Mathe AA; Sousa VC; Zelli D; Svenningsson P; McEwen BS; Nasca C
Article: SCIENTIFIC REPORTS. 2016;6:26285
α-Synuclein induced toxicity in brain stem serotonin neurons mediated by an AAV vector driven by the tryptophan hydroxylase promoter
Wan OW; Shin E; Mattsson B; Caudal D; Svenningsson P; Bjorklund A
Article: JOURNAL OF PARKINSONS DISEASE. 2016;6(2):307-315
Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid
Boman A; Svensson S; Boxer A; Rojas JC; Seeley WW; Karydas A; Miller B; Kagedal K; Svenningsson P
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2016;113(5):1423-1428
Gene therapy blockade of dorsal striatal p11 improves motor function and dyskinesia in parkinsonian mice
Marongiu R; Arango-Lievano M; Francardo V; Morgenstern P; Zhang X; Cenci MA; Svenningsson P; Greengard P; Kaplitt MG
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2016;113(5):1429-1434
p11 modulates L-DOPA therapeutic effects and dyskinesia via distinct cell types in experimental Parkinsonism
Schintu N; Zhang X; Alvarsson A; Marongiu R; Kaplitt MG; Greengard P; Svenningsson P
Article: NEUROLOGY-GENETICS. 2016;2(1):e49
EXPANDING THE ATAXIA WITH OCULOMOTOR APRAXIA TYPE 4 PHENOTYPE
Paucar M; Malmgren H; Taylor M; Reynolds JJ; Svenningsson P; Press R; Nordgren A
Article: NEUROSCIENCE LETTERS. 2016;611:51-58
Overexpression of α-synuclein simultaneously increases glutamate NMDA receptor phosphorylation and reduces glucocerebrosidase activity
Yang J; Hertz E; Zhang X; Leinartaite L; Lundius EG; Li J; Svenningsson P
Journal article: F1000 PRIME REPORTS. 2016;:634
In search of the mechanisms of ketamine’s antidepressant effects: How robust is the evidence behind the mTor activation hypothesis
Popp S; Behl B; Joshi JJ; Lanz T; Spedding M; Schenker E; Jay T; Svenningsson P; Caudal D; Cunningham J; Deaver D; Bespalov A
Article: BEHAVIOURAL BRAIN RESEARCH. 2016;296:129-133
Emotional memory impairments induced by AAV-mediated overexpression of human α-synuclein in dopaminergic neurons of the ventral tegmental area
Alvarsson A; Caudal D; Bjorklund A; Svenningsson P
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2015;25(12):2372-2380
S100B interacts with the serotonin 5-HT₇ receptor to regulate a depressive-like behavior
Stroth N; Svenningsson P
Article: EXPERIMENTAL NEUROLOGY. 2015;273:243-252
Depressive-like phenotype induced by AAV-mediated overexpression of human α-synuclein in midbrain dopaminergic neurons
Caudal D; Alvarsson A; Bjorklund A; Svenningsson P
Article: JOURNAL OF NEUROSCIENCE. 2015;35(41):14057-14069
Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission
Alvarsson A; Zhang X; Stan TL; Schintu N; Kadkhodaei B; Millan MJ; Perlmann T; Svenningsson P
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2015;25(10):1714-1722
Lurasidone and fluoxetine reduce novelty-induced hypophagia and NMDA receptor subunit and PSD-95 expression in mouse brain
Stan TL; Sousa VC; Zhang X; Ono M; Svenningsson P
Article: FRONTIERS IN PHARMACOLOGY. 2015;6:200
5-HT6 receptor agonism facilitates emotional learning
Pereira M; Martynhak BJ; Andreatini R; Svenningsson P
Article: BRAIN. 2015;138(Pt 9):2687-2700
Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease
Jucaite A; Svenningsson P; Rinne JO; Cselenyi Z; Varnas K; Johnstrom P; Amini N; Kirjavainen A; Helin S; Minkwitz M; Kugler AR; Posener JA; Budd S; Halldin C; Varrone A; Farde L
Article: BIOORGANIC & MEDICINAL CHEMISTRY. 2015;23(15):4824-4830
Arylpiperazine agonists of the serotonin 5-HT_1A receptor preferentially activate cAMP signaling versus recruitment of β-arrestin-2
Stroth N; Niso M; Colabufo NA; Perrone R; Svenningsson P; Lacivita E; Leopoldo M
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2015;69(7):365-374
5-HT_1B receptor imaging and cognition: A positron emission tomography study in control subjects and parkinson's disease patients
Varrone A; Svenningsson P; Marklund P; Fatouros-Bergman H; Forsberg A; Halldin C; Nilsson L-G; Farde L
Article: BEHAVIOURAL BRAIN RESEARCH. 2015;287:89-95
NMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDA-GluN2B antagonism
Kiselycznyk C; Jury NJ; Halladay LR; Nakazawa K; Mishina M; Sprengel R; Grant SGN; Svenningsson P; Holmes A
Article: NATURE GENETICS. 2015;47(6):579-581
Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export
Legati A; Giovannini D; Nicolas G; Lopez-Sanchez U; Quintans B; Oliveira JRM; Sears RL; Ramos EM; Spiteri E; Sobrido M-J; Carracedo A; Castro-Fernandez C; Cubizolle S; Fogel BL; Goizet C; Jen JC; Kirdlarp S; Lang AE; Miedzybrodzka Z; Mitarnun W; Paucar M; Paulson H; Pariente J; Richard A-C; Salins NS; Simpson SA; Striano P; Svenningsson P; Tison F; Unni VK; Vanakker O; Wessels MW; Wetchaphanphesat S; Yang M; Boller F; Campion D; Hannequin D; Sitbon M; Geschwind DH; Battini J-L; Coppola G
Article: NATURE NEUROSCIENCE. 2015;18(6):826-835
Dopaminergic control of autophagic-lysosomal function implicates Lmx1b in Parkinson's disease
Laguna A; Schintu N; Nobre A; Alvarsson A; Volakakis N; Jacobsen JK; Gomez-Galan M; Sopova E; Joodmardi E; Yoshitake T; Deng Q; Kehr J; Ericson J; Svenningsson P; Shupliakov O; Perlmann T
Article: JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY. 2015;26(6):934-939
Pyrylium Salts as Reactive Matrices for MALDI-MS Imaging of Biologically Active Primary Amines
Shariatgorji M; Nilsson A; Kallback P; Karlsson O; Zhang X; Svenningsson P; Andren PE
Article: JOURNAL OF NUCLEAR MEDICINE. 2015;56(5):714-720
Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4′-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease
Fazio P; Svenningsson P; Forsberg A; Jonsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A
Article: JOURNAL OF MEDICINAL CHEMISTRY. 2015;58(8):3631-3636
Evaluation of 3-Ethyl-3-(phenylpiperazinylbutyl)oxindoles as PET Ligands for the Serotonin 5-HT₇ Receptor: Synthesis, Pharmacology, Radio labeling, and in Vivo Brain Imaging in Pigs
Herth MM; Andersen VL; Hansen HD; Stroth N; Volk B; Lehel S; Dyssegaard A; Ettrup A; Svenningsson P; Knudsen GM; Kristensen JL
Article: BRAIN. 2015;138(Pt 4):963-973
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study
Svenningsson P; Rosenblad C; Arvidsson KAE; Wictorin K; Keywood C; Shankar B; Lowe DA; Bjorklund A; Widner H
Article: MOVEMENT DISORDERS. 2015;30(4):510-516
EuroInf: A Multicenter Comparative Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease
Martinez-Martin P; Reddy P; Katzenschlager R; Antonini A; Todorova A; Odin P; Henriksen T; Martin A; Calandrella D; Rizos A; Bryndum N; Glad A; Dafsari HS; Timmermann L; Ebersbach G; Kramberger MG; Samuel M; Wenzel K; Tomantschger V; Storch A; Reichmann H; Pirtosek Z; Trost M; Svenningsson P; Palhagen S; Volkmann J; Chaudhuri KR
Article: JOURNAL OF CLINICAL INVESTIGATION. 2015;125(3):1339-1346
Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients
Paul G; Zachrisson O; Varrone A; Almqvist P; Jerling M; Lind G; Rehncrona S; Linderoth B; Bjartmarz H; Shafer LL; Coffey R; Svensson M; Mercer KJ; Forsberg A; Halldin C; Svenningsson P; Widner H; Frisen J; Palhagen S; Haegerstrand A
Journal article: INTERNET INTERVENTIONS-THE APPLICATION OF INFORMATION TECHNOLOGY IN MENTAL AND BEHAVIOURAL HEALTH. 2015;2(1):1-6
Internet-based cognitive behavioral therapy for depression and anxiety in Parkinson's disease — A pilot study
Kraepelien M; Svenningsson P; Lindefors N; Kaldo V
Article: ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS. 2015;63(1):65-71
Impact of Imiglucerase Supply Shortage on Clinical and Laboratory Parameters in Norrbottnian Patients with Gaucher Disease Type 3
Machaczka M; Bjorkvall CK; Wieremiejczyk J; Arce MP; Myhr-Eriksson K; Klimkowska M; Hagglund H; Svenningsson P
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2014;17(12):1981-1993
Ropinirole regulates emotionality and neuronal activity markers in the limbic forebrain
Mavrikaki M; Schintu N; Nomikos GG; Panagis G; Svenningsson P
Article: NEURON. 2014;84(4):697-707
Direct Targeted Quantitative Molecular Imaging of Neurotransmitters in Brain Tissue Sections
Shariatgorji M; Nilsson A; Goodwin RJA; Kallback P; Schintu N; Zhang X; Crossman AR; Bezard E; Svenningsson P; Andren PE
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2014;68(10):480-483
No correlation between serotonin and its metabolite 5-HIAA in the cerebrospinal fluid and [(11) C]AZ10419369 binding measured with PET in healthy volunteers.
Tiger M; Svenningsson P; Nord M; Jabre S; Halldin C; Lundberg J
Journal article: ALZHEIMERS & DEMENTIA. 2014;10(4S_Part_13):p516
P2‐123: BIOMARKERS FOR COGNITIVE DECLINE OF EARLY PARKINSON's DISEASE
Bereczki E; Hoglund K; Svenningsson P; Cedazo‐Minguez A; Francis P; Ballard CG; Aarsland D
Article: PHYSIOLOGY & BEHAVIOR. 2014;132:57-65
Exercise prevents raphe nucleus mitochondrial overactivity in a rat depression model
Wen L; Jin Y; Li L; Sun S; Cheng S; Zhang S; Zhang Y; Svenningsson P
Article: TRANSLATIONAL PSYCHIATRY. 2014;4(6):e395
NMDA receptor antagonists ketamine and Ro25-6981 inhibit evoked release of glutamate in vivo in the subiculum
Stan TL; Alvarsson A; Branzell N; Sousa VC; Svenningsson P
Article: NEUROLOGY. 2014;82(22):2017-2025
Initial cognitive decline is associated with cortical thinning in early Parkinson disease.
Pereira JB; Svenningsson P; Weintraub D; Brønnick K; Lebedev A; Westman E; Aarsland D
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2014;24(4):630-638
Effects of lithium and aripiprazole on brain stimulation reward and neuroplasticity markers in the limbic forebrain
Mavrikaki M; Schintu N; Kastellakis A; Nomikos GG; Svenningsson P; Panagis G
Article: NEUROBIOLOGY OF AGING. 2014;35(4):867-875
Positron emission tomography imaging of 5-hydroxytryptamine_1B receptors in Parkinson's disease
Varrone A; Svenningsson P; Forsberg A; Varnas K; Tiger M; Nakao R; Halldin C; Nilsson L-G; Farde L
Article: AMERICAN JOURNAL OF PSYCHIATRY. 2014;171(3):323-331
Fluoxetine Administered to Juvenile Monkeys: Effects on the Serotonin Transporter and Behavior
Shrestha SS; Nelson EE; Liow J-S; Gladding R; Lyoo CH; Noble PL; Morse C; Henter ID; Kruger J; Zhang B; Suomi SJ; Svenningsson P; Pike VW; Winslow JT; Leibenluft E; Pine DS; Innis RB
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2014;289(8):4660-4673
GPR37 Protein Trafficking to the Plasma Membrane Regulated by Prosaposin and GM1 Gangliosides Promotes Cell Viability*
Lundius EG; Vukojevic V; Hertz E; Stroth N; Cederlund A; Hiraiwa M; Terenius L; Svenningsson P
Article: JOURNAL OF LIPID RESEARCH. 2014;55(2):313-318
7α-hydroxy-3-oxo-4-cholestenoic acid in cerebrospinal fluid reflects the integrity of the blood-brain barrier
Saeed A; Floris F; Andersson U; Pikuleva I; Lovgren-Sandblom A; Bjerke M; Paucar M; Wallin A; Svenningsson P; Bjorkhem I
Article: NEUROSCIENCE LETTERS. 2014;559:163-168
Antidepressant effects on serotonin 1A/1B receptors in the rat brain using a gene x environment model
Shrestha SS; Pine DS; Luckenbaugh DA; Varnas K; Henter ID; Innis RB; Mathe AA; Svenningsson P
Article: JOURNAL OF NUCLEAR MEDICINE. 2014;55(1):141-146
¹¹C-CUMI-101, a PET Radioligand, Behaves as a Serotonin 1A Receptor Antagonist and Also Binds to α₁ Adrenoceptors in Brain
Shrestha SS; Liow J-S; Lu S; Jenko K; Gladding RL; Svenningsson P; Morse CL; Zoghbi SS; Pike VW; Innis RB
Article: BIOMARKERS IN MEDICINE. 2014;8(3):387-394
The influence of preanalytical conditions on the DJ-1 concentration in human cerebrospinal fluid
Salvesen L; Tanassi JT; Bech S; Palhagen S; Svenningsson P; Heegaard NHH; Winge K
Article: PRION. 2013;7(6):501-510
Genotype-phenotype analysis in inherited prion disease with eight octapeptide repeat insertional mutation
Paucar M; Xiang F; Moore R; Walker R; Winnberg E; Svenningsson P
Article: NEUROSCIENCE LETTERS. 2013;555:102-105
Oxysterols and Parkinson's disease: Evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease
Bjorkhem I; Lovgren-Sandblom A; Leoni V; Meaney S; Brodin L; Salveson L; Winge K; Palhagen S; Svenningsson P
Journal article: JOURNAL OF THE NEUROLOGICAL SCIENCES. 2013;333:e137
Safety and efficacy of recombinant human platelet derived growth factor (Rhpdgf) in Parkinson's disease
Paul G; Zachrisson O; Varrone A; Almqvist P; Jerling M; Lindh G; Rehncrona S; Linderoth B; Bjartmarz H; Svensson M; Mercer KJ; Forsberg A; Shafer LL; Lang AMJ; Halldin C; Svenningsson P; Widner H; Frisen J; Pålhagen S; Haegerstrand A
Article: MOLECULAR PSYCHIATRY. 2013;18(10):1096-1105
Bidirectional regulation of emotional memory by 5-HT_1B receptors involves hippocampal p11
Eriksson TM; Alvarsson A; Stan TL; Zhang X; Hascup KN; Hascup ER; Kehr J; Gerhardt GA; Warner-Schmidt J; Arango-Lievano M; Kaplitt MG; Ogren SO; Greengard P; Svenningsson P
Article: NATURE REVIEWS NEUROSCIENCE. 2013;14(10):673-680
p11 and its role in depression and therapeutic responses to antidepressants
Svenningsson P; Kim Y; Warner-Schmidt J; Oh Y-S; Greengard P
Journal article: BRAIN BEHAVIOR AND IMMUNITY. 2013;32:e42
145. Translocator protein (TSPO) as a biomarker of microglia activation: PET imaging using [11C]PBR28 in Parkinson’s disease
Jucaite A; Cselényi Z; Varrone A; Varnäs K; Johnström P; Halldin C; Salter H; McLoughlin MJ; Rinne J; Svenningsson P; Alexander R; Kugler A; Farde L
Article: NATURE GENETICS. 2013;45(9):1077-1082
Mutations in the gene encoding PDGF-B cause brain calcifications in humans and mice
Keller A; Westenberger A; Sobrido MJ; Garcia-Murias M; Domingo A; Sears RL; Lemos RR; Ordonez-Ugalde A; Nicolas G; Gomes da Cunha JE; Rushing EJ; Hugelshofer M; Wurnig MC; Kaech A; Reimann R; Lohmann K; Dobricic V; Carracedo A; Petrovic I; Miyasaki JM; Abakumova I; Mae MA; Raschperger E; Zatz M; Zschiedrich K; Klepper J; Spiteri E; Prieto JM; Navas I; Preuss M; Dering C; Jankovic M; Paucar M; Svenningsson P; Saliminejad K; Khorshid HRK; Novakovic I; Aguzzi A; Boss A; Le Ber I; Defer G; Hannequin D; Kostic VS; Campion D; Geschwind DH; Coppola G; Betsholtz C; Klein C; Oliveira JRM
Article: PLOS ONE. 2013;8(8):e70560
De Novo Mutations in Ataxin-2 Gene and ALS Risk
Miguel Laffita-Mesa J; Rodriguez Pupo JM; Moreno Sera R; Vazquez Mojena Y; Kouri V; Laguna-Salvia L; Martinez-Godales M; Valdevila Figueira JA; Bauer PO; Rodriguez-Labrada R; Gonzalez Zaldivar Y; Paucar M; Svenningsson P; Velazquez Perez L
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2013;16(4):919-924
Reduced phosphorylation of GluA1 subunits relates to anxiety-like behaviours in mice
Kiselycznyk C; Zhang X; Huganir RL; Holmes A; Svenningsson P
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2013;110(6):2360-2365
Transcription factor Nurr1 maintains fiber integrity and nuclear-encoded mitochondrial gene expression in dopamine neurons
Kadkhodaei B; Alvarsson A; Schintu N; Ramskold D; Volakakis N; Joodmardi E; Yoshitake T; Kehr J; Decressac M; Bjorklund A; Sandberg R; Svenningsson P; Perlmann T
Article: JOURNAL OF NEUROCHEMISTRY. 2013;124(3):410-417
Functional GPR37 trafficking protects against toxicity induced by 6-OHDA, MPP+ or rotenone in a catecholaminergic cell line
Lundius EG; Stroth N; Vukojevic V; Terenius L; Svenningsson P
Article: NEUROGENETICS. 2013;14(1):11-22
Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification
Hsu SC; Sears RL; Lemos RR; Quintans B; Huang A; Spiteri E; Nevarez L; Mamah C; Zatz M; Pierce KD; Fullerton JM; Adair JC; Berner JE; Bower M; Brodaty H; Carmona O; Dobricic V; Fogel BL; Garcia-Estevez D; Goldman J; Goudreau JL; Hopfer S; Jankovic M; Jauma S; Jen JC; Kirdlarp S; Klepper J; Kostic V; Lang AE; Linglart A; Maisenbacher MK; Manyam BV; Mazzoni P; Miedzybrodzka Z; Mitarnun W; Mitchell PB; Mueller J; Novakovic I; Paucar M; Paulson H; Simpson SA; Svenningsson P; Tuite P; Vitek J; Wetchaphanphesat S; Williams C; Yang M; Schofield PR; de Oliveira JRM; Sobrido M-J; Geschwind DH; Coppola G
Article: JOURNAL OF NEUROSCIENCE. 2012;32(50):17998-18008
A Noncanonical Postsynaptic Transport Route for a GPCR Belonging to the Serotonin Receptor Family
Liebmann T; Kruusmagi M; Sourial-Bassillious N; Bondar A; Svenningsson P; Flajolet M; Greengard P; Scott L; Brismar H; Aperia A
Article: JOURNAL OF NEUROCHEMISTRY. 2012;123(5):811-823
Pharmacological or genetic blockade of the dopamine D3 receptor increases cell proliferation in the hippocampus of adult mice
Egeland M; Zhang X; Millan MJ; Mocaer E; Svenningsson P
Article: NEUROPHARMACOLOGY. 2012;63(6):1150-1160
5-HT_1A and 5-HT₇ receptor crosstalk in the regulation of emotional memory: Implications for effects of selective serotonin reuptake inhibitors
Eriksson TM; Holst S; Stan TL; Hager T; Sjogren B; Ogren SO; Svenningsson P; Stiedl O
Article: ANALYTICAL CHEMISTRY. 2012;84(16):7152-7157
Deuterated Matrix-Assisted Laser Desorption Ionization Matrix Uncovers Masked Mass Spectrometry Imaging Signals of Small Molecules
Shariatgorji M; Nilsson A; Goodwin RJA; Svenningsson P; Schintu N; Banka Z; Kladni L; Hasko T; Szabo A; Andren PE
Article: JOURNAL OF MEDICINAL CHEMISTRY. 2012;55(14):6375-6380
Investigations on the 1-(2-Biphenyl)piperazine Motif: Identification of New Potent and Selective Ligands for the Serotonin₇ (5-HT₇) Receptor with Agonist or Antagonist Action in Vitro or ex Vivo
Lacivita E; Patarnello D; Stroth N; Caroli A; Niso M; Contino M; De Giorgio P; Di Pilato P; Colabufo NA; Berardi F; Perrone R; Svenningsson P; Hedlund PB; Leopoldo M
Journal article: WILEY INTERDISCIPLINARY REVIEWS: MEMBRANE TRANSPORT AND SIGNALING. 2012;1(4):453-466
Ligand‐specific differential regulation of 5‐hydroxytryptamine receptors: functional selectivity in serotonergic signaling
Stroth N; Svenningsson P
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2012;15(5):669-679
Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression
Melas PA; Rogdaki M; Lennartsson A; Bjork K; Qi H; Witasp A; Werme M; Wegener G; Mathe AA; Svenningsson P; Lavebratt C
Article: ANALYTICAL CHEMISTRY. 2012;84(10):4603-4607
Controlled-pH Tissue Cleanup Protocol for Signal Enhancement of Small Molecule Drugs Analyzed by MALDI-MS Imaging
Shariatgorji M; Kallback P; Gustavsson L; Schintu N; Svenningsson P; Goodwin RJA; Andren PE
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2012;22:s45-s46
P.2.016 Changes in basal and fluoxetine-induced adult neurogenesis and depression-related behaviours in transgenic S100B over-expressing mice
Sousa V; Egeland M; Svenningsson P
Article: MOLECULAR PSYCHIATRY. 2012;17(2):173-184
Emotional memory impairments in a genetic rat model of depression: involvement of 5-HT/MEK/Arc signaling in restoration
Eriksson TM; Delagrange P; Spedding M; Popoli M; Mathe AA; Oegren SO; Svenningsson P
Article: JIMD REPORTS. 2012;3:53-57
A twelve-year follow-up study on a case of early-onset parkinsonism preceding clinical manifestation of Gaucher disease.
Machaczka M; Arce MP; Rucinska M; Yoshitake T; Kehr J; Jurczak W; Skotnicki AB; Månsson J-E; Tylki-Szymanska A; Svenningsson P
Article: JOURNAL OF PARKINSONS DISEASE. 2012;2(2):171-180
MRI Diffusion in Parkinson's Disease: Using the Technique's Inherent Directional Information to Study the Olfactory Bulb and Substantia Nigra
Skorpil M; Soderlund V; Sundin A; Svenningsson P
Article: NEUROPHARMACOLOGY. 2012;62(1):347-357
Neuropeptidomics of mouse hypothalamus after imipramine treatment reveal somatostatin as a potential mediator of antidepressant effects
Nilsson A; Stroth N; Zhang X; Qi H; Falth M; Skold K; Hoyer D; Andren PE; Svenningsson P
Article: NEUROCHEMISTRY INTERNATIONAL. 2011;59(8):1109-1122
Tianeptine potentiates AMPA receptors by activating CaMKII and PKA via the p38, p42/44 MAPK and JNK pathways
Szegedi V; Juhasz G; Zhang X; Barkoczi B; Qi H; Madeira A; Kapus G; Svenningsson P; Spedding M; Penke B
Article: PSYCHOPHARMACOLOGY. 2011;218(4):621-634
Antidepressant-like properties of sarizotan in experimental Parkinsonism
Zhang X; Egeland M; Svenningsson P
Article: JOURNAL OF NEUROSCIENCE. 2011;31(47):16928-16940
Genetic Deletion of Trace Amine 1 Receptors Reveals Their Role in Auto-Inhibiting the Actions of Ecstasy (MDMA)
Di Cara B; Maggio R; Aloisi G; Rivet J-M; Lundius EG; Yoshitake T; Svenningsson P; Brocco M; Gobert A; De Groote L; Cistarelli L; Veiga S; De Montrion C; Rodriguez M; Galizzi J-P; Lockhart BP; Coge F; Boutin JA; Vayer P; Verdouw PM; Groenink L; Millan MJ
Article: NEUROSCIENCE. 2011;193:259-268
GENETIC, PHARMACOLOGICAL AND LESION ANALYSES REVEAL A SELECTIVE ROLE FOR CORTICOHIPPOCAMPAL GLUN2B IN A NOVEL REPEATED SWIM STRESS PARADIGM
Kiselycznyk C; Svenningsson P; Delpire E; Holmes A
Article: BLOOD. 2011;118(11):3172-3181
Regulation of fibrinolysis by S100A10 in vivo
Surette AP; Madureira PA; Phipps KD; Miller VA; Svenningsson P; Waisman DM
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2011;21:s375-s376
P.2.b.014 Modulation of 5-HT2A and 5-HT2C receptor expression levels by fluoxetine in a genetic mice model of depression
Björk K; Zhang X; Yacoubi ME; Vaugeois J; Svenningsson P
Article: NEUROPHARMACOLOGY. 2011;61(3):442-450
Co-expression of serotonin 5-HT_1B and 5-HT₄ receptors in p11 containing cells in cerebral cortex, hippocampus, caudate-putamen and cerebellum
Egeland M; Warner-Schmidt J; Greengard P; Svenningsson P
Article: NEUROCHEMISTRY INTERNATIONAL. 2011;59(2):280-289
Caveolin-1 interacts with alpha-synuclein and mediates toxic actions of cellular alpha-synuclein overexpression
Madeira A; Yang J; Zhang X; Vikeved E; Nilsson A; Andren PE; Svenningsson P
Article: CURRENT PROTOCOLS IN PROTEIN SCIENCE. 2011;Chapter 19:Unit19.21-19.21.9
Identification of protein-protein interactions by surface plasmon resonance followed by mass spectrometry.
Madeira A; Vikeved E; Nilsson A; Sjögren B; Andrén PE; Svenningsson P
Article: JOURNAL OF COMPARATIVE NEUROLOGY. 2011;519(9):1815-1827
Distribution, Level, Pharmacology, Regulation, and Signaling of 5-HT₆ Receptors in Rats and Marmosets With Special Reference to an Experimental Model of Parkinsonism
Zhang X; Andren PE; Glennon RA; Svenningsson P
Article: MAGNETIC RESONANCE IMAGING. 2011;29(2):289-292
Diffusion tensor fiber tractography of the olfactory tract
Skorpil M; Rolheiser T; Robertson H; Sundin A; Svenningsson P
Article: SCIENCE TRANSLATIONAL MEDICINE. 2010;2(54):54ra76
Reversal of Depressed Behaviors in Mice by p11 Gene Therapy in the Nucleus Accumbens
Alexander B; Warner-Schmidt J; Eriksson TM; Tamminga C; Arango-Lievano M; Ghose S; Vernov M; Stavarache M; Musatov S; Flajolet M; Svenningsson P; Greengard P; Kaplitt MG
Article: BIOLOGICAL PSYCHIATRY. 2010;68(6):528-535
A Role for p11 in the Antidepressant Action of Brain-Derived Neurotrophic Factor
Warner-Schmidt JL; Chen EY; Zhang X; Marshall JJ; Morozov A; Svenningsson P; Greengard P
Article: MOLECULAR PHARMACOLOGY. 2010;78(3):486-496
Antipsychotic Drugs Regulate Hedgehog Signaling by Modulation of 7-Dehydrocholesterol Reductase Levels
Lauth M; Rohnalter V; Bergstrom A; Kooshesh M; Svenningsson P; Toftgard R
Article: BLOOD. 2010;116(7):1136-1146
S100A10 regulates plasminogen-dependent macrophage invasion
O'Connell PA; Surette AP; Liwski RS; Svenningsson P; Waisman DM
Article: BIOLOGICAL PSYCHIATRY. 2010;67(11):1048-1056
Neurogenic Effects of Fluoxetine Are Attenuated in p11 (S100A10) Knockout Mice
Egeland M; Warner-Schmidt J; Greengard P; Svenningsson P
Article: JOURNAL OF NEUROLOGY. 2010;257(4):524-532
Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression
Palhagen S; Qi H; Martensson B; Walinder J; Granerus A-K; Svenningsson P
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2009;19:s115-s116
S.2.03 The role of 5-HT1A receptors in emotional memory: implications for anxiety and depression
Ögren SO; Eriksson TM; Kehr J; Svenningsson P; Stiedl O
Article: MOLECULAR & CELLULAR PROTEOMICS. 2009;8(5):1094-1104
Striatal Alterations of Secretogranin-1, Somatostatin, Prodynorphin, and Cholecystokinin Peptides in an Experimental Mouse Model of Parkinson Disease
Nilsson A; Falth M; Zhang X; Kultima K; Skold K; Svenningsson P; Andren PE
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2009;12(2):201-215
S100B overexpressing mutant mice exhibit prolonged behavioural and biochemical responses towards repeated intermittent binge treatments with MDMA
Kindlundh-Hogberg AMS; Zhang X; Svenningsson P
Article: JOURNAL OF NEUROSCIENCE. 2009;29(6):1937-1946
Role of p11 in Cellular and Behavioral Effects of 5-HT4 Receptor Stimulation
Warner-Schmidt JL; Flajolet M; Maller A; Chen EY; Qi H; Svenningsson P; Greengard P
Article: JOURNAL OF PROTEOME RESEARCH. 2009;8(2):974-981
Heat Stabilization of the Tissue Proteome: A New Technology for Improved Proteomics
Svensson M; Boren M; Skold K; Falth M; Sjogren B; Andersson M; Svenningsson P; Andren PE
Article: NATURE PROTOCOLS. 2009;4(7):1023-1037
Coupling surface plasmon resonance to mass spectrometry to discover novel protein-protein interactions
Madeira A; Ohman E; Nilsson A; Sjogren B; Andren PE; Svenningsson P
Article: NEUROPHARMACOLOGY. 2009;56(1):37-46
Antidepressants reverse the attenuation of the neurotrophic MEK/MAPK cascade in frontal cortex by elevated platform stress; reversal of effects on LTP is associated with GluA1 phosphorylation
Qi H; Mailliet F; Spedding M; Rocher C; Zhang X; Delagrange P; McEwen B; Jay TM; Svenningsson P
Article: JOURNAL OF PROTEOME RESEARCH. 2008;7(12):5333-5338
Use of Surface Plasmon Resonance Coupled with Mass Spectrometry Reveals an Interaction between the Voltage-Gated Sodium Channel Type X α-Subunit and Caveolin-1
Oehman E; Nilsson A; Madeira A; Sjoegren B; Andren PE; Svenningsson P
Article: EUROPEAN JOURNAL OF PHARMACOLOGY. 2008;596(1-3):107-110
5-HT₇ receptor stimulation by 8-OH-DPAT counteracts the impairing effect of 5-HT_1A receptor stimulation on contextual learning in mice
Eriksson TM; Golkar A; Ekstrom JC; Svenningsson P; Ogren SO
Journal article: NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY. 2008;378(4):441-446
Cholesterol reduction attenuates 5-HT1A receptor-mediated signaling in human primary neuronal cultures
Sjogren B; Csoregh L; Svenningsson P
Article: NATURE NEUROSCIENCE. 2008;11(8):932-939
Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs
Bateup HS; Svenningsson P; Kuroiwa M; Gong S; Nishi A; Heintz N; Greengard P
Journal article: JOURNAL OF PROTEOMICS AND BIOINFORMATICS. 2008;S2(01):053-054
Metal-Imaging Mass spectrometry (MIMS): A New Imaging Mass Spectrometry Technology to Determine the Distribution of Metal Ions in Tissue Samples
Doble P; Hare D; Austin C; Dawson M; Fryer F; Svenningsson P; Andren P; Grimm R; Zhang X; Reedy B
Article: NEUROPHARMACOLOGY. 2008;54(7):1143-1152
Neurokinin B/NK₃ receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease
Zhang X; Andren PE; Chergui K; Svenningsson P
Article: EXPERIMENTAL NEUROLOGY. 2008;211(2):593-596
Protection of stress-induced impairment of hippocampal/prefrontal LTP through blockade of glucocorticoid receptors - Implication of MEK signaling
Mailliet F; Qi H; Rocher C; Spedding M; Svenningsson P; Jay TM
Article: NEUROPHARMACOLOGY. 2008;54(7):1041-1050
Blockade of 5-HT_1B receptors facilitates contextual aversive learning in mice by disinhibition of cholinergic and glutamatergic neurotransmission
Eriksson TM; Madjid N; Elvander-Tottie E; Stiedl O; Svenningsson P; Ogren SO
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2008;105(6):2163-2168
Evidence for a role of the 5-HT_1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism
Zhang X; Andren PE; Greengard P; Svenningsson P
Article: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 2008;324(2):600-611
S33138[N-[4-[2-[(3aS, 9bR)-8-cyano-1, 3a, 4, 9b-tetrahydro[1]benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D₃ versus D₂ receptor antagonist and potential antipsychotic agent.: II.: A neurochemical, electrophysiological and behavioral characterization in vivo
Millan MJ; Svenningsson P; Ashby CRJ; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaer E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2008;62(2):128-136
Behavioral and biochemical responses to d-amphetamine in MCH₁ receptor knockout mice
Smith DG; Qi H; Svenningsson P; Wade M; Davis RJ; Gehlert DR; Nomikos GG
Article: EUROPEAN JOURNAL OF NEUROSCIENCE. 2007;26(12):3509-3517
Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine
Svenningsson P; Bateup H; Qi H; Takamiya K; Huganir RL; Spedding M; Roth BL; McEwen BS; Greengard P
Article: PROTEOMICS. 2007;7(24):4445-4456
The significance of biochemical and molecular sample integrity in brain proteomics and peptidomics:: Stathmin 2-20 and peptides as sample quality indicators
Skold K; Svensson M; Norrman M; Sjogren B; Svenningsson P; Andren PE
Journal article: NEUROTOXICOLOGY. 2007;28(6):1158-1169
Repeated intermittent MDMA binges reduce DAT density in mice and SERT density in rats in reward regions of the adolescent brain
Kindlundh-Hogberg AMS; Schioth HB; Svenningsson P
Article: FEBS LETTERS. 2007;581(26):5115-5121
Caveolin-1 affects serotonin binding and cell surface levels of human 5-HT_7(a) receptors
Sjögren B; Svenningsson P
Article: JOURNAL OF PROTEOME RESEARCH. 2007;6(10):3952-3961
Increased striatal mRNA and protein levells of the immunophilin FKBP-12 in experimental Parkinson's disease and identification of FKBP-12-binding proteins
Nilsson A; Skold K; Sjogren B; Svensson M; Piersont J; Zhang X; Caprioli RM; Buijs J; Persson B; Svenningsson P; Andren PE
Article: PHYSIOLOGY & BEHAVIOR. 2007;92(1-2):29-33
Changes on 5-HT₂ receptor mRNAs in striatum and subthalamic nucleus in Parkinson's disease model
Zhang X; Andren PE; Svenningsson P
Article: JOURNAL OF PROTEOME RESEARCH. 2007;6(7):2888-2895
An automated method for scanning LC-MS data sets for significant peptides and proteins, including quantitative profiling and interactive confirmation
Kaplan A; Soderstrom M; Fenyo D; Nilsson A; Falth M; Skold K; Svensson M; Pettersen H; Lindqvist S; Svenningsson P; Andren PE; Bjorkesten L
Journal article: EUROPEAN JOURNAL OF NEUROSCIENCE. 2007;25(11):3233-3242
Cellular localization and function of DARPP-32 in the rodent retina
Witkovsky P; Svenningsson P; Yan L; Bateup H; Silver R
Article: JOURNAL OF NEUROSCIENCE. 2007;27(15):4201-4209
Biochemical and behavioral evidence for antidepressant-like effects of 5-HT₆ receptor stimulation
Svenningsson P; Tzavara ET; Qi H; Carruthers R; Witkin JM; Nomikos GG; Greengard P
Article: NATURE REVIEWS DRUG DISCOVERY. 2007;6(3):189-201
Viewpoint -: How can drug discovery for psychiatric disorders be improved?
Agid Y; Buzsaki G; Diamond DM; Frackowiak R; Giedd J; Girault J-A; Grace A; Lambert JJ; Manji H; Mayberg H; Popoli M; Prochiantz A; Richter-Levin G; Somogyi P; Spedding M; Svenningsson P; Weinberger D
Article: ANALYTICAL CHEMISTRY. 2007;79(1):14-21
Neuropeptidomics:: MS applied to the discovery of novel peptides from the brain
Svensson M; Skold K; Nilsson A; Falth M; Nydahl K; Svenningsson P; Andren PE
Article: EUROPEAN JOURNAL OF PHARMACOLOGY. 2006;552(1-3):1-10
Cholesterol depletion reduces serotonin binding and signaling via human 5-HT_7(a) receptors
Sjogren B; Hamblin MW; Svenningsson P
Article: JOURNAL OF NEUROSCIENCE. 2006;26(37):9434-9438
DARPP-32 involvement in the photic pathway of the circadian system
Yan L; Bobula JM; Svenningsson P; Greengard P; Silver R
Article: NEUROPHARMACOLOGY. 2006;51(4):838-847
Quantitative mapping shows that serotonin rather than dopamine receptor mRNA expressions are affected after repeated intermittent administration of MDMA in rat brain
Kindlundh-Hogberg AMS; Svenningsson P; Schioth HB
Article: NEUROSCIENCE. 2006;140(3):897-911
Distinct roles for spinophilin and neurabin in dopamine-mediated plasticity
Allen PB; Zachariou V; Svenningsson P; Lepore AC; Centonze D; Costa C; Rossi S; Bender G; Chen G; Feng J; Snyder GL; Bernardi G; Nestler EJ; Yan Z; Calabresi P; Greengard P
Article: BRAIN RESEARCH. 2006;1095(1):207-210
Repeated L-DOPA treatment increases c-fos and BDNF mRNAs in the subthalamic nucleus in the 6-OHDA rat model of Parkinson's disease
Zhang X; Andren PE; Svenningsson P
Article: JOURNAL OF NEUROSCIENCE. 2006;26(10):2645-2651
Cocaine self-administration in mice is inversely related to phosphorylation at Thr34 (protein kinase A site) and Ser130 (kinase CK1 site) of DARPP-32
Zhang Y; Svenningsson P; Picetti R; Schlussman SD; Nairn AC; Ho A; Greengard P; Kreek MJ
Article: NEUROPSYCHOPHARMACOLOGY. 2006;31(3):555-562
Phosphorylation of DARPP-32 at threonine-34 is required for cocaine action
Zachariou V; Sgambato-Faure V; Sasaki T; Svenningsson P; Berton O; Fienberg AA; Nairn AC; Greengard P; Nestler EJ
Article: JOURNAL OF PROTEOME RESEARCH. 2006;5(2):262-269
Decreased striatal levels of PEP-19 following MPTP lesion in the mouse
Sköld K; Svensson M; Nilsson A; Zhang XQ; Nydahl K; Caprioli RM; Svenningsson P; Andrén PE
Article: SCIENCE. 2006;311(5757):77-80
Alterations in 5-HT_1B receptor function by p11 in depression-like states
Svenningsson P; Chergui K; Rachleff I; Flajolet M; Zhang XQ; El Yacoubi M; Vaugeois JM; Nomikos GG; Greengard P
Article: JOURNAL OF NEUROSCIENCE. 2005;25(37):8432-8438
Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons
Andersson M; Usiello A; Borgkvist A; Pozzi L; Dominguez C; Fienberg AA; Svenningsson P; Fredholm BB; Borrelli E; Greengard P; Fisone G
Article: JOURNAL OF NEUROSCIENCE. 2005;25(28):6601-6609
Physiological role for casein kinase 1 in glutamatergic synaptic transmission
Chergui K; Svenningsson P; Greengard P
Article: NEURON. 2005;47(1):85-100
The Rho-specific GEF Lfc interacts with neurabin and spinophilin to regulate dendritic spine morphology
Ryan XZP; Alldritt J; Svenningsson P; Allen PB; Wu GY; Nairn AC; Greengard P
Article: JOURNAL OF PROTEOME RESEARCH. 2005;4(2):223-226
Increased levels of ubiquitin in the 6-OHDA-lesioned striatum of rats
Pierson J; Svenningsson P; Caprioli RM; Andren PE
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2005;102(2):491-496
Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum
Valjent E; Pascoli V; Svenningsson P; Paul S; Enslen H; Corvol JC; Stipanovich A; Caboche J; Lombroso PJ; Nairn AC; Greengard P; Hervé D; Girault JA
Journal article: ENERGY POLICY. 2004;32(15):1707-1721
Bioenergy policy and market development in Finland and Sweden
Ericsson K; Huttunen S; Nilsson LJ; Svenningsson P
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2004;101(18):7187-7192
Phactrs 1-4: A family of protein phosphatase 1 and actin regulatory proteins
Allen PB; Greenfield AT; Svenningsson P; Haspeslagh DC; Greengard P
Journal article: ENERGY FOR SUSTAINABLE DEVELOPMENT. 2004;8(1):67-81
Seeing the wood for the trees: 25 years of renewable energy policy in Sweden
Nilsson LJ; Johansson B; Åstrand K; Ericsson K; Svenningsson P; Börjesson P; Neij L
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2004;101(7):2191-2196
Cyclin-dependent kinase 5 regulates dopaminergic and glutamatergic transmission in the striatum
Chergui K; Svenningsson P; Greengard P
Article: NEUROPHARMACOLOGY. 2004;47:14-23
The role of DARPP-32 in the actions of drugs of abuse
Nairn AC; Svenningsson P; Nishi A; Fisone G; Girault JA; Greengard P
Article: NEUROSCIENCE. 2004;127(4):983-988
Estradiol affects spinophilin protein differently in gonadectomized males and females
Lee SJ; Romeo RD; Svenningsson P; Campomanes CR; Allen PB; Greengard P; McEwen BS
Article: JOURNAL OF NEUROCHEMISTRY. 2003;87(6):1391-1401
Effect of methylphenidate on dopamine/DARPP signalling in adult, but not young, mice
Fukui R; Svenningsson P; Matsuishi T; Higashi H; Nairn AC; Greengard P; Nishi A
Article: SCIENCE. 2003;302(5649):1412-1415
Diverse psychotomimetics act through a common signaling pathway
Svenningsson P; Tzavara ET; Carruthers R; Rachleff I; Wattler S; Nehls M; McKinzie DL; Fienberg AA; Nomikos GG; Greengard P
Article: JOURNAL OF PROTEOME RESEARCH. 2003;2(2):213-219
Peptidomics-based discovery of novel neuropeptides
Svensson M; Sköld K; Svenningsson P; Andren PE
Article: BRAIN RESEARCH. 2002;955(1-2):8-15
Acute and repeated treatment with L-DOPA increase c-jun expression in the 6-hydroxydopamine-lesioned forebrain of rats and common marmosets
Svenningsson P; Arts J; Gunne L; Andren PE
Journal article: JOURNAL OF NEURAL TRANSMISSION. 2002;109(10):1295-1307
Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism
Klintenberg R; Svenningsson P; Gunne L; Andrén PE
Article: NATURE. 2002;418(6899):774-778
Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine
Lindskog M; Svenningsson P; Pozzi L; Kim Y; Fienberg AA; Bibb JA; Fredholm BB; Nairn AC; Greengard P; Fisone G
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2002;99(5):3188-3193
DARPP-32 mediates serotonergic neurotransmission in the forebrain
Svenningsson P; Tzavara ET; Liu F; Fienberg AA; Nomikos GG; Greengard P
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2002;99(5):3182-3187
Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac)
Svenningsson P; Tzavara ET; Witkin JM; Fienberg AA; Nomikos GG; Greengard P
Article: EUROPEAN JOURNAL OF NEUROSCIENCE. 2002;15(1):133-142
Dopamine D1/5 receptor stimulation induces c-fos expression in the subthalamic nucleus: possible involvement of local D5 receptors
Svenningsson P; Le Moine C
Article: NATURE. 2001;410(6826):376-380
Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5
Bibb JA; Chen JS; Taylor JR; Svenningsson P; Nishi A; Snyder GL; Yan Z; Sagawa ZK; Ouimet CC; Nairn AC; Nestler EJ; Greengard P
Article: JOURNAL OF NEUROSCIENCE. 2000;20(22):8443-8451
Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity
Calabresi P; Gubellini P; Centonze D; Picconi B; Bernardi G; Chergui K; Svenningsson P; Fienberg AA; Greengard P
Journal article: MOLECULAR PHARMACOLOGY. 2000;58(4):771-777
Adenosine A2A Receptors are Colocalized with and Activate Golf in Rat Striatum
Kull B; Svenningsson P; Fredholm BB
Article: MOLECULAR PHARMACOLOGY. 2000;58(4):771-777
Adenosine A_2A receptors are colocalized with and activate G_olf in rat striatum
Kull B; Svenningsson P; Fredholm BB
Article: NEUROPHARMACOLOGY. 2000;39(12):2374-2380
GTP differentially affects antagonist radioligand binding to adenosine A₁ and A_2A receptors in human brain
Kull B; Svenningsson P; Hall H; Fredholm BB
Article: JOURNAL OF NEUROCHEMISTRY. 2000;75(1):248-257
Dopamine D₁ receptor-induced gene transcription is modulated by DARPP-32
Svenningsson P; Fienberg AA; Allen PB; Le Moine C; Lindskog M; Fisone G; Greengard P; Fredholm BB
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2000;97(12):6809-6814
Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice
Bibb JA; Yan Z; Svenningsson P; Snyder GL; Pieribone VA; Horiuchi A; Nairn AC; Messer A; Greengard P
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2000;97(4):1856-1860
Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D₁, dopamine D₂, and adenosine A_2A receptors
Svenningsson P; Lindskog M; Ledent C; Parmentier M; Greengard P; Fredholm BB; Fisone G
Article: NEUROSCIENCE. 2000;98(4):749-757
Co-stimulation of D₁/D₅ and D₂ dopamine receptors leads to an increase in c-fos messenger RNA in cholinergic interneurons and a redistribution of c-fos messenger RNA in striatal projection neurons
Svenningsson P; Fredholm BB; Bloch B; Le Moine C
Article: NEUROSCIENCE. 2000;99(3):457-468
_L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset
Svenningsson P; Gunne L; Andren PE
Article: BIOCHEMICAL PHARMACOLOGY. 1999;58(6):1035-1045
Reciprocal interactions between adenosine A_2A and dopamine D₂ receptors in Chinese hamster ovary cells co-transfected with the two receptors
Kull B; Ferré S; Arslan G; Svenningsson P; Fuxe K; Owman C; Fredholm BB
Article: EUROPEAN JOURNAL OF NEUROSCIENCE. 1999;11(6):2182-2186
μ- and δ-opioid receptor agonists inhibit DARPP-32 phosphorylation in distinct populations of striatal projection neurons
Lindskog M; Svenningsson P; Fredholm B; Greengard P; Fisone G
Article: JOURNAL OF NEUROSCIENCE. 1999;19(10):4011-4022
The stimulatory action and the development of tolerance to caffeine is associated with alterations in gene expression in specific brain regions
Svenningsson P; Nomikos GG; Fredholm BB
Article: NEUROSCIENCE. 1999;89(3):827-837
Opposite tonic modulation of dopamine and adenosine on c-fos gene expression in striatopallidal neurons
Svenningsson P; Fourreau L; Bloch B; Fredholm BB; Gonon F; Le Moine C
Article: JOURNAL OF COMPARATIVE NEUROLOGY. 1998;399(2):229-240
Cellular distribution of adenosine A_2A receptor mRNA in the primate striatum
Svenningsson P; Le Moine C; Aubert I; Burbaud P; Fredholm BB; Bloch B
Article: NEUROSCIENCE. 1998;84(1):223-228
Activation of adenosine A_2A and dopamine D₁ receptors stimulates cyclic AMP dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons
Svenningsson P; Lindskog M; Rognoni F; Fredholm BB; Greengard P; Fisone G
Article: NEUROPHARMACOLOGY. 1998;37(3):331-337
Regional differences in the ability of caffeine to affect haloperidol-induced striatal c-fos mRNA expression in the rat
Svenningsson P; Nergårdh R; Fredholm BB
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 1997;27(4):322-335
Distribution of adenosine receptors in the postmortem human brain: An extended autoradiographic study
Svenningsson P; Hall H; Sedvall G; Fredholm BB
Article: EUROPEAN JOURNAL OF NEUROSCIENCE. 1997;9(11):2370-2382
Increased expression of NGFI-A mRNA in the rat striatum following burst stimulation of the medial forebrain bundle
Chergui K; Svenningsson P; Nomikos GG; Gonon F; Fredholm BB; Svennson TH
Article: JOURNAL OF NEUROSCIENCE. 1997;17(20):8038-8048
Dopamine-adenosine interactions in the striatum and the globus pallidus: Inhibition of striatopallidal neurons through either D-2A receptors enhances D-2 receptor-mediated effects on c-fos expression
LeMoine C; Svenningsson P; Fredholm BB; Bloch B
Article: EUROPEAN JOURNAL OF NEUROSCIENCE. 1997;9(10):2135-2141
Involvement of a c-fos-dependent mechanism in caffeine-induced expression of the preprotachykinin A and neurotensin/neuromedin N genes in rat striatum
Svenningsson P; Georgieva J; Kontny E; Heilig M; Fredholm BB
Article: NEUROSCIENCE. 1997;80(4):1171-1185
Cellular expression of adenosine A(2A) receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas
Svenningsson P; LeMoine C; Kull B; Sunahara R; Bloch B; Fredholm BB
Article: NEUROSCIENCE. 1997;79(3):753-764
Antagonism of adenosine A(2A) receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens
Svenningsson P; Nomikos GG; Ongini E; Fredholm BB
Article: JOURNAL OF MOLECULAR NEUROSCIENCE. 1997;8(1):29-44
On the role of the low-affinity neurotrophin receptor p75(LNTR) in nerve growth factor induction of differentiation and AP 1 binding activity in PC12 cells
Kontny E; Ciruela F; Svenningsson P; Ibanez CF; Fredholm BB
Article: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 1997;280(2):1094-1101
Glucocorticoids regulate the expression of adenosine A(1) but not A(2A) receptors in rat brain
Svenningsson P; Fredholm BB
Article: DRUG DEVELOPMENT RESEARCH. 1996;39(3-4):450-460
Neuropharmacology of the adenosine A(2A) receptors
Ongini E; Dionisotti S; Morelli M; Ferre S; Svenningsson P; Fuxe K; Fredholm BB
Article: DRUG DEVELOPMENT RESEARCH. 1996;39(3-4):262-268
Adenosine (P1) receptor signalling
Fredholm BB; Arslan C; Kull B; Kontny E; Svenningsson P
Article: EUROPEAN JOURNAL OF NEUROSCIENCE. 1996;8(7):1545-1553
Dopamine D-1 receptor-mediated facilitation of GABAergic neurotransmission in the rat strioentopeduncular pathway and its modulation by adenosine A(1) receptor-mediated mechanisms
Ferre S; OConnor WT; Svenningsson P; Bjorklund L; Lindberg J; Tinner B; Stromberg I; Goldstein M; Ogren SO; Ungerstedt U; Fredholm BB; Fuxe K
Journal article: ENERGY CONVERSION AND MANAGEMENT. 1996;37(6-8):1211-1216
Substituting fossil fuels with biomass
Gustavsson L; Svenningsson P
Article: LIFE SCIENCES. 1996;58(9):769-776
Adaptive changes in adenosine receptors following long-term treatment with the adenosine receptor agonist R-phenylisopropyl adenosine
Fernandez M; Svenningsson P; Fredholm BB
Article: BRAIN RESEARCH. 1996;35(1-2):183-189
Caffeine-induced expression of c-fos mRNA and NGFI-A mRNA in caudate putamen and in nucleus accumbens are differentially affected by the N-methyl-D-aspartate receptor antagonist MK-801
Svenningsson P; Johansson B; Fredholm BB
Journal article: ENERGY. 1995;20(11):1097-1113
REDUCING CO2 EMISSIONS BY SUBSTITUTING BIOMASS FOR FOSSIL-FUELS
GUSTAVSSON L; BORJESSON P; JOHANSSON B; SVENNINGSSON P
Article: JOURNAL OF NEUROSCIENCE. 1995;15(11):7612-7624
BIPHASIC CHANGES IN LOCOMOTOR BEHAVIOR AND IN EXPRESSION OF MESSENGER-RNA FOR NGFI-A AND NGFI-B IN RAT STRIATUM FOLLOWING ACUTE CAFFEINE ADMINISTRATION
SVENNINGSSON P; NOMIKOS GG; FREDHOLM BB
Article: JOURNAL OF NEUROSCIENCE. 1995;15(5):3583-3593
INCREASED EXPRESSION OF C-JUN, JUNB, AP-1, AND PREPROENKEPHALIN MESSENGER-RNA IN RAT STRIATUM FOLLOWING A SINGLE INJECTION OF CAFFEINE
SVENNINGSSON P; STROM A; JOHANSSON B; FREDHOLM BB
Article: ACTA PHYSIOLOGICA. 1995;154(1):17-24
EFFECT OF DIFFERENT XANTHINES AND PHOSPHODIESTERASE INHIBITORS ON C-FOS EXPRESSION IN RAT STRIATUM
SVENNINGSSON P; JOHANSSON B; FREDHOLM BB
Journal article: ACTA PHYSIOLOGICA. 1992;146(4):539-541
EVIDENCE THAT THE INCREASE IN STRIATAL C-FOS FOLLOWING ACUTE HIGH-DOSE CAFFEINE IS NOT DUE TO DIRECT INTERACTION WITH STRIATAL ADENOSINE RECEPTORS
JOHANSSON B; SVENNINGSSON P; ADEN U; LINDSTROM K; FREDHOLM BB
Visa fler

Alla övriga publikationer

Preprint: MEDRXIV. 2025
Non-equilibrium dynamics of the neocortex in Parkinson’s disease
Helson P; Benyahiya E; Manikandan S; Waldthaler J; Vinding M; Lundqvist D; Svenningsson P; Mitra D; Kumar A
Preprint: BIORXIV. 2025
Development of a protocol utilizing single-cell analysis for the differentiation of human iPSCs into SOX6+ midbrain dopaminergic neurons
Lyu G; Garcia-Swinburn R; Kreutzmann J; Xiong A; Kojima R; Abaurre C; Tremolanti C; Gellhaar S; Uhlén P; Svenningsonn P; Castelo-Branco G; Dagliyan O; Salto C; Arenas E
Preprint: BIORXIV. 2025
Revealing molecular determinants of ligand efficacy and affinity at the D₂dopamine receptor through molecular dynamics simulations
Chen Y; Kahlous NA; Saarinen M; Conesa SP; Svenningsson P; Delemotte L; Carlsson J
Preprint: BIORXIV. 2025
Computational design of constitutively active mutants of Dopamine D2 receptor inspired by ligand-independent activation mechanisms
Chen Y; Saarinen M; Naraine A; Carlsson J; Svenningsson P; Delemotte L
Preprint: MEDRXIV. 2025
Effects of Parkinson’s Disease on Mechanical and Microstructural Properties of the Brain
Olsson C; Skorpil M; Svenningsson P; Moreno R
Preprint: BIORXIV. 2025
Synaptotoxic forms of amyloid-β and α-synuclein act through a common pathway
Ribe E; Ghosh A; Paslawski W; Savory K; Ballard C; Morin P; Cash D; Hirth F; Williams G; Svenningsson P; Aarsland D; Siow RCM; Killick R
Preprint: BIORXIV. 2025
Met-ID: An Open-Source Software for Comprehensive Annotation of Multiple On-Tissue Chemical Modifications in MALDI-MSI
Bjärterot P; Nilsson A; Shariatgorji R; Vallianatou T; Kaya I; Svenningsson P; Käll L; Andrén P
Preprint: MEDRXIV. 2024;MEDRXIV
Cortical effects of dopamine replacement account for clinical response variability in Parkinson's disease.
Wiesman AI; Vinding MC; Tsitsi P; Svenningsson P; Waldthaler J; Lundqvist D
Review: NATURE REVIEWS NEUROLOGY. 2024;20(11):671-684
Fluid biomarkers of chronic traumatic brain injury
Friberg S; Lindblad C; Zeiler FA; Zetterberg H; Granberg T; Svenningsson P; Piehl F; Thelin EP
Review: MOVEMENT DISORDERS. 2024;39(10):1697-1709
Risk of Dementia in Parkinson's Disease: A Systematic Review and Meta-Analysis
Gibson LL; Weintraub D; Lemmen R; Perera G; Chaudhuri KR; Svenningsson P; Aarsland D
Preprint: BIORXIV. 2024
The CHCHD2-CHCHD10 protein complex is modulated by mitochondrial dysfunction and alters lipid homeostasis in the mouse brain
Gerlach J; Pireddu P; Zhang X; Wetzel S; Mennuni M; Milenkovic D; Nolte H; Branzell N; Kaya I; Villegas RG; Rubalcava-Gracia D; Alsina D; Feederle R; Andrén P; Langer T; Svenningsson P; Filograna R
Review: FRONTIERS IN PHARMACOLOGY. 2024;15:1450493
The leukotriene receptor antagonist montelukast as a potential therapeutic adjuvant in multiple sclerosis - a review
Pietrantonio F; Serreqi A; Zerbe H; Svenningsson P; Aigner L
Editorial comment: CURRENT OPINION IN NEUROLOGY. 2024;37(4):392-393
Update on movement disorders
Svenningsson P
Conference publication: ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. ANNUAL INTERNATIONAL CONFERENCE. 2024;2024:1-6
Usability of a Mobile Application for Patients with Parkinson's Disease.
Ymeri G; Maus B; Wassenburg M; Olsson CM; Svenningsson P; Salvi D
Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2024;25(13):7102
GBA1-Associated Parkinson's Disease Is a Distinct Entity
Skrahin A; Horowitz M; Istaiti M; Skrahina V; Lukas J; Yahalom G; Cohen ME; Revel-Vilk S; Goker-Alpan O; Becker-Cohen M; Hassin-Baer S; Svenningsson P; Rolfs A; Zimran A
Letter: TRANSLATIONAL NEURODEGENERATION. 2024;13(1):31
DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson's disease
Appleton E; Khosousi S; Ta M; Nalls M; Singleton AB; Sturchio A; Markaki I; Paslawski W; Iwaki H; Svenningsson P
Review: JOURNAL OF PARKINSONS DISEASE. 2024;14(4):657-666
Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials Initiative
Wyse RK; Isaacs T; Barker RA; Cookson MR; Dawson TM; Devos D; Dexter DT; Duffen J; Federoff H; Fiske B; Foltynie T; Fox S; Greenamyre JT; Kieburtz K; Kordower JH; Krainc D; Matthews H; Moore DJ; Mursaleen L; Schwarzschild MA; Stott SRW; Sulzer D; Svenningsson P; Tanner CM; Carroll C; Simon DK; Brundin P
Letter: MOVEMENT DISORDERS. 2024;39(6):1077
Comment to: "SCA4 Unravelled After More than 25 Years Using Advanced Genomic Technologies"
Paucar M; Nilsson D; Engvall M; Laffita-Mesa J; Wedell A; Svenningsson P
Editorial comment: MOVEMENT DISORDERS. 2024;39(6):929-933
Basic Science in Movement Disorders: Fueling the Engine of Translation into Clinical Practice
Outeiro TF; Kalia LV; Bezard E; Ferrario J; Lin C-H; Salama M; Standaert DG; Taiwo L; Takahashi R; Vila M; Mollenhauer B; Svenningsson P
Editorial comment: JOURNAL OF THE NEUROLOGICAL SCIENCES. 2024;460:123020
Novel findings in a Swedish primary familial brain calcification cohort
Sennfalt S; Gustavsson P; Malmgren H; Gilland E; Almqvist H; Oscarson M; Engvall M; Bjorkhem I; Nilsson D; Lagerstedt-Robinson K; Svenningsson P; Paucar M
Conference publication: PROCEEDINGS OF THE INTERNATIONAL SOCIETY FOR MAGNETIC RESONANCE IN MEDICINE ... SCIENTIFIC MEETING AND EXHIBITION.. 2024
Changes in Elasticity and Microstructural Properties of the Brain due to Parkinson's Disease
Olsson C; Skorpil M; Svenningsson P; Moreno R
Preprint: BIORXIV. 2024;BIORXIV
Gut-Initiated Alpha Synuclein Fibrils Drive Parkinson's Disease Phenotypes: Temporal Mapping of non-Motor Symptoms and REM Sleep Behavior Disorder.
Dautan D; Paslawski W; Montejo SG; Doyon DC; Marangiu R; Kaplitt MG; Chen R; Dawson VL; Zhang X; Dawson TM; Svenningsson P
Conference publication: 2024;00:112-116
Measuring finger dexterity in Parkinson’s disease with mobile phones
Ymeri G; Grech NS; Wassenburg M; Olsson CM; Svenningsson P; Salvi D
Corrigendum: NPJ PARKINSONS DISEASE. 2024;10(1):57
Generation of G51D and 3D mice reveals decreased α-synuclein tetramer-monomer ratios promote Parkinson's disease phenotypes (vol 10, 47, 2024)
Nuber S; Zhang X; Mccaffery TD; Moors TE; Adom M-A; Hahn WN; Martin D; Ericsson M; Tripathi A; Dettmer U; Svenningsson P; Selkoe DJ
Preprint: RESEARCH SQUARE. 2024
MRI subtypes in Parkinson’s disease: Unraveling differences across diverse populations and clustering approaches
Inguanzo A; Mohanty R; Poulakis K; Ferreira D; Segura B; Albrecht F; Muehlboeck J-S; Granberg T; Sjostrom H; Svenningsson P; Franzen E; Junque C; Westman E
Preprint: RESEARCH SQUARE. 2024
GPR37 Processing and Density in Neurodegeneration: A Potential Marker for Parkinson’s Disease Progression Rate
Argerich J; Garma L; López-Cano M; Álvarez-Montoya P; Gómez-Acero L; Fernández-Dueñas V; Muñoz-Manchado A; Aso E; Boxer A; Andres-Benito P; Svenningsson P; Ciruela F
Book chapter: PERVASIVE COMPUTING TECHNOLOGIES FOR HEALTHCARE: LECTURE NOTES OF THE INSTITUTE FOR COMPUTER SCIENCES, SOCIAL-INFORMATICS AND TELECOMMUNICATIONS ENGINEERING. 2024;p. 515-519
A Smartphone-Based Timed Up and Go Test for Parkinson’s Disease
Caramaschi S; Ymeri G; Olsson CM; Tsanas A; Wassenburg M; Svenningsson P; Salvi D
Preprint: ARXIV. 2023
Deep Learning for Time Series Classification of Parkinson's Disease Eye Tracking Data
Uribarri G; von Huth SE; Waldthaler J; Svenningsson P; Fransén E
Letter: MOVEMENT DISORDERS. 2023;38(11):2136-2137
Isolation of L1CAM-Extracellular Vesicles Reveals Signs of Insulin Resistance in Parkinson's Disease
Markaki I; Paslawski W; Ntetsika T; Engesvik L; Catrina S-B; Svenningsson P
Preprint: PREPRINTS.ORG. 2023
In Silico and In Vitro Study towards the Rational Design of 4,4′-Disarylbisthiazoles as a Selective α-Synucleinopathy Biomarker
Uzuegbunam B; Li J; Paslawski W; Weber W; Svenningsson P; Ågren H; B HY
Preprint: MEDRXIV. 2023
Spinocerebellar ataxia type 4 is caused by a GGC expansion in theZFHX3gene and is associated with prominent dysautonomia and motor neuron signs
Paucar M; Nilsson D; Engvall M; Laffita-Mesa J; Söderhäll C; Skorpil M; Halldin C; Fazio P; Lagerstedt-Robinson K; Solders G; Angeria M; Varrone A; Risling M; Jiao H; Nennesmo I; Wedell A; Svenningsson P
Preprint: BIORXIV. 2023
Parkin is not required to sustain OXPHOS function in adult mammalian tissues
Filograna R; Gerlach J; Choi H-N; Rigoni G; Barbaro M; Oscarson M; Lee S; Tiklova K; Ringnér M; Koolmeister C; Wibom R; Riggare S; Nennesmo I; Perlmann T; Wredenberg A; Wedell A; Motori E; Svenningsson P; Larsson N-G
Preprint: BIORXIV. 2023
Transcriptomic atlas of midbrain dopamine neurons uncovers differential vulnerability in a Parkinsonism lesion model
Yaghmaeian Salmani B; Lahti L; Gillberg L; Jacobsen JK; Mantas I; Svenningsson P; Perlmann T
Review: NATURE REVIEWS NEUROLOGY. 2023;19(6):333-345
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice
Chaudhuri KR; Leta V; Bannister K; Brooks DJJ; Svenningsson P
Conference publication: PROCEEDINGS OF THE INTERNATIONAL SOCIETY FOR MAGNETIC RESONANCE IN MEDICINE ... SCIENTIFIC MEETING AND EXHIBITION.. 2023
Visualizing Neuromelanin in Parkinson’s disease in the presence of motion
Skorpil M; Rydén H; Svenningsson P; van Niekerk A
Conference publication: NUKLEARMEDIZIN-NUCLEAR MEDICINE. 2023;62(02):89
Selective α-Synuclein PET Radiotracer Development- Characterization
Yousefi BH; Uzuegbunam BC; Paslawski W; Kotipalli GB; Luster M; Librizzi D; Weber W; Svenningsson P; Arzberger T
Corrigendum: NEUROPSYCHOPHARMACOLOGY. 2023;48(5):846
TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT_1A receptor agonist SEP- 363856 (vol 47, pg 2319, 2022)
Saarinen M; Mantas I; Flais I; Agren R; Sahlholm K; Millan MJ; Svenningsson P
Preprint: BIORXIV. 2023
Spatial Multimodal Analysis of Transcriptomes and Metabolomes in Tissues
Vicari M; Mirzazadeh R; Nilsson A; Shariatgorji R; Bjärterot P; Larsson L; Lee H; Nilsson M; Foyer J; Ekvall M; Czarnewski P; Zhang X; Svenningsson P; Andrén P; Lundeberg J
Preprint: BIORXIV. 2023
Cortex-wide topography of 1/f-exponent in Parkinson’s disease
Helson P; Lundqvist D; Svenningsson P; Vinding M; Kumar A
Editorial comment: FRONTIERS IN NEUROLOGY. 2023;14:1103116
Editorial: Body fluid biomarkers in neurodegenerative studies: Novel insights into pathophysiology to support clinical practice and drug development
Bougea A; Svenningsson P; Markaki I; Hye A; Mondello S
Preprint: RESEARCH SQUARE. 2022
Aberrant somatic L- and T-type calcium channel function in cNurr1 and LRRK2-G2019S mice
Chergui K; Skiteva O; Yao N; Mantas I; Zhang X; Perlmann T; Svenningsson P
Editorial comment: NEURAL REGENERATION RESEARCH. 2022;17(11):2445-2447
Are ATXN2 variants modifying our understanding about neural pathogenesis, phenotypes, and diagnostic?
Laffita-Mesa JM; Paucar M; Svenningsson P
Preprint: BIORXIV. 2022
SARS-CoV-2 and HSV-1 Induce Amyloid Aggregation in Human CSF Resulting in Drastic Soluble Protein Depletion
Christ W; Kapell S; Sobkowiak M; Mermelekas G; Evertsson B; Sork H; Saher O; Bazaz S; Gustafsson O; Cardenas E; Villa V; Ricciarelli R; Sandberg J; Bergquist J; Sturchio A; Svenningsson P; Malm T; Espay A; Pernemalm M; Lindén A; Klingström J; El Andaloussi S; Ezzat K
Preprint: BIORXIV. 2022
Single cell transcriptomics reveals correct developmental dynamics and high-quality midbrain cell types by improved hESC differentiation
Nishimura K; Yang S; Lee KW; Ásgrímsdóttir ES; Nikouei K; Paslawski W; Gnodde S; Lyu G; Hu L; Saltó C; Svenningsson P; Hjerling-Leffler J; Linnarsson S; Arenas E
Preprint: RESEARCH SQUARE. 2022
Changes in non-oscillatory features of the cortical sensorimotor rhythm in Parkinson's disease across age
Vinding M; Eriksson A; Manting C; Waldthaler J; Ferreira D; Ingvar M; Svenningsson P; Lundqvist D
Editorial comment: NEUROLOGY-GENETICS. 2022;8(3):e668
On Spinocerebellar Ataxia 21 as a Mimicker of Cerebral Palsy
van der Put J; Daugeliene D; Bergendal A; Kvarnung M; Svenningsson P; Paucar M
Conference publication: NUKLEARMEDIZIN-NUCLEAR MEDICINE. 2022;61(02):143-144
High Affinity Radiopharmaceuticals for Alpha-synuclein Aggregates with Improved Pharmacokinetics
Yousefi BH; Uzuegbunam BC; Paslawski W; Zhou Y; Luster M; Svenningsson P; Ågren H; Weber W
Preprint: BIORXIV. 2022
PRC2-mediated repression is essential to maintain identity and function of differentiated dopaminergic and serotonergic neurons
Toskas K; Yaghmaeian-Salmani B; Skiteva O; Paslawski W; Gillberg L; Skara V; Antoniou I; Södersten E; Svenningsson P; Chergui K; Ringnér M; Perlmann T; Holmberg J
Review: MOLECULAR PSYCHIATRY. 2022;27(1):534-558
Update on GPCR-based targets for the development of novel antidepressants
Mantas I; Saarinen M; Xu Z-QD; Svenningsson P
Editorial comment: NEUROLOGY-GENETICS. 2021;7(6):e636
Predominant Spastic Paraparesis Associated With the D178N Mutation in PRNP
Thams S; Paucar M; Wingard L; Thonberg H; Smith C; Nennesmo I; Svenningsson P
Preprint: MEDRXIV. 2021
Genome-wide association study of autopsy-confirmed Multiple System Atrophy identifies common variants near ZIC1 and ZIC4
Hopfner F; Tietz A; Ruf V; Ross O; Koga S; Dickson D; Aguzzi A; Attems J; Beach T; Beller A; van Deerlin V; Desplats P; Deuschl G; Duyckaerts C; Ellinghaus D; Evsyukov V; Flanagan ME; Franke A; Frosch M; Gearing M; Gelpi E; Ghetti B; Glass J; Grinberg L; Halliday G; Helbig I; Höllerhage M; Huitinga I; Irwin DJ; Keene D; Kovacs G; Lee E; Levin J; Martí M; Mackenzie I; McKeith I; Mclean C; Mollenhauer B; Neumann M; Newell K; Pantelyat A; Pendziwiat M; Peters A; Porcel LM; Rabano A; Matěj R; Rajput A; Rajput A; Reimann R; Scott W; Seeley W; Selvackadunco S; Simuni T; Stadelmann C; Svenningsson P; Thomas A; Trenkwalder C; Troakes C; Trojanowski J; White C; Xie T; Ximelis T; Yebenes J; the Alzheimer’s Disease Genetics Consortium; Müller U; Schellenberg G; Herms J; Kuhlenbäumer G; Höglinger G
Review: GENES. 2021;12(10):1529
Genetically Targeted Clinical Trials in Parkinson's Disease: Learning from the Successes Made in Oncology
Sjoegren M; Huttunen HJ; Svenningsson P; Widner H
Preprint: BIORXIV. 2021
Cerebrospinal fluid amyloid beta and glial fibrillary acidic protein concentrations in Huntington’s disease
Korpela S; Sundblom J; Zetterberg H; Constantinescu R; Svenningsson P; Paucar M; Niemelä V
Conference publication: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2021;92:A14
CEREBROSPINAL FLUID AMYLOID BETA AND GLIAL FIBRILLARY ACIDIC PROTEIN CONCENTRATIONS IN HUNTINGTON'S DISEASE
Korpela S; Sundblom J; Zetterberg H; Constantinescu R; Svenningsson P; Arce MP; Niemela V
Conference publication: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2021;92:A42-A43
DISEASE BURDEN IN PATIENTS WITH HUNTINGTON'S DISEASE FROM A NATIONWIDE SWEDISH REGISTRY COMPARED WITH THE GENERAL POPULATION (2002-2019)
Furby H; Moore S; Nordstroem A-L; Houghton R; Graham S; Lambrelli D; Svenningsson P; Petersen A
Preprint: RESEARCH SQUARE. 2021
Mitochondrial Biogenesis, Telomere Length and Cellular Senescence in Parkinson’s Disease and Lewy Body Dementia
Asghar M; Odeh A; Fattahi AJ; Henriksson AE; Miglar A; Khosousi S; Svenningsson P
Letter: MOVEMENT DISORDERS. 2021;36(8):1993
Reply to: "HbA1c and Motor Outcome in Parkinson's Disease in the Mark-PD Study"
Markaki I; Ntetsika T; Svenningsson P
Editorial comment: CURRENT OPINION IN NEUROLOGY. 2021;34(4):539-540
Update on movement disorders
Svenningsson P
Review: CURRENT OPINION IN NEUROLOGY. 2021;34(4):578-588
Ataxin-2 gene: a powerful modulator of neurological disorders
Laffita-Mesa JM; Paucar M; Svenningsson P
Review: CURRENT OPINION IN NEUROLOGY. 2021;34(4):572-577
Update on alpha-synuclein-based biomarker approaches in the skin, submandibular gland, gastrointestinal tract, and biofluids
Andreasson M; Svenningsson P
Preprint: MEDRXIV. 2021
Changes in non-oscillatory features of the cortical sensorimotor rhythm in Parkinson’s disease across age
Vinding M; Eriksson A; Ting Low CM; Waldthaler J; Ferreira D; Ingvar M; Svenningsson P; Lundqvist D
Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2021;22(11):5606
Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson's Disease
Wallin J; Svenningsson P
Letter: MOVEMENT DISORDERS. 2021;36(5):1278-1280
Cerebrospinal Fluid Proteins Altered in Corticobasal Degeneration
Paslawski W; Bergstrom S; Zhang X; Remnestal J; He Y; Boxer A; Manberg A; Nilsson P; Svenningsson P
Editorial comment: ANNALS OF NEUROLOGY. 2021;89(2):418-419
Hyperkinesias and Echolalia in Primary Familial Brain Calcification
Paucar M; Almqvist H; Bjorkhem I; Svenningsson P
Preprint: SSRN ELECTRONIC JOURNAL. 2021
Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Pet Study Using [ ¹¹C ] PBR28 and Machine Learning Enhanced Analysis
Jucaite A; Cselényi Z; Kreisl WC; Rabiner EA; Varrone A; Carson RE; Rinne JO; Savage A; Schou M; Johnström P; Svenningsson P; Rascol O; Meissner WG; Barone P; Seppi K; Kaufmann H; Wenning GK; Poewe W; Farde L
Published conference paper: JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY. 2020;31(12):2553-2557
Bromopyrylium Derivatization Facilitates Identification by Mass Spectrometry Imaging of Monoamine Neurotransmitters and Small Molecule Neuroactive Compounds
Shariatgorji R; Nilsson A; Strittmatter N; Vallianatou T; Zhang X; Svenningsson P; Goodwin RJA; Andren PE
Preprint: PSYARXIV. 2020
Changes in Emotional Regulation May Underlie Emotional Changes in Early Parkinson’s Disease Progression: A Multimodal Study.
Eriksson A; Tsitsi P; Vinding M; Ingvar M; Svenningsson P; Lundqvist D
Conference publication: PARKINSONISM & RELATED DISORDERS. 2020;79:E45
PHYSICIAN PREFERENCES FOR LEVODOPA-CARBIDOPA INTESTINAL GEL AS MONOTHERAPY VERSUS COMBINATION THERAPY FOR ADVANCED PARKINSON'S DISEASE: ANALYSIS FROM THE COSMOS STUDY
Fasano A; Parra JC; Gurevich T; Jech R; Bergmann L; Sanchez-Solino O; Svenningsson P; Szasz J; Vela-Desojo L
Preprint: RESEARCH SQUARE. 2020
Diagnostic value of plasma neurofilament light: A multicentre validation study
Ashton N; Janelidze S; Khleifat AA; Leuzy A; Ende EVD; Karikari T; Benedet A; Pascoal T; Lleó A; Parnetti L; Galimberti D; Bonanni L; Pilotto A; Padovani A; Lycke J; Novakova L; Axelsson M; Velayudhan L; Rabinovici G; Miller B; Pariante C; Nikkheslat N; Resnick S; Thambisetty M; Schöll M; Fernandez-Eulate G; Gil-Bea F; de Munain AL; Al-Chalabi A; Rosa-Neto P; Strydom A; Svenningsson P; Stomrud E; Santillo A; Aarsland D; Swieten JV; Palmqvist S; Zetterberg H; Blennow K; Hye A; Hansson O
Editorial comment: NEUROLOGY-GENETICS. 2020;6(4):e474
SLC1A3 variant associated with hemiplegic migraine and acetazolamide-responsive MRS changes
Paucar M; Granberg T; Lagerstedt-Robinson K; Waldenlind E; Petersson S; Nordin L; Svenningsson P
Preprint: RESEARCH SQUARE. 2020
Reliability of Dopamine Transporter PET Measurements with [18F]FE-PE2I in patients with Parkinson´s Disease
Kerstens V; Fazio P; Sundgren M; Matheson G; Franzén E; Halldin C; Cervenka S; Svenningsson P; Varrone A
Review: TRENDS IN PHARMACOLOGICAL SCIENCES. 2020;41(7):487-497
Modulation of Ion Channels and Receptors by p11 (S100A10)
Seo J-S; Svenningsson P
Preprint: RESEARCH SQUARE. 2020
Reliability of Dopamine Transporter PET Measurements with [18F]FE-PE2I in patients with Parkinson's Disease
Kerstens VS; Fazio P; Sundgren M; Matheson GJ; Franzén E; Halldin C; Cervenka S; Svenningsson P; Varrone A
Review: NATURE REVIEWS NEUROLOGY. 2020;16(5):265-284
An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders
Ashton NJ; Hye A; Rajkumar AP; Leuzy A; Snowden S; Suarez-Calvet M; Karikari TK; Scholl M; La Joie R; Rabinovici GD; Hoglund K; Ballard C; Hortobagyi T; Svenningsson P; Blennow K; Zetterberg H; Aarsland D
Book chapter: NEW OXFORD TEXTBOOK OF PSYCHIATRY. 2020;p. 779-788
Basic mechanisms of, and treatment targets for, depressive disorders
Pereira M; Andreatini R; Svenningsson P
Conference publication: MOLECULAR GENETICS AND METABOLISM. 2020;129(2):S128
Safety, pharmacokinetics, and pharmacodynamics of oral venglustat in Parkinson disease patients with a GBA mutation from Japan and the rest of the world: Results from part 'I of the MOVES-PD study
Peterschmitt MJ; Saiki H; Hatano T; Gasser T; Isaacson S; Kulisevsky J; Simuni T; Takahashi Y; Wills A-M; Guedes LC; Svenningsson P; Takahashi R; Waters C; Katsuno M; Ji AJ; Gaemers SJM; Minini P; Nembo B; Sardi P; Saubadu S; Sharma J; Fischer T
Review: INTERNATIONAL REVIEW OF NEUROBIOLOGY. 2020;155:91-112
Repurposing GLP1 agonists for neurodegenerative diseases
Markaki I; Winther K; Catrina S-B; Svenningsson P
Review: TREMOR AND OTHER HYPERKINETIC MOVEMENTS. 2019;9
Progressive Ataxia with Elevated Aipha-Fetoprotein: Diagnostic Issues and Review of the Literature
Paucar M; Taylor AMR; Hadjivassiliou M; Fogel BL; Svenningsson P
Preprint: BIORXIV. 2019
Reduction of spontaneous cortical beta bursts in Parkinson’s disease is linked to symptom severity
Vinding M; Tsitsi P; Waldthaler J; Oostenveld R; Ingvar M; Svenningsson P; Lundqvist D
Preprint: MEDRXIV. 2019
AETIONOMY, a Cross-Sectional Study Aimed at validating a new taxonomy of Neurodegenerative Diseases: Study design and subject characteristics
Corvol JC; Bujac S; Carvalho S; Clarke B; Marovac J; Mangone G; Rascol O; Meissner W; Magnin E; Foubert-Samier A; Catala H; Markaki I; Tsitsi P; Sanchez-Valle R; Heneka M; Molinuevo J-L; Wuellner U; Svenningsson P; Scordis P; Hofmann-Apitius M
Editorial comment: CURRENT OPINION IN NEUROLOGY. 2019;32(4):564-565
Update on movement disorders
Svenningsson P; Frucht SJ
Review: CURRENT OPINION IN NEUROLOGY. 2019;32(4):597-603
Corticobasal degeneration: advances in clinicopathology and biomarkers
Svenningsson P
Letter: PARKINSONISM & RELATED DISORDERS. 2019;62:253-255
Variant ataxia-telangiectasia with prominent camptocormia
Paucar M; Schechtmann G; Taylor AMR; Svenningsson P
Review: JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY. 2019;188:86-89
On the fluxes of side-chain oxidized oxysterols across blood-brain and blood-CSF barriers and origin of these steroids in CSF
Bjorkhem I; Leoni V; Svenningsson P
Conference publication: MOLECULAR GENETICS AND METABOLISM. 2019;126(2):S117
Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson disease patients with a GBA mutation
Peterschmitt MJ; Gasser T; Isaacson S; Kulisevsky J; Mir P; Simuni T; Wills A-M; Guedes LC; Svenningsson P; Waters C; Ji AJ; Li J; Minini P; Nembo B; Saubadu S; Sharma J; Fischer T
Review: CNS DRUGS. 2019;33(2):143-160
Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways
Green H; Tsitsi P; Markaki I; Aarsland D; Svenningsson P
Editorial comment: NEUROLOGY. 2018;91(15):710-712
Chorea, psychosis, acanthocytosis, and prolonged survival associated with ELAC2 mutations
Paucar M; Pajak A; Freyer C; Bergendal A; Dory M; Laffita-Mesa JM; Stranneheim H; Lagerstedt-Robinson K; Savitcheva I; Walker RH; Wedell A; Wredenberg A; Svenningsson P
Review: CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS. 2018;18(12):85
Novel Imaging Biomarkers for Huntington's Disease and Other Hereditary Choreas
Fazio P; Paucar M; Svenningsson P; Varrone A
Letter: MOVEMENT DISORDERS. 2018;33(10):1661-1662
Eye movements during reading in Parkinson's disease: A pilot study
Waldthaler J; Tsitsi P; Seimyr GO; Benfatto MN; Svenningsson P
Preprint: BIORXIV. 2018
Attenuated beta rebound to proprioceptive afferent feedback in Parkinson’s disease
Vinding M; Tsitsi P; Piitulainen H; Waldthaler J; Jousmäki V; Ingvar M; Svenningsson P; Lundqvist D
Editorial comment: ACTA NEUROLOGICA SCANDINAVICA. 2017;136(6):727-731
First clinical experience with levodopa/carbidopa microtablets in Parkinson's disease
Senek M; Hellstrom M; Albo J; Svenningsson P; Nyholm D
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2017;27:S754-S755
Neuropeptide Y and calcitonin gene-related peptide in CSF in Parkinson's disease with comorbid depression versus major depressive disorder
Mathe AA; Palhagen S; Svenningsson P
Review: TRENDS IN PHARMACOLOGICAL SCIENCES. 2017;38(8):749-760
Folding Underlies Bidirectional Role of GPR37/Pael-R in Parkinson Disease
Leinartaite L; Svenningsson P
Letter: JOURNAL OF THE NEUROLOGICAL SCIENCES. 2017;375:245-247
A SLC20A2 gene mutation carrier displaying ataxia and increased levels of cerebrospinal fluid phosphate
Paucar M; Almqvist H; Jelic V; Hagman G; Jorneskog G; Holmin S; Bjorkhem I; Svenningsson P
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2016;26:S371-S372
Ketamine is antidepressant and enhances neuropeptide Y expression in the prefrontal cortex and hippocampus of a serotonin transporter knock out rat model
Mathe AA; Nikosjkov A; Sousa V; Weide-Fischer C; Lennartsson A; Wegener G; Svenningsson P
Conference publication: BRAIN BEHAVIOR AND IMMUNITY. 2016;57:E24-E25
Peripheral inflammatory mediators and p11 levels in peripheral blood mononuclear cells from patients with Parkinson's disease
Green HF; Brodin L; Greengard P; Berg L; Svenningsson P
Review: JOURNAL OF NEUROCHEMISTRY. 2016;139:290-317
Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders
Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
Conference publication: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2016;87:A78-A79
CHOREA, PSYCHOTIC SYMPTOMS AND LONG SURVIVAL IN A SUBJECT WITH ELAC2 MUTATIONS
Paucar M; Pajak A; Freyer C; Stranneheim H; Wedell A; Wredenberg A; Svenningsson P
Letter: MOVEMENT DISORDERS. 2016;31(9):1422-1423
Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitorsA nationwide case-control study
Svenningsson P; Wirdefeldt K; Yin L; Fang F; Markaki I; Efendic S; Ludvigsson JF
Other: MOVEMENT DISORDERS CLINICAL PRACTICE. 2016;3(2):194-196
Concomitant Facioscapulohumeral Muscular Dystrophy and Parkinsonism Mimicking Multiple System Atrophy
Paucar M; Beniaminov S; Solders G; Svenningsson P
Editorial comment: NEUROLOGY. 2015;85(19):e143-e144
Teaching Video NeuroImages: Feeding dystonia in chorea-acanthocytosis
Paucar M; Lindestad P-A; Walker RH; Svenningsson P
Other: MOVEMENT DISORDERS CLINICAL PRACTICE. 2015;2(1):90-92
Novel APTX Mutation in a Hispanic Subject Affected by Ataxia with Oculomotor Apraxia Type 1
Paucar M; Alonso I; Eriksson M; Beniaminov S; Coutinho P; Svenningsson P
Book chapter: ENCYCLOPEDIA OF PSYCHOPHARMACOLOGY. 2015;p. 1375-1382
Proteomics
Andrén PE; Verhaert P; Svenningsson P
Review: NATURE REVIEWS NEUROLOGY. 2015;11(1):41-55
Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases
Lleo A; Cavedo E; Parnetti L; Vanderstichele H; Herukka SK; Andreasen N; Ghidoni R; Lewczuk P; Jeromin A; Winblad B; Tsolaki M; Mroczko B; Visser PJ; Santana I; Svenningsson P; Blennow K; Aarsland D; Luis Molinuevo J; Zetterberg H; Mollenhauer B
Letter: NEUROLOGY. 2014;82(22):2017-2025
Initial cognitive decline is associated with cortical thinning in early Parkinson disease
Pereira JB; Svenningsson P; Weintraub D; Bronnick K; Lebedev A; Westman E; Aarsland D
Editorial comment: BIOLOGICAL PSYCHIATRY. 2014;76(10):763-764
Reductions of p11 and 5-HT1B Receptor Availability in Limbic Brain Regions in Cocaine Dependence
Svenningsson P
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2014;24:S228-S229
Trace amine-associated receptor 1 inhibits a hyperglutamatergic state induced by dopamine deficiency
Alvarsson A; Stan TL; Schintu N; Kadkhodaei B; Millan MJ; Perlmann T; Svenningsson P
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2014;24:S259
Influence of stress and ketamine in immediate early gene activation in serotonin transporter knockout rats
Pereira M; Sousa VC; Stan T; Fischer CW; Wegener G; Olivier JDA; Mathe AA; Svenningsson P
Letter: MOLECULAR PSYCHIATRY. 2014;19(9):962-964
Preliminary evidence that early reduction in p11 levels in natural killer cells and monocytes predicts the likelihood of antidepressant response to chronic citalopram
Svenningsson P; Berg L; Matthews D; Ionescu DF; Richards EM; Niciu MJ; Malinger A; Toups M; Manji H; Trivedi MH; Zarate CAJ; Greengard P
Book chapter: ENCYCLOPEDIA OF PSYCHOPHARMACOLOGY. 2014;p. 1-8
Proteomics
Andrén PE; Verhaert P; Svenningsson P
Book chapter: CATECHOLAMINE RESEARCH IN THE 21ST CENTURY. 2014;p. 157-158
PET Imaging of Serotonin Transmission in Monkeys Effects of Maternal Separation and Long-Term Fluoxetine Treatment during Adolescence
Shrestha S; Liow J-S; Gladding R; Pike VW; Noble PL; Winslow JT; Suomi SJ; Svenningsson P; Nelson EE; Pine DS; Innis RB
Review: NEUROPSYCHOPHARMACOLOGY. 2014;39(1):34-49
Mass Spectrometry Imaging, an Emerging Technology in Neuropsychopharmacology
Shariatgorji M; Svenningsson P; Andren PE
Book chapter: NEUROPSYCHIATRIC AND COGNITIVE CHANGES IN PARKINSON'S DISEASE AND RELATED MOVEMENT DISORDERS. 2013;p. 109-210
Depression
Svenningsson P; Aarsland D
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2013;23:S34-S35
Effects of L-DOPA and sarizotan treatments in a parkinsonian rat model of depression
Schintu N; Zhang X; Mathe AA; Svenningsson P
Editorial comment: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2013;84(2):119
Using biomarkers to disentangle different causes of Parkinsonism
Aarsland D; Svenningsson P
Review: CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS. 2012;12(5):492-501
Clinical Trials of Dementia With Lewy Bodies and Parkinson's Disease Dementia
Aarsland D; Ballard C; Rongve A; Broadstock M; Svenningsson P
Conference publication: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2012;83:A19
A CASE OF HUNTINGTON DISEASE-LIKE 1 (HDL1) WITH LONG DISEASE DURATION
Paucar M; Winnberg E; Walker RH; Svenningsson P
Review: LANCET NEUROLOGY. 2012;11(8):697-707
Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment
Svenningsson P; Westman E; Ballard C; Aarsland D
Review: NEUROIMAGE. 2012;59(4):3243-3251
Serotonin-1A receptors in major depression quantified using PET: Controversies, confounds, and recommendations
Shrestha S; Hirvonen J; Hines CS; Henter ID; Svenningsson P; Pike VW; Innis RB
Review: JOURNAL OF PARKINSONS DISEASE. 2012;2(2):87-106
Studies of Depression-Related States in Animal Models of Parkinsonism
Schintu N; Zhang X; Svenningsson P
Review: NATURE REVIEWS NEUROLOGY. 2011;8(1):35-47
Depression in Parkinson disease-epidemiology, mechanisms and management
Aarsland D; Pahlhagen S; Ballard CG; Ehrt U; Svenningsson P
Letter: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2011;82(12):1409-1412
Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY
Orth M; Handley OJ; Schwenke C; Dunnett S; Wild EJ; Tabrizi SJ; Landwehrmeyer GB; Bachoud-Levi A-C; Bentivoglio AR; Biunno I; Bonelli R; Burgunder J-M; Dunnett SB; Ferreira JJ; Giuliano J; Heiberg A; Illmann T; van Kammen D; Levey J; Nielsen JE; Paivarinta M; Roos RAC; Rojo Sebastian A; Vandenberghe W; Verellen-Dumoulin C; Zaremba J; Uhrova T; Wahlstrom J; Wallner M; Barth K; Guedes LC; Finisterra AM; Garde MB; Bos R; Burg S; Ecker D; Held C; Koppers K; Laura M; Martinez Descals A; McLean T; Mestre T; Minster S; Monza D; Townhill J; Padieu H; Paterski L; Peppa N; Koivisto SP; Rialland A; Roren N; Sasinkova P; Trigo Cubillo P; Tritsch C; van Walsem MR; Witjes-Ane M-N; Yudina E; Zielonka D; Zielonka E; Zinzi P; Bonelli RM; Herranhof B; Holl A; Kapfhammer H-P; Koppitz M; Magnet M; Otti D; Painold A; Reisinger K; Scheibl M; Hecht K; Lilek S; Mueller N; Schoggl H; Ullah J; Brugger F; Hepperger C; Hotter A; Mahlknecht P; Nocker M; Seppi K; Wenning G; Buratti L; Hametner E-M; Holas C; Hussl A; Mair K; Poewe W; Wolf E; Zangerl A; Braunwarth E-M; Lilek S; Sinadinosa D; Walleczek AM; Ladurner G; Staffen W; Ribai P; Flamez A; Morez V; de Raedt S; Boogaerts A; van Reijen D; Klempir J; Kucharik M; Roth J; Senkarova Z; Hasholt L; Hjermind LE; Jakobsen O; Norremolle A; Sorensen SA; Stokholm J; Nielsen J; Hiivola H; Martikainen K; Tuuha K; Peippo M; Sipponen M; Ignatius J; Karppa M; Aman J; Santala M; Allain P; Guerid M-A; Gohier B; Olivier A; Prundean A; Scherer-Gagou C; Verny C; Babiloni B; Debruxelles S; Goizet C; Lafoucriere D; De Bruycker C; Carette A-S; Decorte E; Delval A; Delliaux M; Dujardin K; Peter M; Plomhouse L; Simonin C; Thibault-Tanchou S; Bellonet M; Duru C; Krystkowiak P; Roussel M; Wannepain S; Azulay J-P; Chabot C; Delphini M; Eusebio A; Grosjean H; Mundler L; Nowak M; Rudolf G; Steinmetz G; Tranchant C; Wagner C; Zimmermann M-A; Calvas F; Cheriet S; Demonet J-F; Galitzky M; Kosinski CM; Milkereit E; Probst D; Sass C; Schiefer J; Schlangen C; Werner CJ; Gelderblom H; Priller J; Pruess H; Spruth EJ; Andrich J; Hoffmann R; Kraus PH; Muth S; Prehn C; Saft C; Salmen S; Stamm C; Steiner T; Strassburger K; Lange H; Friedrich A; Hunger U; Loehle M; Schmidt S; Storch A; Wolz A; Wolz M; Lambeck J; Zucker B; Boelmans K; Ganos C; Hidding U; Lewerenz J; Muenchau A; Schmalfeld J; Stubbe L; Zittel S; Diercks G; Gorzolla H; Schrader C; Heinicke W; Ribbat M; Longinus B; Buerk K; Moeller JC; Rissling I; Peinemann A; Staedtler M; Weindl A; Bechtel N; Beckmann H; Bohlen S; Hoelzner E; Reilmann R; Rohm S; Rumpf S; Schepers S; Beister A; Dose M; Hammer K; Kieni J; Leythaeuser G; Marquard R; Raab T; Richter S; Selimbegovic-Turkovic A; Schrenk C; Schuierer M; Wiedemann A; Buck A; Connemann J; Eschenbach C; Landwehrmeyer B; Lezius F; Nepper S; Niess A; Suessmuth S; Trautmann S; Weydt P; Cormio C; Difruscolo O; Sciruicchio V; Serpino C; de Tommaso M; Capellari S; Cortelli P; Gallassi R; Poda R; Rizzo G; Scaglione C; Bertini E; Ghelli E; Ginestroni A; Piacentini S; Pradella S; Romoli AM; Sorbi S; Abbruzzese G; di Poggio MB; Di Maria E; Ferrandes G; Mandich P; Marchese R; Albanese A; Di Bella D; Di Donato S; Gellera C; Genitrini S; Mariotti C; Nanetti L; Paridi D; Soliveri P; Tomasello C; De Michele G; Di Maio L; Rinaldi C; Russo CV; Salvatore E; Tucci T; Cannella M; Codella V; De Gregorio F; De Nicola N; Martino T; Simonelli M; Squitieri F; Catalli C; Di Giacopo R; Fasano A; Frontali M; Guidubaldi A; Ialongo T; Jacopini G; Loria G; Modoni A; Piano C; Chiara P; Quaranta D; Romano S; Soleti F; Spadaro M; van Hout MSE; van Vugt JPP; de Weert AM; Bolwijn JJW; Dekker M; Leenders KL; van Oostrom JCH; Dumas EM; Jurgens CK; van den Bogaard SJA; 't Hart EP; Kremer B; Verstappen CCP; Frich J; Wehus R; Aaserud O; Borgerod N; Bjorgo K; Fannemel M; Gorvell P; Retterstol L; Overland T; Stokke B; Bjornevoll I; Sando SB; Blinkenberg EO; Hauge E; Tyvoll H; Sitek E; Slawek J; Soltan W; Boczarska-Jedynak M; Jasinska-Myga B; Opala G; Klodowska-Duda G; Banaszkiewicz K; Szczudlik A; Rudzinska M; Wojcik M; Dec M; Krawczyk M; Bryl A; Ciesielska A; Klimberg A; Marcinkowski J; Sempolowicz J; Samara H; Janik P; Kalbarczyk A; Kwiecinski H; Jamrozik Z; Antczak J; Jachinska K; Rakowicz M; Richter P; Ryglewicz D; Witkowski G; Zdzienicka E; Sulek A; Krysa W; Julio F; Januario C; Guedes L; Coelho M; Mendes T; Valadas A; Timoteo A; Costa C; Vale J; Cavaco S; Damasio J; Magalhaes M; Gago M; Garrett C; Guerra MR; Solis P; Duran Herrera C; Moreno Garcia P; Barrero F; Morales B; Cubo E; Mariscal N; Sanchez J; Alonso-Frech F; Rabasa Perez M; Fenollar M; Garcia-Ramos Garcia R; Pin Quiroga P; Vazquez Rivera S; Villanueva C; Bascunana M; Fatas Ventura M; Garcia Ribas G; Garcia de Yebenes J; Lopez-Sendon Moreno JL; Garcia Ruiz PJ; Saiz Artiga MJ; Sanchez V; Noguera Perea MF; Lorenza F; Antequera Torres MM; Reinante G; Vivancos Moreau L; Aguilar Barbera M; Badenes Guia D; Casas Hernanz L; Lopez Catena J; Quilez Ferrer P; Tome Carruesco G; Bas J; Busquets N; Calopa M; Teresa Buongiorno M; Munoz E; Dalmau Elorza M; Diez-Aja Lopez C; Duran-Sindreu Terol S; Floriach Robert M; Garzon Ruiz B; Gonzalez Casado A; Haro Martinez I; Mareca Viladrich C; Pons i Cardenas R; Roca E; Roig Llesoy J; Ruiz Idiago JM; Ruiz Vergara M; Soriano Garcia S; Villa Riballo A; Gonzalez Gonzalez S; Menendez Guisasola L; Salvador C; Suarez San Martin E; Gorospe A; Legarda I; Navas Arques P; Torres Rodriguez MJ; Vives B; Gaston I; Ramos-Arroyo MA; Garcia Moreno JM; Chacon Pena J; Dinca Avarvarei L; Martin Bastida A; Fernandez Recio M; Redondo Verge L; Sanchez Sanchez V; Carrillo F; Teresa Caceres M; Mir P; Lama Suarez MJ; Bosca M; Andres Burguera J; Campos Garcia A; Martinez Martinez L; Lopez del Val J; Loutfi G; Olofsson C; Stattin E-L; Westman L; Wikstrom B; Hoglund A; Palhagen SE; Paucar M; Sandstrom B; Soltani R; Svenningsson P; Reza-Soltani TW; Constantinescu R; Fredlund G; Hosterey-Ugander U; Neleborn-Lingefjard L; Esmaeilzadeh M; Tedroff J; Winnberg E; Bjorn Y; Ekwall C; Goller M-L; Johansson A; Wiklund L; Petersen A; Reimer J; Widner H; Burgunder Y; Stebler Y; Kaelin A; Romero I; Schupbach M; Zaugg SW; Jack R; Matheson K; Miedzybrodzka Z; Rae D; Simpson S; Summers F; Ure A; Crooks J; Curtis A; de Souza (Keylock) J; Rickards H; Wright J; Hayward B; Sieradzan K; Wright A; Barker RA; Di Pietro A; Fisher K; Goodman A; Hill S; Kershaw A; Mason S; Paterson N; Raymond L; Bisson J; Busse M; Clenaghan C; Ellison-Rose L; Handley O; Hunt S; Price K; Rosser A; Edwards M; Hughes T; McGill M; Pearson P; Porteous M; Smith P; Zeman A; Causley A; Harrower T; Howcroft D; Lambord N; Rankin J; Brockie P; Foster J; Johns N; McKenzie S; Rothery J; Thomas G; Yates S; Miller J; Ritchie S; Burrows L; Fletcher A; Harding A; Laver F; Silva M; Thomson A; Burns P; Chu C; Evans C; Hamer S; Markova I; Miller J; Raman A; Barnes K; Hobson E; Jamieson S; Thomson J; Toscano J; Wild S; Yardumian P; Bourne C; Clayton C; Dipple H; Clapton J; Grant J; Gross D; Hallam C; Middleton J; Murch A; Patino D; Bate L; Pate L; Andrews T; Dougherty A; Kavalier F; Golding C; Lashwood A; Robertson D; Ruddy D; Whaite A; Patton M; Peterson M; Rose S; Bruno S; Chu E; Doherty K; Henley S; Lahiri N; Novak M; Patel A; Read J; Rosser E; Say M; Tabrizi S; Taylor R; Warner T; Wild E; Arran N; Callaghan J; Craufurd D; Fullam R; Howard L; Huson S; Oughton E; Partington-Jones L; Snowden J; Sollom A; Stopford C; Thompson J; Trender-Gerhad I; Verstraelen N; Westmoreland L; Nemeth AH; Siuda G; Harrison D; Hughes M; Parkinson A; Soltysiak B; Burn J; Coleman C; Majeed T; Bandmann O; Bradbury A; Gill P; Fairtlough H; Fillingham K; Foustanos I; O'Donovan K; Tidswell K; Quarrell O; Massaro F; Mechi C; Paganini M
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2011;21:S374-S375
Trace amine-associated receptor mRNA expression in the mouse brain
Lundius EG; Svenningsson P
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2011;21:S272
Behavioural and biochemical evaluation of the anti-dyskinetic potential of sarizotan, a 5-HT_1A agonist, in 6-ODHA lesioned rats
Schintu N; Zhang X; Svenningsson P
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2011;21:S408-S409
Cannabinoid CB1 receptor expression and G protein coupling in a genetic model of depression
Sousa VC; Zhang X; Qi H; El Yacoubi M; Vaugeois JM; Svenningsson P
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2011;21:S378
Ablated neurogenic response to fluoxetine in female p11 knockout mice
Egeland M; Warner-Schmidt J; Greengard P; Svenningsson P
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2011;21:S276-S277
The effects of 5-HT1B receptor modulation on glutamatergic neurotransmission in vivo
Alvarsson A; Eriksson TM; Stan T; Hascup KN; Hascup ER; Gerhardt GA; Svenningsson P
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2011;21:S410
Glutamatergic deficits and differential antidepressant regulation in rat model of depression
Eriksson TM; Delagrange P; Spedding M; Popoli M; Mathe AA; Ogren SO; Svenningsson P
Review: ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY. 2011;51:211-242
Modulation of Monoamine Receptors by Adaptor Proteins and Lipid Rafts: Role in Some Effects of Centrally Acting Drugs and Therapeutic Agents
Bjork K; Svenningsson P
Book chapter: NEUROPLASTICITY. 2011;p. 27-39
Regulation of Cellular Plasticity in Mood Disorders: The Role of the AMPA Receptor
Svenningsson P; McEwen BS
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2010;20:S186
Potential therapeutic targets from cellular/molecular signalling mechanisms in depression models
Svenningsson P; Eriksson TM; Bjork K; Ogren SO; Mathe A; El Yacoubi M; Vaugeois JM
Review: EXPERIMENTAL CELL RESEARCH. 2010;316(8):1351-1356
Regulation of serotonin receptor function in the nervous system by lipid rafts and adaptor proteins
Bjork K; Sjogren B; Svenningsson P
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2010;20:S37-S38
Subchronic administration of phencyclidine reduces social interaction and increases aggressive-like behaviour in mice
Elvander-Tottie E; Tai F; Holst S; Beraki S; Wadenberg S; Svenningsson P; Ogren SO
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2010;20:S42-S43
Mice lacking two key phosphorylation sites on the GluR1 subunit exhibit decreased anxiety-like behaviour
Kiselycznyk C; Svenningsson P
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2010;20:S6-S7
Neurogenic and chronic behavioural effects of fluoxetine are attenuated in p11 KO mice
Egeland M; Warner-Schmidt J; Greengard P; Svenningsson P
Review: MOLECULAR PSYCHIATRY. 2010;15(3):237-249
The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation
McEwen BS; Chattarji S; Diamond DM; Jay TM; Reagan LP; Svenningsson P; Fuchs E
Book chapter: ENCYCLOPEDIA OF PSYCHOPHARMACOLOGY. 2010;p. 1075
Protein Microarray
Verheart P; Svenningsson P; Andrén P
Book chapter: ENCYCLOPEDIA OF PSYCHOPHARMACOLOGY. 2010;p. 1077-1083
Proteomics
Andrén PE; Verhaert P; Svenningsson P
Book chapter: ENCYCLOPEDIA OF PSYCHOPHARMACOLOGY. 2010;p. 1052-1053
Post-Translational Modification
Verheart P; Svenningsson P; Andrén P
Book chapter: ENCYCLOPEDIA OF PSYCHOPHARMACOLOGY. 2010;p. 1351
Two-Dimensional Gel Electrophoresis
Verhaert P; Svenningsson P; Andrén PE
Book chapter: ENCYCLOPEDIA OF PSYCHOPHARMACOLOGY. 2010;p. 472
Electrospray Ionization
Verheart P; Svenningsson P; Andrén PE
Book chapter: ENCYCLOPEDIA OF PSYCHOPHARMACOLOGY. 2010;p. 856
Neuropeptidomics
Verheart P; Svenningsson P; Andrén P
Book chapter: ENCYCLOPEDIA OF PSYCHOPHARMACOLOGY. 2010;p. 617
Imaging Mass Spectrometry
Verheart P; Svenningsson P; Andrén PE
Book chapter: ENCYCLOPEDIA OF PSYCHOPHARMACOLOGY. 2010;p. 750
Mass Spectrometry
Verhaert P; Svenningsson P; Andrén PE
Book chapter: ENCYCLOPEDIA OF PSYCHOPHARMACOLOGY. 2010;p. 756
Metabolomics
Verhaert P; Svenningsson P; Andrén PE
Book chapter: ENCYCLOPEDIA OF PSYCHOPHARMACOLOGY. 2010;p. 751
Matrix-Assisted Laser Desorption Ionization
Verhaert P; Svenningsson P; Andrén PE
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2009;19:S181
Sarizotan stimulates cell proliferation in neurogenic regions in experimental Parkinsonism
Egeland M; Zhang X; Svenningsson P
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2009;19:S10-S11
Stimulation of 5-HT7 receptors facilitates emotional contextual learning
Eriksson TM; Youn J; Elvander-Tottie E; Sjogren B; Ekstrom JC; Ogren SO; Svenningsson P; Stiedl O
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2009;19:S9-S10
Sarizotan stimulates cell proliferation in neurogenic regions in experimental Parkinsonism
Egeland M; Zhang X; Svenningsson P
Review: BEHAVIOURAL BRAIN RESEARCH. 2008;195(1):54-77
The role of 5-HT_1A receptors in learning and memory
Ogren SO; Eriksson TM; Elvander-Tottie E; D'Addario C; Ekstrom JC; Svenningsson P; Meister B; Kehr J; Stiedl O
Book chapter: DRUG ADDICTION. 2008;p. 3-16
DARPP-32 Mediates the Actions of Multiple Drugs of Abuse
Svenningsson P; Nairn AC; Greengard P
Book chapter: PEPTIDOMICS. 2007;p. 177-189
The Importance of Sample Handling in Neuropeptidomics
Sköld K; Svensson M; Nilsson A; Fälth M; Svenningsson P; Andrén P
Book chapter: PEPTIDOMICS. 2007;p. 139-152
Strategies for Reliable and Improved Identification of Peptides
Sköld K; Fälth M; Svensson M; Nilsson A; Svenningsson P; Andrén PE
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:S270
5-HT7 receptors interact with NMDA and 5-HT1A receptor-dependent emotional learning and exploratory activity in mice
Eriksson TM; Elvander-Tottie E; Budd JC; Sjoegren B; Svenningsson P; Oegren SO
Conference publication: BIOCHEMICAL SOCIETY TRANSACTIONS. 2007;35(Pt 3):588-593
Neuropeptidomics:: expanding proteomics downwards
Svensson M; Skold K; Nilsson A; Falth M; Svenningsson P; Andren PE
Published conference paper: ACTA PHYSIOLOGICA. 2007;190(1):47-53
Depletion of the lipid raft constituents, sphingomyelin and ganglioside, decreases serotonin binding at human 5-HT_7(a) receptors in HeLa cells
Sjogren B; Svenningsson P
Editorial comment: CURRENT OPINION IN PHARMACOLOGY. 2007;7(1):1-2
Many ways to Rome - multiple approaches to novel drugs
Chergui K; Fredholm BB; Svenningsson P
Review: CURRENT OPINION IN PHARMACOLOGY. 2007;7(1):27-32
p11 (S100A10) - an inducible adaptor protein that modulates neuronal functions
Svenningsson P; Greengard P
Book chapter: IMMEDIATE EARLY GENES IN SENSORY PROCESSING, COGNITIVE PERFORMANCE AND NEUROLOGICAL DISORDERS. 2006;p. 261-290
Parkinson’s Disease, the Dopamine System and Immediate Early Genes
Zhang X; Svenningsson P
Published conference paper: AAPS JOURNAL. 2005;7(2):E353-E360
DARPP-32 mediates the actions of multiple drugs of abuse.
Svenningsson P; Nairn AC; Greengard P
Review: INTERNATIONAL REVIEW OF NEUROBIOLOGY. 2005;63:191-270
Adenosine and brain function
Fredholm BB; Chen JF; Cunha RA; Svenningsson P; Vaugeois JM
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2004;14:S117-S118
Diverse psychotomimetics act through a common signaling pathway
Svenningsson P; Tzavara ET; Carruthers R; Nomikos GG; Greengard P
Editorial comment: SCIENCE. 2004;305(5681):180d
Response to comment on "Diverse psychotomimetics act through a common signaling pathway"
Svenningsson P; Nomikos GG; Greengard P
Review: JOURNAL OF PROTEOME RESEARCH. 2004;3(2):289-295
Molecular profiling of experimental Parkinson's disease: Direct analysis of peptides and proteins on brain tissue sections by MALDI mass spectrometry
Pierson J; Norris JL; Aerni HR; Svenningsson P; Caprioli RM; Andrén PE
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2004;14:S9-S10
Diverse psychotomimetics act through a common signaling pathway
Svenningsson P; Tzavara ET; Fienberg AA; Nomikos GG; Greengard P
Review: ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY. 2004;44:269-296
DARPP-32: An integrator of neurotransmission
Svenningsson P; Nishi A; Fisone G; Girault JA; Nairn AC; Greengard P
Other: NEUROLOGY. 2003;61(11 Suppl 6):S10-S11
Exciting news about A2A receptors.
Svenningsson P; Fredholm BB
Review: NEUROLOGY. 2003;61(11 Suppl 6):S5-S9
Adenosine-dopamine interactions: development of a concept and some comments on therapeutic possibilities.
Fredholm BB; Svenningsson P
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2003;13:S102-S103
Biochemical modulation of AMPA receptor function by antidepressants
Svenningsson P; Tzavara E; Nomikos G; McEwen B; Greengard P
Review: CURRENT TOPICS IN MEDICINAL CHEMISTRY. 2003;3(4):413-426
Pharmacology of adenosine A_2A receptors and therapeutic applications
Fredholm BB; Cunha RA; Svenningsson P
Book chapter: EMERGING TECHNOLOGIES IN PROTEIN AND GENOMIC MATERIAL ANALYSIS: JOURNAL OF CHROMATOGRAPHY LIBRARY. 2003;p. 155-167
Chapter 8 Peptidomics-based Discovery of Endogenous Neuropeptides in the Brain
Andren PE; Svensson M; Sköld K; Svenningsson P
Published conference paper: DRUG DEVELOPMENT RESEARCH. 2001;52(1-2):274-282
Adenosine receptor signaling in vitro and in vivo
Fredholm BB; Arslan G; Halldner L; Kull B; Schulte G; Ådén U; Svenningsson P
Review: PROGRESS IN NEUROBIOLOGY. 1999;59(4):355-396
Distribution, biochemistry and function of striatal adenosine A_2A receptors
Svenningsson P; Le Moine C; Fisone G; Fredholm BB
Letter: NEUROSCIENCE. 1999;88(4):1005-1008
Activation of dopamine D₂ receptors decreases DARPP-32 phosphorylation in striatonigral and striatopallidal projection neurons via different mechanisms
Lindskog M; Svenningsson P; Fredholm BB; Greengard P; Fisone G
Published conference paper: DRUG DEVELOPMENT RESEARCH. 1998;45(3-4):324-328
Locating the neuronal targets for caffeine
Fredholm BB; Arslan G; Kull B; Svenningsson P
Doctoral thesis: 1998
Striatal adenosine A2A receptors
Svenningsson P
Letter: TRENDS IN PHARMACOLOGICAL SCIENCES. 1998;19(2):46-48
Striatal adenosine A_2A receptors - where are they? What do they do?
Fredholm BB; Svenningsson P
Published conference paper: NEUROPHARMACOLOGY. 1997;36(9):1309-1317
Caffeine mimics the effect of a dopamine D-2/3 receptor agonist on the expression of immediate early genes in globus pallidus
Svenningsson P; Fredholm BB
Visa fler

Forskningsbidrag

Perfusion and dopamine transporter availability in parkinsonian disorders - machine-learning-based differential diagnosis using positron emission tomography
Swedish Research Council
1 January 2024 - 31 December 2026
Parkinson’s disease and related disorders are the second most common neurodegenerative diseases. Parkinsonian disorders present with similar symptoms at their onset. The diagnosis, which is based on clinical criteria and follow-up, is challenging. An uncertain or wrong diagnosis may lead to inappropriate treatment and unwanted side effects for the individual patient and increased costs for the healthcare system. Early, precise diagnosis is crucial for the development of treatments targeting molecular mechanisms of underlying disease.The aim of the present work is to identify characteristic patterns of cerebral blood flow (CBF) and their association with dopamine transporter (DAT) availability in parkinsonian disorders. This will be used to develop methods for precise differential diagnosis with PE2I positron emission tomography (PET) and supervised machine learning (ML). 18F-FE-PE2I PET/CT scans providing both CBF and DAT availability from a single scan will be acquired in a cohort of at least 2500 patients from five Swedish university hospitals and will, together with comprehensive clinical diagnosis, be used to train ML-based classification.The project will result in a more precise method for differential diagnosis of parkinsonian disorders that will be available beyond specialized academic centres. It will further increase understanding of parkinsonism, support appropriate treatment in individual patients, and provide improved imaging biomarkers for drug development.
A Noradrenergic Marker for the Early Detection and Personalized Treatment of Alzheimer’s and Parkinson’s diseases
Swedish Research Council
1 January 2023 - 31 December 2025
The aim of this project is to identify the alterations in the major source of noradrenaline in the brain, the locus coeruleus, and establish whether these alterations can detect Alzheimer’s disease and Parkinson’s disease at an early stage. We will use a non-invasive technique called magnetization transfer ratio to measure the locus coeruleus in four different cohorts. Our results will establish whether changes in the locus coeruleus precede abnormalities in cerebrospinal fluid, plasma and imaging markers in the course of these neurodegenerative diseases. Moreover, we will establish whether different subregions within the locus coeruleus can predict different clinical symptoms and clinical trajectories, being useful to create a precision medicine approach that takes into account individual patient characteristics. Finally, we will use the locus coeruleus as an outcome measure in current multi-domain clinical trials to identify patients that are most likely to benefit from treatment. This will also allow us to obtain information on how new preventive therapies might be created to boost the neuroprotective functions of the locus coeruleus against pathological protein accumulation. We are confident that we can achieve these aims in a timely manner due to our excellent team of experts and our access to all the necessary equipment and a unique infrastructure that will allow a fast translation of our findings to clinical trials.
Exploration of neurochemical changes associated with L-DOPA-induced dyskinesia in Parkinson´s disease by mass spectrometry imaging
Swedish Research Council
1 January 2023 - 31 December 2026
The aim of this project is to elucidate L-DOPA-induced dyskinesia (LID) in Parkinson’s disease (PD) by clarifying the pathophysiological mechanisms involved, which are currently unknown although LID is one of the most difficult problems facing patients with PD. We will use innovative matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) to simultaneously image and quantify neurotransmitter and neuropeptide systems, endogenous metabolites and lipids, and proteins directly in brain tissue sections. Achievement of this aim will be facilitated by access to a biobank of brain tissues of non-human primates providing unprecedentedly comprehensive coverage of an LID model and controls, neurotoxic and genetic rodent PD models, as well as human brains and cerebrospinal fluid. We will develop methodology for highly multiplex protein imaging by MALDI-MSI. To enable imaging of single cells directly in tissue sections we will increase the spatial resolution to &lt
1 µm by using deep learning technology. We will also design and synthesise chemical tools enabling imaging of hitherto undetectable endogenous substances in the samples, and apply pathway analysis to determine the signalling status of the cells, quantitatively, from measured expression levels of molecular species. Thus, the project will provide novel insights into the underlying mechanisms of LID (and PD), which may enable development of new therapy targets and/or clinically useful biomarkers.
A RCT study of Montelukast in Parkinson’s disease
Swedish Research Council
1 January 2023 - 31 December 2026
Parkinson’s disease (PD) is the fastest growing neurodegenerative disease, and the development of a disease-modifying therapy is the most important unmet goal in the therapy of PD. Preclinical and clinical studies have shown promising results of the anti-inflammatory agent Montelukast in PD. We have now designed a multi-center, randomized, double-blind, placebo-controlled trial with Montelukast in PD.PICO Population: Diagnosis of PD. Males or Females. H&Y stage ≤ 2. ≥35 and ≤80 years of age. Signed informed consent to participate in the trial. Clinical diagnosis &lt
4 years. Ability to self-administer the trial drug. Intervention: 18 months of daily buccal Montelukast 2x30 mg. Control: Placebo. Primary outcome: Change of MDS-UPDRS motor score in OFF medication state at 18 months. Secondary outcomes are changes in effects on non-motor symptoms of Montelukast using MDS-NMSS and HADS. There is also a safety objective and several exploratory outcomes.Ninty patients with early-moderate PD in Stockholm, Lund, Uppsala, Göteborg and London will be recruited. Ethical permits and MPA applications will be submitted in the beginning of 2023. Patient recruitment will start in April 2023 and the last patient follow-up will be in March 2026 followed by data analysis/reporting. The study is endorsed by the Swedish PD patientorganization and Cure Parkinson. If this RCT is successful and since Montelukast is repurposed, patients will soon benefit from the therapy.
Park-MOVE: Moving towards personalized rehabilitation for Parkinson’s disease informed by diversity, exercise responders and brain activity during motion.
Swedish Research Council
1 January 2023 - 31 December 2026
Life means combining motor-cognitive skills, e.g., walking, talking and navigating. Aging or neurological diseases, e.g., Parkinson’s disease (PD) compromises these skills needed for an independent life. It is uncertain which brain alterations lead to these difficulties and how to target these heterogenous motor-cognitive difficulties. Current treatments apply a "one-size-fits-all" approach, which needs to evolve towards personalized rehabilitation, reaching beyond a simple adaption to disease severity.Our multimodal project combines physiotherapy, neurology, psychology and neuroimaging to characterize motor-cognitive skills during complex walking, identify underlying brain alterations and subtype PD to inform a novel exercise approach for people with PD. This 5 years proposal has 4 stages: 1) Exploring brain alterations and links to the motor-cognitive skills in healthy and PD 2) PD subtyping using neuroimaging, motor, cognitive and clinical data 3) Characterization of exercise responsiveness in PD and 4) Development and testing of a personalized motor-cognitive exercise program. We combine novel techniques for data collection with in-depth analysis of existing data (EXPANd trial). The results will have an immediate application and clinical relevance for personalized rehabilitation in older and PD. There is no cure for PD yet, thus positive findings would revolutionize treatment, giving new hope to patients for a life with improved health, independence and higher quality.
CAPSI - Cancer related major depression treated with a single dose of pslilocybin - a randomised placebo controlled double blind clinical trial
Swedish Research Council
1 January 2023 - 31 December 2026
Background: The age standardised rate of yearly new cancer cases is 190/100 000 globally, by WHO. 30-40% of these will develop depression. There is currently no specific antidepressant treatment regime implemented in the cancer population. This is in spite of the specific needs given by concurrent cancer treatments, limited quality of life from the cancer per se and the often limited life expectancy from a cancer disease. A single dose of psilocybin combined with 3 hours of psychological support has shown rapid (within days) and long term (months or years) antidepressant effect in several small studies in different cancer populations. Large, well designed RCTs are still lacking, as is response predictors for treatment guidance. I am PI of the first RCT of psilocybin treament of depression in Sweden, expected to end randomisation in june 2022. CAPSI: 100 patients with cancer and depression will be randomised to psilocybin or active placebo (2:1) at 4 different regions in Sweden during 2024-2025. Primary end point is depressive symptoms 6 weeks post dose and follw up is 6 months. All subjects will undergo EEG and blood sampling, a subsample (n=50) will also undergo MEG and fMRI, and 25 of them also PET, in order to develop a EEG proxy response signature. Together with markers in blood we will develop a predictor model for psilocybin treatment response. All data will be used to motivate a phase three study with the same PICO and further development of the response markers.
Spatial Omics Enable Improved Pathophysiology-based Diagnosis of Parkinson´s Disease Dementia and Dementia with Lewy Bodies
Swedish Research Council
1 January 2022 - 31 December 2027
We propose an innovative interdisciplinary research environment to investigate the pathophysiology of dementia in Parkinson’s disease (PDD) and Lewy Body dementia (LBD). Based on the identified molecular fingerprints we will also develop diagnostic and prognostic wet biomarkers. PDD and LBD are difficult to diagnose in the clinic and no diagnostic test is available. Differentiation from parkinsonian plus syndromes and Alzheimer’s disease is a major challenge and will be examined. The research environment consists of a unique combination of spatial omics methodologies, i.e., spatial transcriptomics, -proteomics, and -mass spectrometry combined with state-of-the-art bioinformatic tools. We synthesise chemical tools to enable detection low-abundant potential biomarkers compatible with the spatial analysis of a particular imaging modality. Clinical samples are available from the Stockholm BioPark cohort and King’s College Dementia Brain biobank. First, we will examine a comprehensive set of cortical post-mortem brains from control, PD, PDD and LBD. The biomarker potential of pathologically relevant molecules will then be assessed in CSF and plasma from a cohort of 650 patients. We aim at stimulating the needed of collaborations in correlated spatial omics, promoting and disseminating its benefits, and paving the way for its technological advancement and implementation in the neurological field to ultimately impact on clinically unmet medical needs for PDD and LBD patients.
Development of an imaging marker for synaptic vesicular glycoprotein SV2C: a specific target for synaptic density in Parkinson´s disease
Swedish Research Council
1 January 2021 - 31 December 2023
Receptor-mediated mechanisms in Parkinson´s disease and depression
Swedish Research Council
1 January 2020 - 31 December 2024
Molecular evolution and design of G protein-coupled receptors with tailored ligand specificity
Knut and Alice Wallenberg Foundation
1 January 2019 - 1 January 2024
Biopharmaceutical Mass Spectrometry Imaging Provides Novel Information in Drug Research and Development
Swedish Research Council
1 January 2019 - 31 December 2022
Neurochemical changes associated with Parkinson´s disease and L-Dopa induced dyskinesia studied with mass spectrometry imaging
Swedish Research Council
1 January 2019 - 31 December 2022
Patients in the driver’s seat! A multimethod partnership program on patient-driven innovations
Swedish Research Council for Health Working Life and Welfare
1 December 2018 - 30 November 2024
Proteinopathies in neurodegenerative disorders-new imaging biomarkers for early disease detection and new drug targets
Swedish Research Council
1 December 2017 - 31 December 2022
Utveckling av TNC001, en ny dopamin D1/D2 agonist, för behandling av Parkinsons sjukdom Fokus på kognition
VINNOVA
3 July 2017 - 29 June 2018
Balance training for people with Parkinson´s disease (BETA-PD): clinical effectiveness, neuroplasticity and implementation
Swedish Research Council
1 January 2017 - 31 December 2020
NEUROBIOLOGY OF MAJOR DEPRESSION AND DEPRESSION IN PARKINSON´S DISEASE: TOWARDS NOVEL BIOMARKERS AND THERAPIES
Swedish Research Council
1 January 2016 - 31 December 2019
Presymptomatic biomarkers for Parkinson´s disease and atypical parkinsonism
Swedish Research Council
1 January 2016 - 31 December 2019
Prosaposin and GPR37 in synucleinopathies
European Research Council
1 August 2015 - 31 January 2022
Mass Spectrometry Imaging in Drug Discovery - Targeting drugs, metabolites, peptides and neurotransmitter
Swedish Research Council
1 January 2015 - 31 December 2018
Treatment of late stages of Parkinson´s disease with a highly concentrated DOPA solution administered subcutaneously or intravenously ? a national, multicenter, academia-based trial
Swedish Research Council
1 January 2014 - 31 December 2017
Functional neuroproteomic changes associated with L-Dopa-induced dyskinesia in Parkinson´s disease
Swedish Research Council
1 January 2014 - 31 December 2017
Cognitive impairment in Parkinson´s disease: Biomarkers and mechanisms
Swedish Research Council
1 January 2013 - 31 December 2015
A randomized, placebo-controlled, double-blind, multi-center trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson´s disease
Swedish Research Council
1 January 2013 - 31 December 2015
Maintaining Neuronal Identity – Transcriptional control of the aging brain
Knut and Alice Wallenberg Foundation
1 January 2013 - 1 January 2018
Translational studies of major depression and organic defined depression in Parkinson´s disease
Swedish Research Council
1 January 2012 - 31 December 2015
Imaging Mass Spectrometry: Direct analysis of peptides, proteins and drugs in tissue sections
Swedish Research Council
1 January 2011 - 31 December 2014
Functional neuroproteomic changes associated with L-Dopa-induced dyskinesia in Parkinson´s disease
Swedish Research Council
1 January 2011 - 31 December 2013
Imaging Mass Spectrometry and Functional Proteomics Resource for Disease Diagnostic, Prognostic and Physiopathology
Swedish Research Council
1 July 2010 - 30 June 2015
Parkinson's disease models for translational research
Swedish Foundation for Strategic Research
1 January 2010 - 31 December 2015
Serotonin and glutamate in emotional memory: Implications for depression and schizophrenia
Swedish Research Council
1 January 2010 - 31 December 2012
Neurotransmission and plasticity in the striatal complex: role of NMDA receptors, gender and effect of drugs of abuse
Swedish Research Council
1 January 2009 - 31 December 2011
Molecular pharmacological and neurobiological studies on various subtypes of depression – A translational approach
Swedish Research Council
1 January 2009 - 31 December 2011
DRUGS OF ABUSE - ROLE OF PROTEIN PHOSPHORYLATION
National Institute on Drug Abuse
1 April 1996 - 29 February 2016
Visa fler

Anställningar

Professor/Överläkare, Klinisk neurovetenskap, Karolinska Institutet, 2021-
Överläkare, Klinisk neurovetenskap, Department of Clinical Neuroscience, 2016-

Examina och utbildning

MEDICINE DOKTORSEXAMEN, Institutionen för fysiologi och farmakologi, Karolinska Institutet, 1998
Läkarexamen, Karolinska Institutet, 1996

Handledning

Handledning till doktorsexamen
- Behzad Iravani, Novel measure of olfactory bulb function in health and disease, https://www.dissertations.se/dissertation/65d3a5f9b9/, 2021
- Lovisa Brodin, Parkinson's disease and Gaucher disease : focus on the GBA1 link, https://openarchive.ki.se/xmlui/handle/10616/48972, 2024

Om mig

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Handledning

Handledning till doktorsexamen

Nyheter från KI

Kalenderhändelser från KI